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Patient adherence is critical for ART success to ensure adequate viral suppression,
therefore, long-acting antiretrovirals are soon replacing current daily regimens. In recent
years, two drugs were successfully transformed into long-acting injectables; CAB LA and
RPV LA. These long-acting nanoformulations made it possible to abandon the daily pill
burden, instead approximately a bimonthly injection of both drugs is enough to suppress
and maintain viral load suppression. Our laboratory has been instrumental in
transforming FDA-approved and experimental-HIV medications into long-acting slow
effective release drugs, also known as LASER ART. LASER ART consists of slow drug
metabolism and high permeability and retention inside cellular reservoirs eventually
increasing the apparent life of the drugs. In this work, we apply LASER strategies to
darunavir, a protease inhibitor (PI). DRV is a preferred PI due to its potency against wild
type HIV as well as many mutant resistant viral strains. Among other drugs from its
class, DRV is considered to have the highest genetic barrier to HIV mutations. To
transform DRV into a LASER DRV, we chemically modified DRV to a prodrug, an
inactive form of the drug, by conjugation of different lengths of fatty acids/lipids; M1DRV
and M2DRV. These prodrugs were encased in amphiphilic polymer, NM1DRV and
NM2DRV, to increase nanoparticles stability and permeability across cell membranes.
The prodrug nanoformulations improved uptake, retention, release and antiretroviral
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activities in macrophages and T cells. Pharmacokinetics studies in mice affirmed the
advantage of the modifications in extending the apparent half life of DRV in animal
models. Long-acting DRV offers the option of a long-acting PI that does not require a
booster to maintain high concentrations in plasma, blood, and tissues. Therefore, DRV
prodrugs nanoformulations can eliminate heavy pill burden and reduce drug-drug
interactions that are prominent with PI boosters such as ritonavir and cobicistat.
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Chapter 1: Overview
Introduction
Human immunodeficiency virus type one (HIV-1) causes a chronic incurable
infection. If not treated, viral replication progresses to the acquired immune deficiency
syndrome (AIDS) where the patient commonly develops a plethora of coinfections that
when left untreated lead to death1. Clinical cases of AIDS were documented as early as
19812. Early in the epidemic, AIDS principally affected previously healthy homosexual
men2. These cases revealed that virus progression was characterized by many
opportunistic infections such as Pneumocystis carinii pneumonia, Mycobacterium avium,
herpes simplex virus, mucosal candidiasis cryptosporidiosis, Kaposi’s sarcoma (KS),
and many types of lymphomas2. The already known KS was a malignant and slowgrowing tumor in the lower extremities2. However, AIDS-related KS was found in 20
cases where the Kaposi’s skin lesions were multifocal and disseminated to various body
parts including the lymph nodes and visceral organs2. Thus, upon initial discovery,
infections signaled a definite death sentence with no available treatment2. However, with
the development of antiretroviral therapy (ART), the disease was controlled and
treatment confers a good prognosis3. Indeed, patients are now able to lead healthy
normal lives with reasonably normal lifespans conditioned by strict adherence to ART
medications4. As of 2016, 36.7 million people are infected with HIV worldwide5. HIV
infection is transmitted through unsafe/unprotected sex, use and sharing of needles for
drugs, blood transfusions, and men who have sex with men6. In 1985, HIV was
molecularly cloned and sequenced leading to the development of diagnostic tests and
later determinations of viral load and antiretroviral drug (ARV) resistance tests6. Each
and all were used to measure infection and monitor patients’ response to medications6.
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Symptoms of a primary HIV infection may start within 4-10 weeks post infection
and resemble normal flu symptoms; fever, joint pain, sore throat and swollen lymph
nodes in addition to skin rashes5. Once infection progresses, additional symptoms
develop which can continue for years and include fever and fatigue, diarrhea, weight
loss, oral thrush, shingles, and persistent generalized lymphadenopathy5. Lymph node
biopsies taken from HIV-1 infected patients show florid follicular hyperplasia, mixed
follicular hyperplasia, follicular involution, or lymphocyte depletion patterns5. Coinfections contribute dramatically to the morbidity and fatality of HIV – common coinfections include but are not limited to tuberculosis, cryptococcosis, hepatitis B virus,
hepatitis C virus, and malaria1. Several serological tests that include ELISA with
confirmatory Western blots can confirm infection7. However, polymerase-chain-reaction
(PCR) have emerged as a sensitive and specific test for HIV-1 diagnosis and
confirmatory tests5. PCR can also determine the viral load and be used to monitor the
efficacy of therapeutic regimens5, 8. HIV exhibits latency within the host genome
shielding the virus from recognition and clearance by the immune system9. These viral
reservoirs represent the main obstacle for curing HIV completely. The virus can be
suppressed by ART, however no available treatment to eradicate the virus has been
realized, except by transplantation of stem cells with a mutant CCR5 gene as in the case
for the Berlin patient10. In this overview we briefly examine HIV-1 viral life cycle, available
antiretroviral treatments and its limitations that eventually led to the development of longacting (LA) ART strategies.

Structure of HIV-1
HIV-1 was first isolated in 1983 starting a journey of intensive research on the
virus infection and treatment to this current day6. The virus belongs to the Retroviridae
family and Lentivirus genus. It is an enveloped retrovirus containing 2 copies of positive
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sense single-stranded RNA. There are two types of HIV; HIV-1 and HIV-2. The two
subtypes are similar in structure however differ in their origin, prevalence, infectivity, and
virulence. HIV-1 is more virulent and higher in infectivity than HIV-2 and frequently
causes more disease of the CNS as well as more spread throughout the world11. HIV-1
originated from chimpanzees and HIV-2 from the sooty mangabey. The former is the
main culprit of AIDS in the United States and worldwide, while the latter is more common
in Western and Central Africa11.
Enveloped RNA viruses possess specific vital proteins that must be able to
perform certain functions to preserve the virus’ life and infectivity12. These proteins
enable the genomic condensation of the virus into an RNA-protein complex into a protein
shell enclosed by a lipid membrane, also known as the viral envelope12 that recognizes
host cellular receptors such as the gp120 and CCR5 in T-cells in the case of HIV-112.
Retroviruses replicate through a DNA intermediate, flanked by two long terminal repeats
containing a promoter required to synthesize genomic and regulatory RNAs13. The
promoter is located towards the 3’ end of the RNA sequence. The main HIV-1 viral
genes found in the reverse transcribed virus DNA are gag, pol, pro, and env11, 12. These
genes encode for proteins with specific functions (Fig 1.1). These include the gag gene
which encodes for the main structural proteins such as matrix, capsid and
nucleoproteins represented in p24, p7, p6 (core), and p17 (matrix)11,

12

. Pol genes

encode for vital enzymes responsible of viral DNA formation and integration into the host
genome; reverse transcriptase, RNase H, and integrase11. Pro genes encode the viral
protease that mediates proteolytic cleavage of polyproteins resulting from encoding by
gag and pol11. Env encodes essential glycoproteins and transmembrane proteins
responsible for host cell recognition and interaction leading ultimately to fusion and entry
of the viral particle into the host cell, these are gp120 and gp4111, 12. Once transformed
into the viral DNA, the long terminal repeats (LTRs) represent a main characteristic of
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these viruses13. LTRs consist of three elements; U3, R, and U5. The 5’ and 3’ LTRs play
different roles in the virus survival where the first functions as viral promoter and the
second as transcription termination site13. The virus genome also encodes for accessory
genes such as tat, rev, vpr, vpu, vif, and nef11. These genes encode for proteins Tat,
Rev, Vpr, Vpu, Vif, and Nef that are implicated in facilitating viral replication and
generation of new infectious virions to continue the infectious cylce11. Briefly, Tat protein
enhances viral genes expression and Rev facilitates and ensures the correct transport of
viral mRNA and genomic RNA from the nucleus after transcription to the cytoplasm for
translation and/or packaging into new viral particles11, 14. Vpr has a critical role in halting
the cell cycle at G2 and Vpu has important roles in the release of newly formed viral
particles11. Vif enhances virions’ infectivity, where Nef is implicated in cellular signal
transduction and CD4 down regulation allowing for virions’ budding during late
replication stages where mature infectious virions are released from a replicating host
cell9, 11.

HIV-1 life cycle
The HIV replication cycle consists mainly of 7 stages. These are binding,
uncoating, transcription, integration of viral DNA into host genome, protein synthesis,
assembly and budding of new HIV particles11 (Fig 1.2). HIV viral particles, 100 nm, have
a lipoprotein membrane decorated with trimers of glycoprotein heterodimer complex of
external surface receptor gp120 and transmembrane gp41 bound together noncovalently
and represent the first responsible keys for infections11, 15. In the first stages of the viral
cycle, the surface receptor gp120 binds to CD4 on the target cell. Because the two
glycoproteins, heterodimers, gp120 and gp41 are not bound covalently, gp120 has a
tendency to shed and fall off spontaneously and can be detected in the serum and
lymphatic tissue of HIV patients11. Initial binding of gp120 to CD4’s Phe43 residue
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promotes structural changes in the viral Env allowing coreceptor binding (CCR5 or
CXCR4 depending on tropism) to the V3 loop16. This interaction initiates membrane
fusion facilitated by gp41, which inserts its fusogenic hydrophobic peptide located at the
amino terminus of the receptor into the membrane ultimately causing fusion of the two
membranes together through six-helix bundle formation11,

14, 16

and allowing for the

subsequent entry of the infecting capsid. Upon membrane fusion and entry, the virus
particle uncoats into the target cell’s cytoplasm releasing the infectious viral RNA and
other vital proteins14.
Once inside the cell, the viral enzyme reverse transcribes the viral RNA at the
minus-strand polymerization into a RNA/DNA hybrid double helix through the enzyme’s
ribonuclease H active site11, 14. Ribonuclease H then degrades and breaks down the
RNA strand of the hybrid helix and proceeds to complete a complementary DNA strand
to form a double helix DNA through its polymerase active site forming the pre-integration
complex (PIC)13, 14, 17. The proviral DNA is then cleaved at each 3’ end to create sticky
ends and is transported into the host nucleus where it is integrated into the host genome
by the action of the integrase13. Post integration shifts HIV-1 replication to late phase14.
Upon cellular activation, the transcription of proviral DNA into mRNA takes place from
U3 promoter within the upstream LTR and produces regulatory HIV-1 proteins such as
Tat and Rev11, 14. Tat protein recruits enhancer transcription factor b (P-TEFb) that binds
to the transactivation response element (TAR site) of the viral RNA11, 14, 17. Similarly, Rev
enhances transcription of longer RNA transcripts leading to expression of structural and
enzymatic genes enhancing formation of mature virions11.
Long mRNA is transported to the cytoplasm where it is translated into structural
and other viral proteins for the assembly of new virions. Translation leads to formation of
proteins resulting from pol and gag genes form the nucleus of the virus where proteins
encoded by the env form the viral envelope with its glycoproteins9, 11. New virions require
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the assembly of two identical viral RNA strands with other vital viral proteins for
replication encapsulated inside core proteins forming the viral capsid11. Assembly takes
place by the arrangements of multifunctional polyprotein precursors; Gag, Gag-Pol, and
Env18. Specifically Gag precursor (Pr55) plays a critical role in assembly of HIV-1 particle
because of its many interactions with other subunits such as RNA and lipids thus
incorporates the major components to form a functional virus18. Following the capsid
assembly, the immature viral capsid particle migrates to the cell surface where Gag Pol
polyproteins are cleaved by the HIV protease into their active final forms11, 18-20. Upon
cleavage and activation by HIV-1 protease mature virions are unleashed and cause a
highly reproductive infection in cells that meet their entry/fusion requirements11. After
activation by the viral protease, these viral particles bud through the host membrane
taking a part of it to form their new envelope taking on phospholipids and cholesterol
from the host cell membrane11. This is done to improve its own infectivity, as the virus
has eventually evolved to acquire and incorporate host cell membrane proteins on its
surface improving its adhesion to target cells. These proteins may include HLA class I
and II proteins and ICAM-1 adhesion proteins11.
In T-lymphocytes, new viral particles bud in the extracellular space where, in
monocytes and macrophages the virions first collect in intracellular vaculoes and then
are released11, 18. Three types of filaments known as intermediate filaments, actin, and
microtubules make up the cell’s cytoskeleton where their main function is to support cell
movement, division, and transport of the organelles in the cytoplasm21. HIV-1 uses the
cell cytoskeleton to ease its entry and infection into cells and during cell-to-cell
transmission using virological synapses. Transmission of HIV-1 from cell-to-cell was
found to be 100–18000 times more efficient than in cell-free infection21. This is because
cell-to-cell transfer has many advantages to the virus such as dodging of the virus to
neutralizing antibodies, speeding diffusion time to new cells, and increasing viral fusion
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by the action of virological synapses that work to concentrate virus and its entry
receptors21.

HIV-1 interaction with host immunity
Virus isolation led to the identification of CD4 T cells as the main viral target6.
Infection occurs through CD4 cell surface receptors6,

17

. CD4, a 58 kDa monomeric

glycoprotein is expressed on surfaces of circulating T-lymphocytes and precursors in the
bone marrow and thymus, monocytes/macrophages, eosinophils, dendritic cells, and
microglia11. This discovery introduced the knowledge of CD4+ T-cell depletion as a
result of HIV infection, which directly led to monitoring of CD4 cell counts clinically to
follow up with HIV+ patients as well as check on their response to the different ART
treatments9,

11

. It was not until mid-1990s that the specific co-receptors/chemokine

receptors on the CD4 cells were finally identified; CXC-chemokine receptor 4 (CXCR4)
in the case of T/X4-tropic HIV-1 and CC-chemokine receptor 5 (CCR5) in the case of
M/R5-tropic HIV-19,

11

. CXCR4 chemokine is found expressed on a plethora of cells

including T-lymphocytes and CCR5 is found on antigen presenting cells and activated Tlymphocytes11. Deletion mutations of CCR5 offered resistance to R5-tropic HIV6. The
host cell was found to contain many viral restriction factors such as tripartite motifcontaining 5α (TRIM5 α), APOBEC3G, SAMHD1 and tetherin, however all these factors
are also counteracted and inhibited by HIV antagonists Vif, Vpx, and Vpu14, 19.
Immune cells possess innate defense mechanisms in attempts to fight off the
virus, however these defenses are not enough to prevent HIV-1 infection. Eventually HIV
infects CD4 T cells as activated CD4 T cells are the most susceptible to infection,
however not all CD4 T cells are depleted22. Upon infection of CD4+ T cells with HIV-1
the cells produce IFN-β and IL-1β leading to pyroptosis with the help of IFI16 DNA
detector which eventually leads to the formation of the inflammasome23. Many HIV non-
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permissive CD4 T cells perform cellular suicid by pyroptosis, mediated by caspase-124.
HIV infection in quiescent CD4 T cells in the lymph nodes led to an accumulation of
incomplete dysfunctional reverse transcripts24. These transcripts are detected by cellular
DNA IFI16, which leads to formation of the inflammasomes, eventually activating
caspase-1 leading to cells depletion22, 24. HIV viral replicates inside lymph nodes 5-10
higher than peripheral blood22. Although CD4 T cells are known to be cellular viral
reservoirs and the most cell types being affected by the infection, they may not be the
first cells infected. HIV infection in rhesus macaques (having similar histologic
anatomical genital tracts of humans) through the intravaginal route crossed the
cervicovaginal mucosa within an hour infecting first the intraepithelial DC that later are
found in draining lymph nodes within 18 hours of inoculation25. DCs are antigen
presenting cells found in all tissues and specifically lymphoid tissues. In humans,
dendritic cells in the vaginal tissues/foreskin epithelium are the CD1a+ intraepithelial DC
also known as Langerhans cells (LC) an immature MHC II positive and CD+ DC in the
stratified squamous epithelia25, 26. Upon activation by a pathogen, these cells migrate to
the draining lymph nodes in durations range from minutes to hours depending on
species and pathogen25. Hence, these cells and others in the female reproductive tract
enhance the initial spread of HIV infection27. The vaginal CD1a+ LCs endocytose HIV-1
virions, migrate from the epithelium, and pass the virions to CD4+ T cells

26

. Transferring

nonproductive virus in the LC has viral advantage because it enables the bypassing of
topical antiviral drugs while these cells spread the virus to lymphatic CD+ T cells26.
Immune cells; plasmacytoid dendritic cells (pDCs), monocyte-derived DC, MDM,
and CD+ T cells utilize sensing defense mechanisms to sense exogenous and
endogenous virus23. pDCs were found less susceptible to HIV-1 infection where infection
was detected at low levels both in vivo and in vitro23. The low infectivity and thus
protection of these cells is most likely connected to the high levels of IFN-α produced in
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response to HIV-1 RNA binding to TLR7 in early endosomes where the virus is
contained after endocytosis23. However pDCs are unable to function as efficient APCs
when crossing exogenous viral particles since they are considered procurators of mature
DCs23 and hence require activation that is separate from signals that would induce type I
IFN production. High levels of type I IFNs are seen in HIV-1 patients, which finally led to
suggesting that pDCs contribute to the viral-driven immunopathogenesis23. In MDMs,
sensing and infection with HIV-1 is dependent on the viral capsid function in binding to
the cell’s cyclophilin A (CypA), which modulated the capsid uncoating and subsequent
viral replication23, 28. Sensing of the cells by CypA depends on their detection of viral
DNA synthesis. In human cells, interaction of host cell’s CypA with the viral capsid
protein enhances infection28. In infected MDMs, breaking of the tight interactions leads to
production of type I IFN and suppression of viral replication23. Natural killer (NK) cells
eliminate infected cells making them vital in fending off the immune system. They differ
from the cytotoxic T-lymphocytes in their ability in responding to infected cells in the
absence of prior exposure thus they play a critical role taking the initiative to eliminate
virus during early stages before the adaptive immunity has kicked into gear. Studies
showed that natural killer cells control the virus through the function of KIRs (Killer
Immunoglobulin-like receptors)6, 29.

HIV-1 Latency
HIV-1 infection leads to productive replicative infection as well as latent infection
where the virus essentially forms a reversible nonproductive infection with the ability to
replicate functionally yet transcription is latent/silent30. Latency is established directly
after infection necessitating the regular administration of suppressive antiretrovirals to
inhibit the rebound and activation of the latent virus30. Two kinetically different latent
reservoirs have recently been identified represented in different memory CD4 T-cell
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subsets30. T-cell infection starts when naive CD4 T-cells become activated by the
interaction with antigen presenting cells (APCs) such as dendritic cells and
macrophages where the APCs present T-cells with HIV antigens. In response, the nowactivated T cells proliferate and differentiate into several subsets; the effector T cell
subsets such as Th1, Th2, and Th17 the effector subsets and regulatory T-cells30. A
fraction of these effector cells survive and transform into resting memory CD4 T-cells
that migrate to the lymphoid tissue functioning as ready-guards against the same
antigen enhancing future immune responses30. These cells can generate secondary
effector cells upon recognizing the antigen again. Characteristics such as their small
size, low RNA levels, and absence of activation markers such as CD69, CD25, and
HLA-DR make it possible to differentiate between resting and activated cells30.
Latency can take place using two main methods of infection. The first is infection
during deactivation where virus infects an effector cell that later differentiates and reverts
to resting memory cell generating the common route of latency or a second method
through the direct infection of resting cells where these cells can be naive or memory
cells30. While it takes place, infection of resting CD4 T-cells is difficult due to the low
expression of CCR5 co-receptor slowing viral fusion, cytoskeletal barriers, low levels of
deoxynucleoside triphosphates (dNTPs), and poor nuclear import and integration with
host genome. In vivo, infection in resting cells is aided by high levels cytokine/chemokine
in lymphoid tissues leading to generation of latent virus in these cells30. Homeostatic
proliferation of latent infected cells induced by homeostatic cytokines like IL-7 and IL-15
is a key factor in survival of these secret viral storage cells30. Research is still ongoing to
determine the exact route of establishing latency.
Mechanisms that aid the occurrence of latency include but are not limited to
transcriptional interference, unavailability of certain transcription, post-transcriptional and
elongation factors, certain chromatin modifications, and low Tat activity30. Studies have
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shown latent provirus in resting CD4 T-cells integrated within highly expressed
transcriptional gene regions, which may lead to transcriptional interference and
contribute to latency30. Low levels of certain transcription factors such as NF-κB and
NFAT or mutation in the binding sites of these factors were shown to contribute to the
onset of latency in the quiescent T-cells30. Scarcity of certain elongation factors such as
P-TEFb in memory cells were also shown to contribute to latency30. Furthermore, many
factors may contribute to progression of HIV, some of these are; an impaired innate
and/or adaptive immune responses, polyclonal B-cell activation, increased T-cell
turnover and decreased thymic activity, short lifespan of central memory CD4+ T cells,
breakdown of mucosal barriers leading to infection and immune activation, increasingly
dysfunctional T cells that mimic an activated phenotype, and high levels of
proinflammatory cytokines and chemokines31. To study these factors, investigating elite
controllers (ECs), long-term nonprogressors (LTNPs), and viremic nonprogressors
(VNPs) become an essential tool to understanding their contribution to HIV
progression31. Microarray gene-expression analysis on jejunal biopsies of three groups,
ART-naive HIV-1 seropositive individuals, HIV-1 seronegative, and LTNPs showed that
gene-expression profiles differ between groups. Compared to uninfected individuals,
HIV-1 seropositive individuals showed upregulation of 369 genes whereas LTNPs
showed upregulation of only 150 genes. In addition, some genes implicated in activation
of lymphocytes and inflammation, such as RANTES (major CCR5 ligand) which was
downregulated in the LTNP group and upregulated in the HIV-1 seropositive individuals
compared to the control seronegative group. Seropositive individuals were found to have
upregulated cell cycling-related genes such as CCNA2 and MCM4 as well as genes
related to growth and cell adhesion31. However, both seropositive and LTNP groups
showed induced immune response genes such as IFITM1 and OAS2 involved in the
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interferon pathway, cell surface receptors such as PD-1, leukocyte immunoglobulin
receptor, and B2, and Eotaxin and MCP-1 involved in chemotaxis31.

Treatments
Antiretrovirals
In response to the devastating epidemic, major efforts from governments, public
institutions, and pharmaceutical companies yielded approximately 30 anti-HIV drugs,
antiretroviral therapies (ART) that are still used32. US Food and Drug Administration
(FDA) approved many drugs that target five different stages of the virus32, 33. These are
nucleoside reverse transcriptase inhibitors (lamivudine, abacavir, tenofovir and
emtricitabine) and non-nucleoside reverse transcriptase inhibitors (rilpivirine and
efavirenz) that inhibit the reverse transcriptase where the former function as analogues
of nucelosides/nucleotides causing chain termination and the latter inhibit the reverse
transcriptase and both ultimately inhibit reverse transcription of the viral RNA32,

33

.

Integrase inhibitors (raltegravir, dolutegravir and cabotegravir) inhibit viral DNA
integration into host genome33. Protease inhibitors (such as atazanavir, saquinavir,
amprenavir and darunavir) inhibit the viral protease that is responsible for maturation of
HIV-1 entailed in the cleavage of the polyproteins32, 33. Fusion inhibitors (enfuviritide),
and entry inhibitors (maraviroc)32, 33 are less used in regimens however are promising
alternatives. In the absence of an effective ART therapy, CD4 cell counts fall to below
200 cells per microliter causing HIV-positive individuals to eventually progress to AIDS
within 10 years and become very susceptible to a plethora of opportunistic infections5, 34.
Many complications and coinfections arise from AIDS such as tuberculosis, candidiasis,
cryptosporidiosis, Kaposi’s sarcoma, and many other neurological AIDS-related
complications5. In a meta-analysis, Poorolajal et al estimated that most AIDS patients on
HAART have survival expectancy for more than 10 years when starting regimens with
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the onset of the disease which is significant compared to only 2 years of life from the
onset of the disease in those who do not receive HAART34. Viral exposure to
subtherapeutic drug levels due to lack of adherence leads to development of drug
resistance mutations which represents a major setback for current ART33, 35.
The first drug to be used in HIV ART is the anticancer drug azidothymidine
(AZT)6. The drug was able to suppress the virus by blocking the reverse transcription of
viral RNA into DNA6. As a result, major decline in death and HIV-associated infections
rates were achieved. However, due to the high mutation rate of the virus, resistance
against AZT quickly aroused forcing scientists to go back to the drawing board to
develop new drugs. A decade later, it was discovered that these drugs may be combined
into the combinational ART therapy (cART) of 3 drugs to limit resistance, increase viral
suppression, and enable lower doses of each drugs to avoid specific drug toxicities6. In
addition, many studies showed that combination of two nucleoside reverse transcriptase
inhibitors (NRTIs) combined with a protease inhibitor showed superior therapeutic
effects and reduced mortality6. Development of cART decreased AIDS related deaths by
almost 50% between 2005 and 201622. In South Africa, life expectancy of HIV-1 patients
increased by 11 years6. Adhering effective antiretroviral regimens, patients who reach a
CD4 count more than 500 are expected to have normal life span expectancy and lead a
healthy life5. Mother-to-infant HIV transmission was thought unpreventable until the
ACTG076/ANRS 024 study in 1994 showed that the administration of AZT during anteand intra-partum periods provided significant reduction in newborn viral acquisition
paving the way to Pre-Exposure Prophylaxis (PrEP)-directed research.
To tackle preventive regimens, tenofovir disoproxil fumarate was investigated for
use as a prophylaxis drug to prevent or decrease HIV-1 transmission in prone
individuals. Initially, a Caprisa 004 trial in South Africa studied the effect of the drug as
vaginal gel applied before and after sexual intercourse and the results were promising
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showing reduction in HIV acquisition by 54% where results were affected by the
individuals adherence to the treatments6,

36

. Additionally, the iPrEX trial looked into

prophylaxis effects of a once daily oral emtricitabine and tenovofir disoproxil fumarate in
the population of men and transgender women who have sex with men showing a
reduction of 44% in viral infection6, 37, 38. In another study involving 9 different countries,
1763 serodiscordant sexually active couples were enrolled where one partner was HIV-1
positive and the other is negative. The study investigated the prophylaxis effect of
antiretroviral therapy to limit HIV-1 transmission between serodiscordant couples. The
study showed that early initiation of ART reduced sexual transmission of the virus and
the onset of clinical events by 96%, where suppression was due to suppressed virus
levels in the genital secretions39. More clinical trials such as Partners PrEP and TDF2
studies showed more than 60% efficacy in HIV reduction when tenofovir tablets or
Truvada (tenofovir and emtricitabine combined) were given to heterosexual couples
prone to HIV transmission38, 40, 41. Currently, Truvada shows a leading role in reducing
HIV-1 acquisition in different populations of sexual exposure and HIV high risk
individuals42, 43. Truvada has good safety profiles in kidneys and bones and pregnancy
cases42.

HIV broad neutralizing antibodies (bnAb)
Neutralizing antibodies (nAbs) are targeted against viral epitopes to fight
infectious disease44. Antibodies have been extensively used in infectious disease
prevention and treatment such as measles, hepatitis A and B, tetanus, varicella, rabies,
and cases of cytomegalovirus, parvovirus B19 and enterovirus45. BnAbs are antibodies
targeted to conserved viral structures, the envelope protein (Env) and its different
epitopes/structures46. In turn, viruses evolved to protect their Env trimer from neutralizing
antibodies by mutations or masking its epitopes employing a glycan shield

47

. BnAbs can
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also recruit effector cells response to apparent infection47. These antibodies are often
characterized by long half-lives48 and increase in potency and neutralization
characteristics with time with viral exposure49. Newly engineered antibodies; bi-specific
mAbs and dual-affinity re-targeting (DART) proteins can recruit effector cells as well as
recognize HIV-1 Env epitopes50. A few of these bnAbs are 3BNC117, VRC01, N6-LS,
and VRC07-LS that target CD4 binding site (CD4bs); 10-1074 and PGT121 that bind to
the V3 loop; PGDM1400, PG9, and PG16 that target the V1/V2 loop; PGT151 that
targets gp120-gp41 interface; 10E8V-LS that target the membrane-proximal region; and
finally glycan-dependent SF12 and VRC-PG05 that bind to glycans on the center of the
‘silent face’ of gp120. Many of these are progressing to early clinical trials46, 48, 50-52.
BnAbs are produced from B cells surviving in spleen and lymph node germinal
centers and are characterized by having one or more unique features that set them apart
from

other

antibodies;

long

complementarity-determining

antibody

regions

autoreactivity to some self-antigens53,

combining

(HCDR3),
54

regions

high

heavy

somatic

chain

third

mutations,

and

. While, these unique features contribute

significantly to the breadth and efficacy of bnAbs, they down regulate their own
production due to immune intolerance54. For these reasons, bnAbs production could be
increased in individuals with a certain autoimmune disease where many antibodies are
frequently made by avoiding immune responses via defective immune tolerance. In a
chronic HIV-1 patient that is also diagnosed with systemic lupus erythematosus (SLE),
the patient was found to be able to control the virus53. Hence, the immune system
response to the development and maturation of effective bnAbs presents a considerable
limitation to their use in vaccination and treatments where other medications may need
to be administered to dampen the immune responses against production of bnAbs. This
explains the delay in the production of bnAbs since their production is correlated with the
high viral loads in plasma also this could be a result of the slow antigen-dependent
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maturation process these bnAbs have to go through where the antibodies also undergo
many somatic mutations51, 55, 56.
Moreover, bnAbs were shown to be prophylactic against viral challenges in
animal models. Administering 10-1074 or 3BNC117 showed prophylaxis against
intrarectal SHIVAD8EO challenge in rhesus monkeys57. The antibodies were administered
a day before viral infection and showed inhibition of virus in all animal treated. Gautam et
al. showed that modifying antibodies by introducing two amino acid mutations referred to
as LS (M428L and N434S); 3BNC117-LS of 10-1074-LS, were able to increase their
half-lives and confer further protection against repeated viral challenge in monkeys for a
longer duration than the native antibodies did

58

. To simplify future bnAb regimens while

increasing their breadth and potency, Xu et al. designed a trispecific bnAb that contained
V1V2, MPER, and CD4bs binding sites59. The first two bind the virus/virus-infected cells
and the CD4bs domain binds and recruits killer T lymphocytes to elicit additional immune
responses59. The trispecific bnAbs were tested against a large panel of viruses (208
different

viruses)

where

4

resistant

viruses

were

found

in

the

case

of

VRC01/PGDM1400-10E8v4 and only one resistance with N6/PGDM1400-10E8v4. The
individual parental bnAbs showed neutralization efficiency but not as potent and efficient
as when combined in the trispecific bnAbs designs. Furthermore, in attempts to improve
antibodies binding to the neonatal Fc receptor to ultimately extend their half-lives and
confer further protection, a mutation to CD4bs-targeting bnAb, VRC01 and N6, was
incorporated. When tested in rhesus macaques, mutated parenteral VRC01 showed
longer half-life than mutated N6. The same results were paralleled when the animals
were treated with the trispecific bnAbs that incorporated the mutations to VRC01 and N6
reflecting the half-lives of 7.4 and 4.8 days, respectively

59

. The study reflects the

significance of engineering bnAbs with multispecificity and mutations to increase their
breadth, potency and circulation time.
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Gaudinski et al. recently concluded a phase 1 open-label clinical trial testing the
monoclonal antibody VRC01LS. VRC01LS is a modified version of VRC01. The
modification is a mutation in two amino acids that render the antibody with a longer halflife by increasing its binding to neonatal Fc receptor

60

. The trial confirmed the safety of

the antibody with only a few cases of mild adverse effects and showed the advantage of
modifying the antibody to extend its half-life, which enables it to stay in circulation fourfold longer than the native form in healthy volunteers. Study participants’ sera were
tested for their antibodies neutralization activity using standardized assays against three
Env-psudoviral strains confirming that VRC01LS still retained its neutralizing activity in
serum 36 weeks after injection into the patients

60

. Also, sera were tested for resistant

antibodies to VRC01LS confirming the safety of the antibodies in evading an
autoimmune response. In another clinical study, 10-1074 was tested for safety in 14
healthy and 19 HIV-1 infected volunteers. Antibody infusion on day zero, followed by a
period of 24 weeks follow up deemed the antibody tolerated in all participants with halflives of 24 and 12.8 days in non-infected and infected participants, respectively

61

. The

shorter antibody half-life in infected individuals points to the presence of viral targets that
are being neutralized by the antibody administered leading to clearance of the
complex61.
In another phase II clinical study, the efficacy of 3BNC117 against HIV-1 was
evaluated in infected volunteers who were on ART for a year where ART was stopped
for analytical treatment interruptions. The study enrolled participants with viral strains
sensitive to the antibody and administered antibody infusions every 2-3 weeks. Two
infusions of 3BNC117 (30 mg/kg) succeeded in viral inhibition for a period ranging from
5-9 weeks, where four infusions were able to maintain viral delay for up to 19 weeks

62

.

However, in more than 50% of the participants, viral escape was detected where
resistant strains had emerged. Therefore, a downside of using a single antibody for
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treatment is the rise of resistant viral strains that may have been a pre-existing minority
or de-novo generated from the virus turnover61, thus current studies are steering towards
the path of combinational antibodies to circumvent the viral escape dilemma.
Mendoza et al. used both 3BNC117 and 10-1074 in a combinational therapy in a
phase 1b clinical trial where the antibodies (30 mg/kg each) were administered in 3
different doses to HIV-1 infected individuals during and after ART treatment interruption
63

. The antibodies had half-lives of 17.6 and 23.2 days for 3BNC117 and 10-1074,

respectively. Antibody combination was administered at weeks 0,3, and 6 and ART were
completely interrupted two days post the first antibodies infusion. Over 80% of the
participants (9 out of 11) showed viral suppression for 15 weeks, and the rest had
rebounded by 5-7 weeks

63

. Taken together, the studies confirm the positive antiviral

effects of bnAbs in human subjects. Moreover, the role of bnAbs in vaccines was tested
in the most recent human clinical trial for HIV vaccine in a phase I clinical trial (IAVI
W001) testing the BG505 SOSIP.664 gp140 candidate administered via intramuscular
injection. The vaccine consists of glycosylated HIV-1 envelope glycoprotein trimers
containing disulfide bonds to stabilize gp120 and gp41 domains resembling the actual
virus envelope, a three-pronged spike64. Previous studies in infected animals showed
the vaccine is capable of inducing B cells to produce bnAbs neutralizing the virus64.

Pathways to viral eradications
Although no readily available cure has been developed for HIV, stem cell
transplant-based therapy has been shown to be a promise for a permanent cure. This
was demonstrated and confirmed in only one case thus far where the patient, the Berlin
patient has been cured. The Berlin patient has shown persistent aviraemia and
prolonged viral suppression even in the absence of ART following stem cells
transplantation from a donor that had a CCR5 mutation, rendering the recipient resistant
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to new HIV viral infections

10

. Initially, the Berlin patient received the transplantation to

treat his acute myeloid leukemia. The donor had homozygous 32-bp deletion in the
CCR5 allele rendering CCR5 receptor ineffective in aiding HIV-entry as its co-receptor
and enabling the first known HIV cure to go down in history 6, 10.
One approach for viral eradication explored the ability of combination ART
(cART) to inhibit reservoir formation if administered during acute infections/primary
infection65. Although, initial results were promising where studies showed post-treatment
controllers controlled viremia after halting therapy, the probability of controlling the virus
at 24-month post-halting early treatment intervention was found to be approximately
15%66. One case that confirmed early ART treatment insufficiency for eradication is the
Mississippi Child. The baby was administered antiretrovirals as soon after birth by 30
hours and treatment was halted after 18 months where remission lasted for 27 month
before rebound67. No signs of acute retroviral syndrome were observed but her plasma
viral load was at 16,750 copies/mL which dropped to 2,658 copies/mL within 72 hours of
antiretroviral therapy with an increase in CD4+ T cells by 43%

67

. Moreover, early

treatment is difficult strategy to establish due to difficulty assessing infection onset.
Another strategy for eradication explored the shock and kill method that utilizes
latent reversal agents (LRA)65 like histone deacetylase (HDAC), a most common LRA.
The approach is based on shock/activation of HIV from latent cells to be recognized and
killed by the immune system and administered antiretrovirals68. The treatment has
various limitations that include lack of targeting to cellular reservoirs68, which may lead to
the need of an increased dose increasing the risk of toxicities65. Another limitation is the
necessary need of a potent combination of LRA to effectively penetrate the tissues and
activate reservoirs in order to achieve eradication69. The lacking efficacy of this approach
was seen in clinical settings where LRAs were administered to HIV-infected patients who
were on ART. The treatment showed activation of virus seen in the elevating levels of
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HIV RNA in CD4 T cells and plasma without change in latent cells frequency69. Various
strategies were explored to cure HIV by activation, making the latent virus susceptible to
cytopathic effects and immune responses, however a complete long-term solution has
yet to be attained30. Of these strategies, histone deacetylase (HDAC) inhibitors were
explored however elimination of latent reservoirs was not achieved because of
remaining viral transcription due to survival-cellular mechanisms where the cells did not
die promoting further infection70.
A study investigated the effect of administering latency inducers (LARs) to
assess if combination therapy may decrease reservoir maintenance using the shock and
kill strategy. A combination of inducers; vorinostat, I-BET151, and α, were administered
after multiple tri-mix bnAbs treatments, caused 57% of mice to maintain viremia
suppression compared to 10% of the mice showing non-rebound in the groups where
only antibodies were given or antibodies plus one inducer

71

. Since the latent reservoirs

represent unbreakable barrier to viral eradication, Borducchi et al. tested the extent of
the shock and kill-strategy using combination of bnAb treatment with an immune system
activator to decrease/eliminate the viral reservoirs. Indian rhesus monkeys were infected
intrarectally with SHIV-SF162P3 and were administered ART cocktail subcutaneously
(tenofovir disoproxil fumarate, emtricitabine, dolutegravir) starting from 1-130 weeks
post-infection. The combination group received oral doses of GS-9620 (TLR7 A agonist)
and intravenous infusions of PGT121 (V3 glycan-dependent bnAb). A period of antibody
washout was followed by ART termination on day 130
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. By week 120, no virus was

detected in the treatment or control groups (including groups that were treated with
either drugs; PGT121 or GS-9620). To measure viral rebound from reservoirs, the group
monitored plasma viral loads for 196 days after ART discontinuation. As a result, groups
that received either GS-9620 or PGT121 alone had rebounded with a percentage of 91%
or 82% of animals. However, in the group that was treated with both only 55% of the
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animals showed a rebound, highlighting the significance of immune system activation to
sharpen the antiviral effects of both bnAbs and antiretroviral therapy. The study showed
promising results using a triple-strategy therapy on HIV-1 administering a combination of
ART, bnAb, and LRA. The study is a proof-of-concept that HIV-1 eradication strategy is
possible if the right strategies are combined and utilized together.
In the recent decade, gene editing has been explored as a promising tool to
eradicate latent HIV-1 from resting memory T cells to eventually allow for therapy
termination. DNA sequence targeted CRISPR/Cas9 genome editing of HIV-1 provirus
has been explored to eradicate transcriptionally latent virus that is not affected by
therapy70. The biggest obstacle to gene editing is the viral diversity, which requires
multiple sites’ targeting in the viral genome. An additional obstacle is the possible offtarget effects in host genome. CRISPR/Cas9 consists of Cas9 endonuclease, which
causes a double strand break at a specific virus sequence. This is guided by a 20
nucleotides long guide RNA. CRISPR/Cas9 was used to target the LTRs of the provirus
using a single gRNA where some reports showed 8.5 kb provirus excision70. Moreover, it
was noted recently from post treatment controllers’ data that there’s a correlation
between the viral copies and the efficacy of CRISPR/Cas970. Notably, Dash et al. were
able to show viral elimination in 33% of humanized mice treated with long-acting slow
effective release ART (LASER ART) and CRISPR/Cas9 targeting the LTRs and Gag
genes of the provirus73. Elimination of virus in this fraction of humanized mice was only
possible with the initial administration of LASER ART, which restricted viral infection to
very low levels followed by the administration of CRISPR/Cas9 to excise the remaining
latent virus. These mice showed elimination of competent HIV-1 in blood and tissues
confirmed by nested and digital-droplet PCR and RNAscope assays73. The study is a
proof-of-concept of complete eradication of the virus from previously infected animals.
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Long-Acting Slow Effective Release Antiretroviral Therapies (LASER
ART)
The many obstacles to an HIV-1 cure necessitate the improvement of current
ART. ART is the most critical aspect known to date to suppress HIV-1 where HIV-1
patient can live a longer lifespan leading a fulfilling life. Nevertheless, the daily doses of
ART create a pill burden on HIV-1 patients, and hence, regimen adherence is found to
be an issue in the HIV-1 population. In recent years, pharmaceutical companies and
researchers invested efforts into transforming the current daily ART into a long-acting
(LA) ART that may be dosed monthly or bimonthly74,

75

. However, current LA ART

approaches depend on whether these drugs can be nanoformulated and possessing
certain physiochemical characteristics such as poor water solubility and high potency76.
Nevertheless, many ART are highly water-soluble with low potency like many NRTIs. To
overcome these many limitations, prodrug and nanoformulation strategies as well as
targeting and harnessing the macrophage depot system were combined and were
shown to significantly improve the current antiretroviral therapies by transforming native
drugs into long-acting slow effective release ART (LASER ART)77 (Fig 1.3). LASER ART
utilizes prodrugs as well as nanoformulation strategies to improve current drugs
transforming them into LA regimens. Specifically, these LASER ARTs are characterized
by poor water-solubility, slow drug dissolution, increased bioavailability, extended
apparent

half-life

and

decreased

off-target

pharmacokinetic and pharmacodynamic profiles

toxicities
75, 77, 78

ultimately

improving

. LASER ART strategies

improved on many relevant and current HIV-1 drugs such as lamivudine, emtricitabine,
dolutegravir, cabotegravir, abacavir, and rilpivirine to date75, 78-82.
Briefly, modifications to parent drugs were explored to alter physicochemical
characteristics of the drugs making them more hydrophobic hence improving their
uptake in addition to their retention inside HIV-1 cellular reservoirs77,

79

. Prodrug
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strategies are used to improve drug’s absorption, distribution, metabolism and excretion
profiles (ADME) of many drugs and can be exploited to improve aqueous solubility,
hydrophobicity, permeability, half-life and many other factors that affect the drug’s
pharmacokinetics and potency83, 84. Modifying DTG and CAB, integrase inhibitors, with
14-carbon fatty acid chains by covalent ester bonds yielded more hydrophobic and
lipophilic drugs that were able to maintain high drug potency. These modified drugs were
coined as MDTG and MCAB. These drugs showed superior pharmacokinetic and
pharmacodynamic profiles as newly developed prodrug nanoformulations over the
control treatments75,

78

. In HIV-1 infected human-reconstituted peripheral blood

lymphocytes (PBL) reconstituted NOD/SCID/IL2Rγc−/− (NSG) mice, NMCAB treatment
showed viral restriction in terms of reduction in plasma viral RNA and DNA levels by
more than one log in magnitude and in tissues by more than 3 logs10 in magnitude when
compared to HIV-1 positive and GSK’s CAB LA controls. Furthermore, in preliminary PK
in rhesus macaques MCAB had a more superior PK profile when compared to GSK’s
CAB LAP as evident in the increase in half-life (t1/2) by 2-4 folds 75, 85.
Moreover, LASER ART was utilized to improve many current NRTIs. NRTIs are
the backbone of many ART regimens where common regimens would include two
NRTIs and an integrase inhibitor, NNRTI, or a protease inhibitor. Modifying the
hydrophilic lamivudine (3TC) with a myristic acid after blocking the drug’s amine group to
avoid side products yielded M3TC79. This modification decreased the drug’s aqueous
solubility and improved its protein binding. Previously, 3TC could not be nanoformulated
with polymers due to its high aqueous solubility but upon modification of the drug to
M3TC, nanoformulation with P407 through high pressure homogenization was plausible
and yielded stable nanoformulations79. Compared to free 3TC, M3TC showed high
uptake and retention levels inside monocyte-derived macrophages (MDM). Once inside
the cells these nanoparticles were stored in late and recycling endosomes where viral
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replication/reservoirs were suggested to reside in macrophages. Inside the cells,
different esterases such as (lysosomal acid lipase, phospholipase, and acetylhydrolase)
can cleave the ester bond releasing 3TC and myristic acid where 3TC is free to be
phosphorylated into the active moiety. Moreover, myristic acid, the modifying moiety,
may have additional antiviral by inhibiting N-myristoyltransferase (NMT) that is
responsible for the myristolyation of different capsid proteins. Administration of M3TC
nanoformulation in BALB/cJ mice showed improved PK profiles with increase in 3TC
plasma levels 10 days post treatment compared to undetected 3TC levels from native
3TC beyond 8 hours post treatment. Similarly, modification of another NRTI, abacavir,
with myristic acid as in the case in M3TC yielded a more hydrophobic drug that can be
formulated with P407 with comparable antiretroviral potency as ABC80. More recently our
laboratory has combined long-acting and ProTides strategies to further improve ABC by
delivering slow effective release of monophosphorylated abacavir into cells and
tissues86. LASER ART utilizes many strategies used in currently used contraceptives
and antipsychotic drugs to synthesize long-acting ART that may in the near future be
available in clinical settings where these LA regimens will be dosed less frequently and
ultimately improve patient-drug adherence

77, 87

. Hence our lab extends the LASER ART

strategies to many different ART classes such as protease inhibitors such as darunavir.

Darunavir (DRV)
Darunavir, DRV, also known as TMC114 is a nonpeptidic peptidomimetic
protease inhibitor that was approved by the FDA in 2006 as a twice-daily RTV-boosted
regimen for treatment-experience patients and was later approved for once daily dose
92

88-

. DRV is effective against wild-type HIV-1 and a wide range of multidrug-resistant

strains making DRV a preferred HIV PI treatment in pregnant women, pediatrics, HIV-2,
and HCV co-infection93. DRV binds to the viral protease inhibiting its function to cleave
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precursor proteins, the gag-pol polyproteins, of newly formed viral particles leading to a
halt in the virus cycle and ultimate viral turnover 94-96.
Protease inhibitors are considered a cornerstone in the treatment of HIV and
hence are found in most of the first line HIV treatments for adults and adolescents97. In a
study investigating PIs’ mechanisms, Hayashi et al. showed that DRV not only inhibits
the enzyme’s activity but also inhibits its dimerization. DRV can bind to viral proteases
preventing their dimerization while conventional drugs such as saquinavir only inhibit the
proteolytic activity of the protease and not the dimerization98. The drug molecule has
high affinity for the viral protease’s active site forming a stable complex with it, which
explains the drug’s antiretroviral activity even in the presence of resistance-associated
mutations96. The reported binding affinity of DRV to wild-type HIV-1 protease is Kd 4.5 x
10-12 mol/L and decreases by a factor of 13.3 to 6.0 x 10-11 mol/L when binding to
multidrug-resistance HIV-1 protease89. With mutant proteases however, DRV still bound
more efficiently that first-generation PIs. DRV is similar in structure to the first-generation
PI amprenavir, however DRV binds to multidrug resistant (MDR) HIV-1 protease 33 fold
more tightly than amprenavir89.
In vitro antiviral activity revealed the EC50 to range from 1-5 nmol/L and EC90
from 2.7-12 nmol/L in HIV-1/2 infected cells such as MT-4, peripheral blood
mononuclear cells (PBMCs) and macrophages89. In structure and binding studies, it was
found DRV forms 11 hydrogen bond interactions and 4 water-mediated ones with a
typical viral protease however several mutations can lead to inhibition of dimerization
due to separation in the flaps and hence affect the binding of DRV with the viral
proteases99. One such mutation is the PRP51-D25N which is resistant to DRV. The mutation
leads to lower affinity to DRV and dimer dissociation. Mutant protease binds DRV in a
perpendicular manner to its original binding conformation with only 2 hydrogen
interactions and 2 water-mediated bonds99. Three different viral mutations must exist to
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have negative impact against DRV. In vitro experiments showed lower resistance
development to DRV when compared to other protease inhibitors such as amprenavir,
nelfinavir, and lopinavir. Clinical and observational studies also reported that resistance
associated mutations to DRV was rare in both naive and experience ART-individuals.
Two recent retrospective studies further showed that PI RAM is very rare with ritonavir
(RTV) boosted darunavir (DRV/r) treatment and that mutations are more common in the
ART-experienced compared to the naive-ART patients. DRV is an effective drug with a
high genetic barrier enabling it to remain effective against PI-resistant isolates. In an
analytical study assessing prevalence of DRV mutations from 2010 to 2017, it was found
that DRV RAM were maintained at low levels in the samples being analyzed resulting in
high drug susceptibility88. In a sample of 60,760 HIV-1 patients, 91.7% showed no DRV
RAM in 2010 and remaining high in 2017 by 95.8%. The study showed that all drugs
compared; darunavir, atazanaivr, and lopinavir fared equally well when tested in
samples that demonstrated phenotypic susceptibility to the PI being analyzed in the
study. However when the three drugs were compared in a sample of 4,799 that showed
phenotypic resistance to one or more PIs the results toppled and showed leading
susceptibility to DRV by 73.3%, followed by 41.5% for atazanavir, and 46.0% for
lopinavir when assessed in 2010. When revisited in 2017, the susceptibility had
remained the same for all three drugs; DRV by 70.7%, atazanavir by 53.7% and 48.8%
for lopinavir 88.
DRV is a highly plasma protein-bound drug and more specifically bound to 1-acid
glycoprotein. Elimination time of boosted DRV is around 15 hours and is eliminated in
feces (79.5%) and urine (14%). The drug is detected in the CSF unbound (90%) and is
detected more with boosted twice-daily doses (600/100) over once-daily dose (800/100).
In many Phase III trials, the PI has been shown to treat naive and non-naive patients for
HIV suppression when used with other drug combinations. ARTEMIS, a 192-week phase
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III study compared two different regimens consisting of TDF and FTC with either DRV/r
or LPV/r. At the end of the 192 weeks, DRV/r regimen was found to be more statistically
superior over the LPV/r regimen. Adverse events with DRV/r were fewer than with LPV/r
as well as diarrhea treatment (grade 2-4) was significantly less with the DRV/r treatment
96

. Phase II clinical study ARIEL assessed safety of DRV/r in ART-experienced pediatric

patients showing no resistance to the drug over a period of 48 weeks leading to lowering
the age of ART-experienced children to 3 years highlighting the drug’s safety due to its
high genetic barrier. The patients were monitored for normal growth and virology
responses

100

. In a study to estimate the cost of DRV/r regimen as a first-line therapy for

HIV-1, it was found that for 96-week treatment period the cost would be $87,680. DRV/r
cost more than RAL or ATV/r regimen needed for the same treatment period, RAL
regimen being the lowest in cost

101

. A recent study found that a dual regimen consisting

of a boosted DRV and lamivudine (3TC) had effectiveness similar to a triple therapy
consisting of the boosted drug administered with two different nucleoside reverse
transcriptase inhibitors

102

. Boosted DRV is also given in combination with emtricitabine

and tenofovir in a recommended and approved regimen in the Europe, Canada, and the
US

88

. SymtuzaR is the first PI-based single-tablet regimen containing DRV boosted by

cobicistat in combination of two NRTIs emtricitabine and tenofovir AF used in treatment
of both ART-naive/experiences adults

103

. HIV is still an ongoing global epidemic where

an average of 37 million people living with HIV with 1.8 million of new HIV infection that
took place in 2016 and an estimated of a million death AIDS-related in the same year 22.
Protease inhibitors target HIV proteases efficiently but they are known for their
poor oral bioavailability. The poor bioavailability is a result of oxidation/biotransformation
by cytochrome P450 3A4 (CYP3A4) in gut and liver (human small intestinal enterocytes
and hepatocytes) in addition to the high P-glycoprotein efflux transporters on the apical
surface of intestinal enterocytes that pump the drug out of the gut wall back in the
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intestinal lumen; all contributing to major loss of active drug during first-pass metabolism
104

. PIs are all CYP3A4 substrates hence administering a PI booster/CYP3A4 inhibitor

increases level of active drug available. Ritonavir and cobicistat are both CYP3A
inhibitors ultimately acting as a PK enhancer for many protease inhibitors. A recent in
vitro study confirmed the similarities between both enhancers referring to them as high
potent inhibitors of CYP3A and weak inhibitors of other CYP enzymes with high IC50
(two orders of magnitude). Both drugs enhance absorption of the PIs by inhibition of Pgp efflux. Ritonavir was initially administered as a PI in 1996 for treatment of HIV-1
however because of its required high dose of 600 mg twice a day and its side effects it
was soon used as an enhancer of PIs instead. As a PK enhancer, RTV dose is lowered
to 100 mg once a day and hence is well-tolerated and dramatically increases half-life
and bioavailability of the coadministered PI105. DRV’s low oral bioavailability 37% is
enhanced up to 82% in the presence of RTV boost

106

. Similarly, cobicistat is a PK

enhancer that was approved by the FDA. The drug acts only as booster due to inhibition
of CYP3A4 and P-glycoprotein transporters from binding the PI substrates. Its boosting
effect is comparable to RTV. Cobicistat is a potent and more specific inhibitor of CYP3A
and has no effect on other CYP enzymes while RTV is known to inhibit beyond CYP3A4;
(2C19, 2C8, 2D6, and 2E1) and induces CYP1A2, CYP2B6, CYP2C9 and CYP2C19
and uridine 5’-diphospho-glucuronosyltransferase

104, 105

. Substituting RTV with cobicistat

may be favorable to avoid RTV-side effects such as alterations in lipid metabolism,
gastrointestinal issues, and many drug-drug interactions. However switching regimen
from ritonavir to cobicistat may not be appropriate with drugs that have a narrow
therapeutic index104, 105. On the other hand, in certain cases of co-infection boosters may
cause additional drug interactions leading to severe side effects. Few cases showed that
drug-drug interactions between ritonavir and a corticosteroid, digoxin, caused a severe
toxicity in HIV-1 positive patients107. Moreover, due to the associated co-infections that
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accompany HIV-1, drug-drug interactions are to be expected between the different drug
regimens targeting different diseases. Potential drug interactions were found between
HIV protease inhibitors and the 3D antiviral regimens prescribed for HCV reflecting
significant reduction in DRV concentration and many other boosted-PIs post HCV
treatment108-111. HCV medications; elbasvir and grazoprevir (potent inhibitors of NS5A
and NS3/4A, respectively) were found to have increased exposure when coadministered
with ritonavir or ritonavir-boosted PI making boosted-PI-inclusive HIV treatment
undesirable for HCV/HIV co-infected patients

112

. Similarly, co-infection with TB and its

subsequent treatment with rifampicin was found to show dramatic decreases in PI
concentrations administered hence PI dose increase would be essential to achieve the
same PI effect in co-infection absence. This happens due to the combined effect of the
booster ritonavir and rifampicin eventually negatively affecting DRV bioavailability

113

.

Pretreatment of PXR/CYP3A4-humanized mice with rifampicin lowered the intestinal
permeability for DRV by 50% compared to the untreated controls suggesting the
importance of a different dosage route for DRV in HIV+ patients with TB co-infection

114

.

Since alcohol consumption is prevalent in the HIV+ population, a study showed ethanol
negatively affects apparent half-life of RTV-boosted DRV and speeds its degradation
and metabolism in the liver but not for DRV alone

115

. As previously mentioned, RTV

induces and inhibits beyond CYP3A4 leading to switching of booster to cobicistat, being
a more specific CYP3A4 inhibitor with less drug-drug interactions. However, while RTV
causes more interactions with co-medications both boosters may cause drug-drug
interactions with medications like with dihydrocodeine, pethidine, phenprocoumon,
warfarin, duloxetine, sertraline, nateglidine and many contraceptives such as oestradiol
and

norethisterone116.

In

a

cobicistat

boosted-DRV/DTG

regimen,

cobicistat

coadministered with triamcinolone (glucocorticoid to treat greater trochanteric pain
syndrome and other rheumatic disorders) in a HIV+ patient lead to clearance inhibition of
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triamcinolone leading to exogenous glucocorticoid excess and ultimately adrenal
suppression making this HIV+ regimen problematic and requiring instant re-evaluation
117

. Attempts were made to eliminate the need for CYP3A inhibitors/PI boosters

preventing resistance and drug interactions. One such group did so by encapsulating
darunavir in solid lipid nanoparticles engrafted with certain peptides to increase uptake in
CD4+ cells specifically. Uptake of the DRV NLS via caveole-dependent endocytosis in
Caco-2 cells was reported to be 4-fold over the DRV suspension control. Particle uptake
was confirmed by confocal microscopy of Molt-4 cells (containing the CD4 receptors).
Desai et al. also showed improved the drug’s bioavailability in rats increasing the Cmax by
2.68-fold when using the peptide decorated darunavir SLN compared to the regular drug
suspension upon oral administration at a dose of 40 mg/kg

106

. Inugala et al. attempted

improving dissolution and oral bioavailability of DRV through the development of solid
self-nanoemulsifying drug delivery system

118

. Using their delivery system composed of

Capmul MCM C8 and surfactants such as Tween 90 and Transcutol, the team improved
the dissolution rate of DRV by 3 times greater mean dissolution rate when compared to
the free drug in vitro. In vivo, PK in Wistar rats showed enhanced peak drug
concentration at 1 hour of 3.7 ug/mL for the solid self-nanoemulsifying DRV as
compared to 1.57 ug/mL on the pure DRV treatment arm however concentrations were
undetectable by 24 hours

118

. Half-life of both treatments was 6.41 and 9.91 hours for

pure DRV and solid self-nanoemulsifying DRV. Therefore, to ultimately eliminate
boosters would be the best scenario for individuals taking ART therapy hence this would
eliminate many side effects and complications119. Hence modifying drugs into prodrugs
may obliterate the need for a booster, which can decrease many side effects and
circumvent many negative drug-drug interactions that accompany the various coinfections that accompany HIV-1 infection.
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Protease inhibitors are infamous for their short half-life, low plasma levels, poor
cell penetration, and low oral bioavailability

120, 121

. Chronic administration of PIs may

also lead to complications such as hyperlipidemia, insulin resistance, and bone density
loss

121

. This led to further research where prodrug strategies were explored to improve

the ADME properties of these drugs

121-124

. However most previous modifications were

directed towards improving solubility and the overall oral bioavailability of the drugs.
These modifications were directed to the hydroxyl groups on the various PIs and many
were specifically targeted on hydroxyl groups existing in the pharmacophore region of
the drugs

121, 124-127

. As a result many of these prodrugs resulted in a marked loss of

antiviral activity or only exhibited comparable half-lives to that of parent drugs 120, 126, 127.
Hostetler et al. modified PI at the C-terminal valine with a phospholipid (DPPE) to
produce phospholipid prodrug to improve its plasma levels and extend drug’s half-lives.
Reducing rapid elimination of PI can extend tissue exposure time to these drugs These
modifications improved penetration into the cell membrane because of the lipid chains
inserting into the cell membrane facilitating entry of the drug. However, the modification
yielded a prodrug that only extended the drug’s half-life from 0.04h to 0.299h after one
dose in rats showing modest improvements

120

. Modifying saquinavir with myristic or

oleic acids yielded highly stable prodrugs with decreased IC50 and long hydrolysis halflives of more than a month. Similarly, modifying indinavir with oleic acid yielded a stable
prodrug with a hydrolysis half-life of 24 days. However modifying indinavir with myristic
on C-8 hydroxyl group yielded a produrg that only showed 3-fold decrease in efficacy
127

123,

. This is critical to note because same modification when targeted to the internal

hydroxyl group on C-14 yielded a highly stable prodrug with more than 400-folds
increases in the IC50. By the same token, carbamate modifications on the internal
hydroxyl group on indinavir, nelfinavir and saquinavir yielded stable prodrugs that
showed significant increase in the IC50 with increments ranging from 400 to more than
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5200-folds

126

. It’s suggested that the significant changes in potency due to the hydroxyl

group’s role in peptidomimetic noncleavable transition state responsible for the drug’s
activity against the viral protease therefore blocking that group interferes with drug
interactions with the enzyme

126

. On the other hand, ester modifications to the internal

hydroxyl groups of these PIs yielded prodrugs with IC50 increases by only 1- to 26-fold
which could be due to the reversible and labile nature of ester bonds making the
prodrugs hydrolysable to the parent active moiety. Hence, utilizing this knowledge and
these strategies we can synthesize DRV prodrugs that may show extended half-lives
without

sacrificing

potency.

Development

of

long-acting

stable

DRV

prodrug

nanoformulations could potentially lead to infrequent drug administration and improve
drug cell penetrance and tissue biodistribution. To this day, no long-acting injectables of
protease inhibitors are available.
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Figures

Figure 1. 1 HIV-1 Structure*
Outer HIV-1 membrane is decorated with surface and transmembrane envelope glycoproteins
such as gp120 and gp 41 that are the main keys responsible for viral attachment to CD4 for entry
and fusion into host cell. Viral matrix includes the viral proteins and capsid. The capsid is
composed of p24 antigens and encases the nucleocapsid proteins complexed with two positive
sense RNAs and other proteins for transcription initiation and integrations such as reverse
transcriptase and integrase.

*Adapted with permission from Catherine S. Adamson and Eric O. Freed: Human
Immunodeficiency Virus Type 1 Assembly, Release, and Maturation. Advances in
Pharmacology (2007) pp. 347-387. (Copyright Elsevier)
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Figure 1. 2 HIV-1 Life Cycle

ϕ

Briefly, viral cycle starts with entry of the virus (1) through the binding of CD4 on the host cells
and coreceptor (CXCR4 or CCR5). Upon entry the virus uncoats (2) and empties its contents
from viral RNA and initiating proteins inside host cell. Viral RNA is then (3) reverse transcribed
into the viral DNA and transported into the nucleus where it is integrated (4) into the host genome
by the action of integrase. New viral mRNA is produced and translated in the cytoplasm
producing new viral proteins (5). New viral genomic RNA and proteins move to cell surface to
assemble (6) and bud from the cell where the final maturation (7) takes place through the action
of the viral protease.
ϕ

Adapted with permission from Alice K. Pau and Jomy M. George: Antiretroviral therapy:
current drugs. Infectious Disease Clinics of North America (2014) Vol 28(3), pp. 371-402.
(Copyright Elsevier)
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Figure 1. 3 LASER ART

Σ

(A) Schematic illustrates the main difference between regular NanoART and the recently coined
LASERT ART defined in the hydrophobic and lipophilic modifications to the native drug followed
by the nanoformulations techniques used in NanoART. (B) Prodrug strategy allows the
conjugation of a reversible promoity to the parent drug, which increases drug’s hydrophobicity
and lipophilicity. This improves drug permeability inside cells where the promoity is eventually
cleaved through the action of esterases to release the free drug where it can induce its
therapeutic effect.
Σ

Adapted with permission from Howard E. Gendelman, JoEllyn McMillan, Aditya N. Bade,
Benson Edagwa, Bhavesh D. Kevadiya: The Promise of Long-Acting Antiretroviral
Therapies: From Need to Manufacture. Trends in Microbiology (2019) Vol 27(7), pp. 593606. (Copyright Elsevier)
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Chapter 2: Synthesis and Characterization of Long-Acting
Darunavir Prodrugs
Abstract
Antiretroviral therapy (ART) has improved the quality of life in patients infected with HIV1. However, viral suppression at anatomical sites of infection remains a formidable task.
This is further complicated by adverse side effects and poor adherence to lifelong
therapy that leads to emergence of drug resistant viral strains. Thus, the need for cellular
and tissue targeted ART delivery platforms with potential for less frequent dosing cannot
be overstated. Herein, we describe two long-acting prodrug formulations of darunavir
(DRV), a potent protease inhibitor and component of HIV-1 treatment regimen. Two
classes of DRV prodrugs; M1DRV and M2DRV were synthesized and stabilized into
long-acting slow effective release (LASER) aqueous nanosuspensions designated
NM1DRV and NM2DRV, respectively. NM2DRV was found to exhibit enhanced
intracellular prodrug levels with sustained retention and efficacy for 30 days compared to
drug washout within hours for native DRV formulation (NDRV) and 15 days for NM1DRV
following single treatment of monocyte derived macrophages (MDM) and CD4+ T cells
at equivalent drug concentrations. Pharmacokinetics of NM1DRV and NM2DRV
administered to mice demonstrated sustained drug levels in blood and tissues with
higher concentrations of the prodrugs observed for 30 days. These data, taken together,
support the idea that extended release of DRV with sustained antiretroviral responses
could be realized through lipophilic prodrug formulations.
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Graphic 1: Nanoformulation of native drug, DRV, does not achieve high uptake into cells
resulting in HIV-1 infection in antiretroviral efficacy studies. Modified DRV nanoformulations,
M1DRV and M2DRV, show higher uptake and retention inside cells leading to viral inhibition.
M2DRV shows longer and higher retention inside MDM resulting in longer sustained
antiretroviral activities.

Introduction
While antiretroviral therapy has revolutionized human immunodeficiency virus type
one (HIV-1), treatment and preventative drug regimens require strict adherence to daily
dosing. With substantive extensions in longevity and quality of life, ART still remains
associated with a number of adverse drug reactions, poor compliance and drug
resistance128-130. Comorbid events include stigma of infection, depression and other
neuropsychiatric disorders associated with or without substance abuse. These all
negatively affect regimen adherence131,

132

. These events ultimately lead to the

emergence of virus drug resistance mutations133. Moreover, associated acquired
opportunistic infections and drug-drug interactions commonly emerge134, 135. These affect
clinical outcomes such as viral transmission and disease progression impeding ART
virologic suppression goals set by United Nations Programme on HIV and AIDS
(UNAIDS) and the US national HIV/AIDS strategic plan136-139. Such complications have
set the stage for the development of long-acting (LA) ART77, 140-142.
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Recent surveys support an immediate need for LA ART for HIV-1 infected patients
including those who would prefer the ease of extended release regimens compared to
taking daily pills141. Thus currently in development are monthly injectables of
cabotegravir and rilpivirine (CAB and RPV) for treatment and prevention of viral
infection140, 143. These suffer limitations that include large injection volumes, injection site
reactions and restricted access to tissue compartment sites of viral replication75, 140, 143.
Moreover, most antiretroviral drugs (ARVs) used in combination therapy have either
poor physicochemical properties or require high doses limiting their potential
reformulation into long-acting therapies. To overcome such obstacles we transformed
ARVs into lipophilic and hydrophobic prodrugs in our laboratory75, 78-80, 86. These longacting slow effective release ART (LASER ART) are surfactant stabilized nanocrystals
with enhanced drug loading and tissue penetrance properties. Indeed, each of our
LASER ART formulations were designed to facilitate rapid diffusion across physiological
barriers allowing sustained therapeutic drug concentrations at sites of viral replication75,
78-80, 86, 144

. With these advances established, we now describe the development of two

LA DRV prodrug formulations with extended apparent drug half-lives and improved
antiretroviral activities.
DRV is a second-generation unnatural peptidomimetic PI used in combination ART for
treatment of HIV-1 infection89, 102. Compared to other approved PIs, DRV has a higher
genetic barrier to resistance with potent antiviral activity against multidrug resistant viral
strains93. However, limitations of DRV use include its short half-life and restricted access
to cellular and tissue reservoirs of infection. Moreover, DRV and other PIs require high
doses and pharmacokinetic boosting agents increasing the potential for secondary
toxicities121. Thus, there is an immediate need to develop improved means for delivery of
these medicines. One strategy is utilizing prodrugs to extend the half-life and
biodistribution of the agent. While such prodrug approaches were previously explored in
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attempts to improve ADME, none have yet to be applied to the generation of reservoir
targeted LA DRV121-124. Prior efforts included, but were not limited to, carrier-mediated
drug delivery approaches that incorporate amino acids to minimize p-glycoprotein efflux
and mitigate first pass metabolism121,

145

. Notably, extensive prodrug efforts have

previously led to development and approval of fosamprenavir, a phosphorylated watersoluble prodrug of amprenavir125. Various fatty ester prodrugs of indinavir and saquinavir
have been described but are significantly less potent compared to the parent drugs122.
Overall, the reported prodrug and formulation approaches sought to improve aqueous
solubility of native drugs and the few lipophilic ester modifications made had proven
limitations120,

122, 123

. Specifically, PI prodrug designs were exclusively focused on

modifications of the free hydroxyl group and such attempts have resulted in a marked
loss of antiviral activity with comparable half-lives to that of parent drugs120, 126, 127. Thus,
LA delivery systems for PIs have remained elusive. Based on extensive prior works from
our laboratory on LASER ART platforms we sought to transform DRV into LA
nanoparticles. We reasoned that conversion of DRV into prodrugs was not only feasible
and economical but also a much faster strategy for overcoming ADME and formulation
challenges associated with the parent drug. Lipophilic M1DRV and M2DRV ester
prodrugs were created by covalent linkage of hydrolysable fatty acid promoieties to
functional groups present in the parent drug. These chemical modifications improved
physicochemical properties of the modified compounds compared to the parent drug,
thereby enabling transformation of DRV into LA nanosuspensions with improved
intracellular and tissue drug accumulation and sustained antiretroviral activities (Figure
2.1).
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Experimental Section
Reagents
Darunavir (DRV) was purchased from Boc Sciences (Shirley, NY). Anhydrous pyridine,
dichloromethane (CH2Cl2), chloroform (CHCl3), dimethyl sulfoxide (DMSO), N,Ndimethylformamide (DMF), deuterated chloroform (CDCl3), triethylamine (Et3N), diethyl
ether, tetrahydrofuran (THF), triethylsilane (Et3SiH), pluronic F127 (P407), 4dimethylaminopyridine (DMAP), stearoyl chloride, myristoyl chloride, zinc chloride,
paraformaldehyde (PFA), sodium iodide (NaI), sodium hydride (NaH), potassium iodide
(KI),

hexanes,

ethyl

acetate,

ciprofloxacin,

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT), and 3,3′-diaminobenzidine (DAB) were purchased
from Sigma-Aldrich (St. Louis, MO). Benzyl chloroformate was purchased from
MilliporeSigma (Burlington, MA). Live/Dead Fixable Green Dead Cell Stain Kits were
purchased from Thermo Fisher Scientific (Waltham, MA). LC-MS grade methanol,
acetonitrile, LC-MS-grade water, cell culture grade water (endotoxin-free), gentamicin,
ammonium formate, bovine serum albumin (BSA), TRIzol reagent and Triton X-100
were purchased from Fisher Scientific (Hampton, NH). Palladium, 10% on activated
carbon, was purchased from STREM Inc. (Newburyport, MA). All chemical synthesis
reactions were performed under a dry argon atmosphere. Flash column chromatography
was performed on 32-63 µm flash silica gels from SiliCycle Inc. (Quebec, Canada).
Reactions were monitored by thin-layered chromatography on precoated silica plates
(250 µm, F-254 from SiliCycle Inc.). The compounds were visualized by UV fluorescence
or stained with potassium permanganate. Heat-inactivated pooled human serum was
purchased from Innovative Biologics (Herndon, VA). Dulbecco’s Modification of Eagle’s
Medium (DMEM) was purchased from Corning Life Sciences (Tewksbury, MA). CEM
CD4+ T cells were obtained from the National Institute of Health. Monoclonal mouse
anti-human HIV-1p24 (clone Kal-1), monoclonal mouse anti-human leukocyte antigen
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(HLA-DP/DQ/DR; clone CR3/43), and the polymer-based HRP-conjugated anti-mouse
EnVision+ secondary were purchased from Dako (Carpinteria, CA). Alexa Fluor 700
mouse anti-human CD3, FITC mouse anti-human CD45, APC mouse anti-human
CD4, BV421 mouse anti-human CD8, PE mouse anti-human CD14, APC mouse antihuman CD4 and PE-Cy5 mouse anti-human CD19 from BD Biosciences (San Jose,
CA).

Methods
Prodrug synthesis and physicochemical characterization
To synthesize M1DRV, DRV (0.5 g, 0.9130 mmol, 1 equivalent) was dried from
anhydrous toluene (20 mL), dissolved in anhydrous THF (10 mL), cooled to -78°C,
followed by slow addition of NaH (0.07303 g, 1.826 mmol, 2 equivalents) and allowed to
stir for 15 minutes under an argon atmosphere. A solution of iodomethyl tetradecanoate
(0.58121 g, 1.3694 mmol, 1.5 equivalents) was prepared as previously described146 and
added to the precooled DRV solution. The reaction mixture was gradually warmed to
room temperature and stirred for 48h after which M1DRV was isolated by silica column
chromatography purification using 2:1 ethyl acetate-hexanes to form a colorless powder
(84% yield). 1H NMR (500 MHz, CDCl3): 7.59 (br, 2H), 7.17-7.35 (m, 6H), 6.66-6.78 (m,
1H), 5.67 (dd, J = 20.5, 4.9 Hz, 1H), 5.55 (dd, J = 32.9, 5.8 Hz, 1H), 5.25-5.40 (m, 1H),
4.88-5.22 (m, 2H), 4.73 (br, 1H), 4.12-4.23 (m, 1H), 3.63-4.10 (m, 3H), 3.45-3.59 (m,
1H), 3.36 (app. d, J = 11.4 Hz, 1H), 2.80-3.20 (m, 4H), 2.63-2.75 (m, 1H), 2.60 (t, J =
12.5 Hz, 1H), 2.25-2.45 (m, 2H), 1.85-1.97 (m, 1H), 1.50-1.74 (m, 4H), 1.20-1.40 (m,
20H), 0.80-1.05(m, 9H).

13

C NMR (125 MHz, CDCl3): δ 173.1, 155.1, 137.7, 129.6,

129.2, 128.3, 126.4, 113.9, 112.3, 109.4, 81.7, 73.5, 73.4, 73.3, 71.4, 69.6, 58.9,
53.7, 45.3, 36.3, 34.2, 33.6, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 26.9, 25.9,
24.6, 22.6, 20.3, 20.2, 20.1, 19.9, 14.1. MS-ES+ (m/z): calcd. for C42H65N3O9S, 787.44
(100%), 788.45 (45.4%), 789.45 (10.1%); found, 811.05 [M+Na+]. M2DRV was
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synthesized in a three-step process that involved protection of the primary amine in the
parent drug using a carbobenzoxy (Cbz) group, coupling to stearoyl chloride and a final
Cbz deprotection to yield the desired product as a colorless powder. Specifically, DRV
(1.0 g, 1.8256 mmol, 1 eq.) was dried from anhydrous pyridine (10 mL) and dissolved in
a mixture of anhydrous THF (10 mL) and DMF (10 mL) under an argon atmosphere. The
reaction mixture was cooled to 0°C, followed by drop wise addition of Et3N (254 µL,
1.8256 mmol, 1 eq.) then benzyl chloroformate (388 µL, 2.7389 mmol, 1.5 eq.) and left
to stir for 48h under protection from light. The desired protected Cbz-DRV was isolated
by silica column chromatography purification eluting with 1:1 ethyl acetate-hexanes. The
Cbz-DRV was dissolved in 15 mL of DMF and cooled to 0°C followed by addition of 1.5
equivalents of 4-dimethylaminopyridine and 2 equivalents of Et3N. The mixture was
stirred for 15 minutes after which 1.5 equivalents of stearoyl chloride were added and
warmed to 45°C over 24h. The formed Cbz-M2DRV was isolated by column
chromatography and subjected to catalytic hydrogenolysis using 10% palladium on
activated carbon and 20 equivalents of Et3SiH in a mixture of methanol and chloroform
(1:1) solvents. After reaction completion, the mixture was filtered through a pad of celite
to remove carbon followed by further purification by column chromatography eluting with
a mixture of 2:1 ethyl acetate-hexanes to isolate M2DRV as a colorless powder. 1H NMR
(500 MHz, CDCl3): 7.58 (d, J = 8.3 Hz, 2H), 7.18-7.34 (m, 7H), 6.70 (d, J = 4.8 Hz, 2H),
5.65 (d, J = 4.8 Hz, 1H), 5.17 (br, 1H), 5.10 (d, J = 9.0 Hz, 1H), 5.02 (dd, J = 13.9, 6.9
Hz, 1H), 4.21-4.39 (m, 1H), 3.98 (t, J = 7.8 Hz, 1H), 3.82 (t, J = 7.6 Hz, 1H), 3.76 (app. t,
J = 7.7 Hz, 1H), 3.67 (dd, J = 15.8, 8.9 Hz, 1H), 3.53 (dd, 1H J = 14.8, 5.3 Hz, 1H), 3.11
(app. d, J = 10.7 Hz, 1H), 2.93-3.09 (m, 2H), 2.82-2.92 (m, 1H), 2.65-2.79 (m, 2H), 2.222.40 (m, 2H), 1.93 (app. t, J = 6.3 Hz, 1H), 1.50-1.70 (m, 6H), 1.20-1.38 (m, 28H), 0.810.95 (m, 9H).

13

C NMR (125 MHz, CDCl3): δ 173.3, 155.1, 150.7, 137.4, 129.5, 129.2,

128.4, 126.7, 126.6, 113.9, 109.3, 73.9, 73.3, 70.8, 69.6, 57.7, 53.5, 49.3, 45.4, 36.9,
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34.2, 31.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 26.8, 25.7, 24.6, 22.6, 20.2, 20.2,
19.9, 14.1. MS-ES+ (m/z): calcd. for C45H71N3O8S, 813.50 (100%), 814.50 (48.7%),
815.50 (11.6%); found, 837.14 [M+Na+]. Nuclear magnetic resonance (1H-NMR and
13

C-NMR) spectra were recorded on a Varian Unity/Inova-500 NB (500 MHz; Varian

Medical Systems Inc., Palo Alto, CA, USA. Fourier Transform Infrared Spectroscopy
(FTIR) was performed on a Spectrum Two FT-IR spectrometer (PerkinElmer,Waltham,
MA, USA). LC-MS quadrupole infusion was performed on a Waters TQD (Boston, MA)
to confirm the desired molecular ion peaks of M1DRV and M2DRV. Solubilities of DRV,
M1DRV, and M2DRV were determined in water. Briefly, homogeneous saturated
solutions of each compound were mixed at room temperature for 24 hours and
centrifuged at 17,000 x g for 10 minutes to pellet insoluble drug. The amount of drug in
the supernatants was quantified by multiple reaction monitoring (MRM) on a liquid
chromatography tandem mass spectrometry (LC-MS/MS) system comprised of an
Waters ACQUITY ultra-performance liquid chromatography (UPLC) system (Waters,
Milford, MA) coupled to a triple quadrupole mass spectrometer with electrospray
ionization (ESI) source (Waters Xevo TQ-XS).
Prodrugs stability in different pH
Prodrugs’ stabilities were evaluated in different pH of 1, 7 and 11. Stocks of M1DRV or
M2DRV with concentrations of 1-2 mg/mL were prepared in MeOH. For stability in acidic
pH (pH 1) the drugs were incubated separately in a solution of pH adjusted 0.1 M HCl.
Similarly, drugs were incubated in pH adjusted 0.1 M NaOH (pH 11) to test stability in
basic environments. Finally, incubation in water (pH 7) determined stability in neutral pH.
Triplicate samples of both prodrugs were kept on a shaker either at room temperature
(25°C) or incubated at 37°C. Aliquots were collected from the samples at different time
points; 8, 24, 72, 120, 168, and 336 hours. Samples were stored at -80°C until drug
quantitation where the samples were dried using a speed vacuum, then the pellets were
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dissolved in 100 µL MeOH. Drug concentrations/stabilities were determined from
samples using Waters Alliance e2695 HPLC Separations Module.
Prodrugs stability and cleavage profiles in plasma
To evaluate plasma stability of M1DRV and M2DRV, 100 µL of plasma samples from
mouse or rat were spiked with 1 µM M1DRV or M2DRV. Free prodrugs stocks were
prepared in dimethyl sulfoxide (DMSO). Triplicate samples were kept on a shaker at
37°C. At various time points (0, 2, 6, 24, and 48), 1 mL of MeOH was added to each
tube and vortexed for 3 minutes to stop enzymatic cleavage, then stored at -80°C until
drug quantitation. Negative controls were used to normalize for non-specific binding.
Specifically, 100 µL ice cold plasma was added to 1mL MeOH followed by addition of the
prodrugs. Additional negative controls were prepared using heat-inactivated plasma to
determine whether drug hydrolysis was due to enzymatic activity or non-enzymatic
hydrolysis. At various time points, 1mL MeOH was added to the samples. Samples were
then vortexed for 3 minutes and centrifuged at 15,000 g for 15 minutes. For UPLCMS/MS sample prep to quantify prodrugs, 40 µL of supernatant was added to 10 µL of
internal standard (IS) and 50 µL of 75% MeOH. For DRV quantitation, 50 µL of sample
was added to 10 µL of IS and 40 µL of water. Samples were vortexed and plated for
UPLC-MS/MS analyses.
Nanoformulations of DRV, M1DRV and NM2DRV
Poloxamer 407 (P407) coated DRV (NDRV), M1DRV (NM1DRV) and M2DRV
(NM2DRV) nanoformulations were produced by high-pressure homogenization (Avestin
EmulsiFlex-C3; Avestin Inc, Ottawa, ON, Canada). Briefly, each compound (1% w/v)
was premixed in a P407 solution (0.5% w/v in PBS) for 16h at room temperature
followed by homogenization at 20,000 psi at 0°C until the desired particle size was
achieved (150 – 450 nm). Particle size, polydispersity index (PDI), and zeta potential
were determined by dynamic light scattering (DLS) on a Malvern Nano-ZS
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(Worcestershire, UK). Drug nanoparticles were diluted in water and triplicate
measurements were observed and recorded over 10 weeks to determine particles’
stabilities for the translational potential of these nanoparticles in terms of shipping and
storage. For animal studies, the different nanoformulations were concentrated using
differential centrifugation to allow for small injection volumes during in vivo studies.
Formulations were centrifuged and pelleted at 5,000 x g for 5 minutes. Supernatants
were transferred to a new centrifuge tube and centrifuged at 20,000 x g for 20 minutes.
Finally, supernatant was discarded and both pellets were suspended in a total of
approximately 500 µL of PBS. Drug content in the concentrated formulations was
quantified using HPLC and known standards ranging from 0 – 50 µg/mL. Nanoparticle
morphologies were analyzed by FEI Tecnai G2 Spirit transmission electron microscopy
(TEM) (Hillsboro, OR) using negative staining. Small volume (10 µL) of diluted
nanoformulation (1 mg/mL) was applied on a formavar/silicone monoxide coated 200
mesh copper grid. Grid was left 2-5 minutes to absorb the nanoparticles. Excess sample
was dried carefully using a clean filter paper and allowed to dry for 2 minutes. Pipet a
drop of Nanovan negative stain on the grid and allow to stain for no longer than a minute
while shielding the sample using a filter paper tent to minimize any air contaminants. Blot
excess stain and allow grid to dry before viewing under TEM.
Cytotoxicity and cell viability
Effects of NDRV, NM1DRV, and NM2DRV on cell viability were assessed in human
monocyte-derived macrophages (MDM) and CEM-SS CD4+ T cells. Briefly, human
monocytes were isolated by leukapheresis (from HIV-1/2 and HBV seronegative donors)
and purified by current centrifugal elutriation147. Cell were then cultured for 7-10 days in
96-well culture plates (80,000 cells/well) with Dulbecco’s Modified Eagles Media
(DMEM) supplemented with 10% heat-inactivated pooled human serum, 1,000 U/ml of
macrophage colony stimulating factor, 1% glutamine, 10 µg/mL ciprofloxacin, and
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50 µg/mL gentamicin in a 37°C in a 5% CO2 incubator148-150. A stock solution of each
drug nanoformulation was serially diluted in DMEM to produce drug concentrations
ranging from 50-400 µM. Cells were treated for 24 hours, washed and incubated with
200 µL/well 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution
(5 mg/mL) for 45 minutes. Upon MTT removal, 200 µL/well of DMSO was added and
absorbance measured at 490 nm on a SpectraMax M3 plate reader with SoftMax Pro
6.2 software (San Jose, CA). Samples’ absorbances were normalized to that of nontreated controls. For CEM-SS CD4+ T cell studies, the cells were seeded on round
bottom 96-well culture plates at a density of 80,000 cells/mL per well in Roswell Park
Memorial Institute (RPMI) media with 10% fetal bovine serum (FBS), 1% penicillin, and
1% streptomycin and treated with each nanoformulation as described for MDM. After 24
hours, cells were centrifuged at 650 x g, dispersed in PBS, centrifuged again at 650 x g,
and resuspended in PBS. Excitation dye (0.1 µL) (Molecular Probes, Live/Dead Fixable
Green Dead Cell Stain Kits) was added to each well. Cells were excited at 488nm and
the percent dead cells determined by flow cytometery.
Evaluation of drug potency (EC50)
To evaluate drug potency, MDMs were seeded on round bottom 96-well culture plates
(80,000 cells/well) and exposed to DRV, NM1DRV or NM2DRV containing media at
concentrations ranging from 0.0005 nM-50 µM in tenfold dilution increments for 60 min
and replaced with drug-containing HIV-1ADA media at a multiplicity of infection (MOI) of
0.1 infectious particles per cell. After 4 hours, infection medium was removed, and the
cells were incubated an additional 10 days in the presence of the same concentration of
drug prior to infection. Half media changes were done every other day. After 10 days of
infection, culture media was collected for measures of HIV-1 reverse transcriptase (RT)
activity148-150. For CEM-SS CD4+ T cells studies, the cells were cultured in suspension in
96 well plates, spun at 650 x g and re-dispersed in 100µL drug-containing media. After
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60 minutes, cells were challenged with HIV-1NL4-3-eGFP at a MOI of 0.1 by spin-inoculation
followed by incubation in drug-containing media for 2 hours. Cells were kept at 37°C in
a 5% CO2 incubator for 12 hours, after which media containing drug and FBS was
added. Twenty-four hours post infection, all cells were washed twice with PBS to remove
extracellular virus and drug-containing media was replaced with medium containing the
same drug concentration prior to infection. Every other day, cells were centrifuged at 650
x g and resuspended in fresh drug-containing medium. Ten days post HIV-1 challenge;
supernatants were collected for RT activity measurements. Antiretroviral activities were
further confirmed using flow cytometry in the case of CEM-SS CD4+ T cells studies
infection with the HIV-1NL4-3-eGFP. The EC50 was calculated using sigmoidal 4-point
logarithmic regression from RT activity using GraphPad Prism v7 (San Diego, CA).
Cell drug uptake and retention
MDM were cultured on 12-well culture plates and treated with media containing 100µM
of NDRV, NM1DRV or NM2DRV

148-150

. At 2, 4 and 8 hours post treatment, media was

removed and adherent cells were washed twice with PBS then scraped into 1mL PBS.
Cells were counted on an Invitrogen Countess Automated Cell Counter (Carlsbad, CA),
pelleted by centrifugation at 956 x g for 8 minutes. The cell pellets were reconstituted
and sonicated in 100 µL methanol for 5 minutes followed by centrifugation at 20,817 x g
for 5 min. For CD4+ T cell experiments, CEM-SS cell line was used151, 152. The cells were
plated on to poly-L-lysine pre-coated cell culture plates that make it possible for them to
adhere and uptake experiment was done following the same steps performed for MDM.
For drug retention studies, MDM were treated for 8 hours then washed with PBS and
maintained in media with half-media changes every other day until collection days. In
collection days, media were collected and cells were washed with PBS then scraped and
collected in PBS for drug analysis. Intracellular and supernatant drug content were
analyzed using a Waters Alliance e2695 HPLC Separations Module and a Waters
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Acquity H-class UPLC with a Waters Acquity QDa detector (Waters, Milford, MA). For
HPLC quantitation, a Kinetex 5 µm C18 column (150 × 4.6 mm) (Torrance, CA) was
used for separation using mobile phases of 55% 10 mM ammonium formate, pH
3.0/45% ACN, 80% ACN/20% 10 mM ammonium formate pH 3.0, and 90% MeOH/10%
water for DRV, M1DRV, and M2DRV, respectively, with a flow rate of 1.0 mL/min and
UV detection at 265 nm. For UPLC quantitation using a Waters Acquity QDa detector,
an ACQUITY UPLC® BEH Shield RP18 1.7 µm analytical column (2.1mm×100mm,
Waters Corp.) was used for separation using mobile phase of 60% MeOH/40% 7.5 mM
ammonium formate pH 3.0 at a flow rate of 0.25 mL/min using a mass range of 50 – 600
Da and cone voltage of 12. Transmission electron microscopy (TEM) was used to image
the morphology of MDM-loaded with the different drug nanoparticles. Cells were loaded
with the different nanoparticles for 4 hours then washed twice with PBS. Cells were
collected in PBS, centrifuged, fixed in 2% paraformaldehyde (PFA) and kept at 4°C until
TEM processing.
Antiretroviral activities
To assess long-term antiretroviral efficacy, MDM were treated for 8 hours with 100 µM
NDRV, NM1DRV or NM2DRV as previously described for uptake studies. After
treatment, cells were washed twice with PBS and cultured in fresh media without drug
followed by half-media changes every other day. At 5-day intervals from days 1 to 30
after treatment, cells were challenged with HIV-1ADA at a MOI of 0.1 for 16 hours. After
infection, HIV-1ADA media was removed, cells were washed with PBS and replaced with
fresh media without drug. Ten days after viral challenge culture media were analyzed for
RT activity, while adherent MDM were fixed with 2% PFA and assessed for HIV-1p24
protein expression by immunocytochemistry148-150.
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Pilot NDRV, NM1DRV and NM2DRV pharmacokinetics (PK)
Male BALB/cJ mice (25 g) (Jackson Labs, Bar Harbor, ME, USA) were administered a
single 50 mg/kg DRV-equivalent dose of NDRV, NM1DRV and NM2DRV intramuscularly
(IM) into the caudal thigh muscle to determine PK over a month-long study to assess
drug bioavailability in plasma and blood and drugs’ distribution into the different tissues.
Heparinized tubes were used for blood collection to obtain plasma and blood samples at
days 1, 7, 14, 21, and 28 from treated mice. Tissues were collected at time points 7, 14,
and 28 of the study and stored at -80°C until drug analysis. Plasma, blood and tissue
samples were analyzed by LC-MS/MS to determine parent and prodrug levels.
Pharmacokinetics of NM1DRV and NM2DRV in CYP3A humanized mice
To assess the effect of an RTV boost with the modified DRVs, PK studies were done in
mice with human CYP3A enzymes responsible for DRV’s metabolism. Mice models
used for these studies are the PXR/CAR/CYP3A4/7 tADMET (Taconic Biosciences, Inc)
and PXR/CAR/CYP3A/NOG (hCYP3A-NOG developed and characterized in153). Only
NM1DRV, with and without boost, was tested PXR/CAR/CYP3A4/7 model due to the
limited number of animals. However, both NM1DRV and NM2DRV, with and without
boost, were evaluated in the hCYP3A-NOG model. The humanized mice were
administered 50 mg/kg DRV-equivalent dose of NM1DRV or NM2DRV intramuscularly.
RTV-boosted groups were given IM boost injections of RTV nanoformulation (NRTV) on
days 0, 7 and 14 of the study. Similar to the BALB/cJ PK studies, plasma and blood
samples were collected in heparinized tubes on days 1, 7, 14 and 21. Tissues were
collected at the end of the study and stored at -80°C until drug analysis. Plasma, blood
and tissue samples were analyzed by LC-MS/MS to determine parent and prodrug levels
as well as the effect of the boost on drugs’ bioavailability. NRTV used for boosting was
formulated and characterized as previously described154. Briefly 1% (w/v) RTV was
suspended in a solution of 0.2% (w/v) P407 in 15 mL solution of 10 mM HEPES buffer
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(pH 7.8) and was left to stir at room temperature overnight. The premix was
homogenized using high-pressure homogenization (Avestin EmulsiFlex-C3; Avestin Inc,
Ottawa, ON, Canada) at a pressure between 15,0000 – 20,000 psi at 0°C until the
desired particle size was achieved. After homogenization, the nansuspension was
differentially centrifuged as for the DRV formulations and diluted in PBS. Particle size,
polydispersity index (PDI), and zeta potential were determined by dynamic light
scattering (DLS) on a Malvern Zetasizer Nano-ZS (Worcestershire, UK).
NDRV, NM1DRV and NM2DRV pharmacodynamics (PD)
In a pre exposure prophylaxis (PrEP) PD study, drugs nanoformulations’ antiretroviral
activities to protect from viral infection were evaluated in NSG (NOD/scid-IL-2Rγcnull)
mice-reconstituted with CD34+ human hematopoietic stem cells at birth. Before
treatment, mice were assessed for human CD45+, CD3+, CD4+, CD8+, and CD14+
lymphocytes by flow cytometry to confirm the integrity of the model. Mice were
administered a single 50 mg/kg DRV-equivalent dose of NDRV, NM1DRV or NM2DRV
IM. One week post drug treatment, mice were challenged with 2 x 104 TCID50 of HIV-1ADA
(100-200 µL) by an intraperitoneal injection. Plasma samples were collected one week
after infection for viral load determination. At the end of the study, viral loads were
determined in plasma and HIV-1 gag RNA levels in the collected spleens were
measured by reverse transcription polymerase chain reaction (RT-PCR) to further
assess the antiretroviral efficacy of the treatments78. Plasma and tissues (lymph nodes,
liver, lungs, kidneys, gut and bone marrow) were collected for plasma drug quantitation
by LC-MS/MS, human T cell counts, viral load and HIV-1 p24 expression.
Drug quantitation by LC-MS/MS
Briefly, 25 uL of blood samples from mice were immediately mixed with 1 ml ice-cold
ACN, and spiked with internal standard (a fourteen carbon fatty-acid modified
dolutegravir prodrug (MDTG)78 and d3-dolutegravir (DTG-D3) at 500 ng/ml each, final
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concentration of 50 ng/ml). Samples were then vortexed, and centrifuged at 17,000 x g
for 10 minutes. The resulting supernatants were dried under vacuum, reconstituted in
100 µL, and injected for separate LC/MS/MS analysis. For DRV analysis, 45 µL
supernatant was mixed with 30 µL of H2O and for prodrug analysis 35 µL supernatant
was mixed with 35 µL of 85% MeOH. Finally 10 µL of samples were injected for
separate drug and prodrug LC/MS/MS analyses. Blood and plasma standards were
extracted at a final concentration of 0.5-500 ng/mL. For tissue sample preparation,
approximately 20-100 mg of spleen, lymph nodes, and liver were weighed and
homogenized in 5–20x dilutions of 90% MeOH. 100 µl of the homogenates were mixed
with the same internal standards as blood, vortexed, and centrifuged. Supernatant were
collected for LC/MS/MS analysis. For DRV analysis, 60 µL of supernatant was mixed
with 40 µL of 50% MeOH and for prodrug analysis, 60 µL supernatant was mixed with 40
µL of 85% MeOH before LC/MS/MS analyses. Tissue standards were extracted at a final
concentration of 0.5-500 ng/mL. DRV and prodrugs were quantified by injection onto a
LC/MS/MS consisting of a Waters ACQUITY H class UPLC coupled to a Waters Xevo
TQ-Smicro mass spectrometer (Waters Corp., Milford, MA, USA) with an ESI source in
positive mode. Analyte separation was achieved on an ACQUITY UPLC® BEH C18 1.7
µm analytical column (2.1mm×50mm, Waters Corp.). Mobile phase A was composed of
7.5mM ammonium formate in water (MS grade, Fisher), pH adjusted to 3.0 with formic
acid (MS grade, Fisher). Mobile phase B was 100% methanol (MS grade, Fisher). For
the prodrugs, the isocratic program was held at 20% A for 10 minutes with the flow rate
at 0.28 mL/min. For DRV, the isocratic program was held at 40% A for 4.5 minutes. To
wash the column, the percentage was decreased to 5% A, held for another minute and
then ramped back for equilibration to 40% A for 2 minutes. The flow rate was 0.25
mL/min. On the mass spectrometer, the MRM transitions, cone voltage and collision
energy were optimized by direct infusion of each drug and internal standard. Transitions
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for DRV were 548.00 < 112.81 m/z for quantification, while transitions 548.00< 68.89
m/z and 548.00 < 392.2 m/z were used for identity confirmation. Internal standard (DTGd3) was monitored at 422.84 < 129.94 m/z. Dwell time was 20 msec for each transition.
Transitions for M1DRV were 758.4 < 155.93, 758.4 < 112.89 m/z and 758.4 < 602.33
m/z for quantification and identification respectively. Transitions for M2DRV were 814.52
< 155.93, 814.52 < 240.97 m/z and 814.52 < 658.44 m/z for quantification and
identification respectively. The internal standard (MDTG) was monitored at a MRM
transition 616.27 < 126.95 m/z. Dwell time was 25 msec for each transition.

Study Approvals
All animal studies were approved by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee in accordance with the standards
incorporated in the Guide for the Care and Use of Laboratory Animals (National
Research Council of the National Academies, 2011). Human blood cells were isolated by
leukapheresis from HIV-1/2 and hepatitis seronegative donors and were deemed exempt
from approval by the Institutional Review Board of UNMC.

Statistics
All data sets are presented as mean ± standard error of the mean (SEM). In vitro studies
were performed using three biological replicates (n=3). In vivo studies included a
minimum of 5 animals per group (n=5). For comparisons of two groups, Student’s t test
(two-tailed) was used. For comparison between multiple groups, one-way ANOVA with
Bonferroni correction was performed. For studies with multiple time points, two-way
ANOVA and Bonferroni’s post hoc tests for multiple comparisons were performed.
Results with P < 0.05 were considered significant. All data were graphed and analyzed
using GraphPad Prism 7.0 software (La Jolla, CA).
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Results
Synthesis and characterization of M1DRV and M2DRV
First, we synthesized DRV ester prodrugs by either derivatizing the amine (M1DRV) or
hydroxyl (M2DRV) functional groups in the parent drug (Fig 2.12) using fatty acids of
variable carbon chain length to form lipophilic compounds with high chemical yields after
column chromatography purification (Figures 2.2 and 2.3). The chemical structures were
confirmed by proton (1H) and carbon (13C) nuclear magnetic resonance (NMR)
spectroscopy (Fig 2.4, 2.5, 2.6, and 2.7). Specifically, broad peaks at 0.9 and 1.26 ppm
in the

1

H NMR spectra of both prodrugs correspond to the terminal methyl and

methylene protons of the fatty esters (Fig 2.4 and 2.6). Additional peaks from the
carbonyl groups at 173 ppm and aliphatic carbon atoms from the fatty acids (14.1 and
29.3 ppm) in the

13

C-NMR spectra further confirmed M1DRV and M2DRV prodrug

synthesis (Fig 2.5 and 2.7). Further prodrug characterization by Fourier transform
infrared (FTIR) spectroscopy showed absorption bands at 2917, 2915 and 2848 cm-1
representing asymmetric and symmetric C-H stretches in the long chain fatty acids (Fig
2.8 and 2.9). Infusion of each prodrug into a Waters Xevo TQ-Smicro triple quadrupole
tandem mass spectrometer showed the desired molecular ion peaks at 811.05 [M+Na+]
and 837.14 [M+Na+], for M1DRV and M2DRV, respectively (Fig 2.10 and 2.11). The
water solubility of the prodrugs was at 212 ng/mL (M1DRV) and 130 ng/mL (M2DRV)
compared to 150 ug/mL for the parent drug (Fig 2.13). The 700-fold decrease in
aqueous solubility for the two prodrugs confirmed their hydrophobicity as conferred by
the lipid conjugates. Prodrugs’ stability was measured in different pH at 25 and 37°C
where M1DRV showed most stability in pH 7 in both temperatures (Fig 2.14). Similarly
M2DRV showed stability in pH 7 and also pH 1 for both temperatures (Fig 2.15). The
stability of the prodrugs was determined in plasma of mice and rats. Incubation of the
prodrugs in plasma resulted in a decline in prodrug concentrations by more than 45 %
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over 24 h (Fig 2.16 and Fig 2.17). In both plasma matrices, M1DRV and M2DRV
concentrations declined over time and levels of DRV cleaving from the prodrugs were
detected at increasing concentrations. Parallel studies in heat inactivated plasmas
showed no decrease in prodrug concentrations or formation of DRV indicating that the
compounds are activated enzymatically through ester bond cleavage (Fig 2.18).

Formulation and Characterization of NM1DRV and NM2DRV
Poloxamer 407 (P407) stabilized native drug (NDRV) and prodrug nanoparticles
(NM1DRV and NM2DRV) were produced by high-pressure homogenization with drug
encapsulation efficiencies of 57, 74 and 85% for NDRV, NM1DRV and NM2DRV,
respectively. The NDRV, NM1DRV and NM2DRV nanoparticles exhibited uniform
particle sizes of 384 ± 10, 322 ± 7 and 149 ± 2 nm, narrow polydispersity indices (PDI) of
0.27 ± 0.01, 0.26 ± 0.01 and 0.28 ± 0.01, and zeta potentials of -7.78 ± 0.36, -7.03 ±
0.02, and -1.74 ± 0.09 mV, respectively, and remained stable at 4°, 25° and 37°C for 13
weeks (Fig 2.19, 2.20, 2.21). Notably, concentrated formulations for animal injections
remained stable for 17 weeks at 4°C (Fig 2.22 and 2.23). Nanoparticle morphologies
were examined by transmission electron microscopy (TEM). NDRV and NM2DRV
exhibited uniform rod-shaped morphologies, while NM1DRV showed spherical/globular
morphologies (Fig 2.24), all with diameters in the nanometer range (150 – 450 nm).
Physicochemical and particle stabilities supported further preclinical development of the
prodrug formulations.

Cytotoxicity and efficacy of NM1DRV and NM2DRV
Toxicity of the prodrug nanoformulations in MDM was assessed by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for mitochondrial
function. Similarly, toxicity of the different drug nanoformulations was determined in CEM
CD4+ T cells by MTT as well as Live/Dead Fixable Dead Cell Stain Kits. No adverse
effects on cell vitality were observed in MDM (Fig. 2.25) or CEM-SS CD4+ T cells (Fig
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2.26) after 24h of incubation with concentrations up to 400 µM of drug nanoformulations.
Given the hydrophobic nature of the two prodrugs, homogenous nanosuspensions of the
prodrug with enhanced apparent aqueous solubility were employed for efficacy studies.
The amine modified ester prodrug formulation of DRV (NM1DRV) demonstrated
comparable antiretroviral activity to native DRV formulation in human MDM and CEM
CD4+ T cells. Modification of the hydroxyl functional group in DRV to form NM2DRV
nanoparticles resulted in a 10-fold loss in activity. Nevertheless, the half maximal
effective concentration (EC50) of NM2DRV against HIV-1ADA in MDM and CD4+ T cells
was in the nanomolar range and the formulation exhibited long-term efficacy when
compared to native drug or M1DRV formulations. EC50 values of the free DRV and
M1DRV in MDM were 20.3 and 26.2 nM respectively. However, because of the
hydrophobic nature of M2DRV, the drug was precipitating in media therefore it was
necessary to nanoformulate M2DRV to form a suspension that was capable of cell
penetration highlighting the significance of the nanoformulations. The EC50 values for
NDRV, NM1DRV and NM2DRV in MDM were 20.5, 19.1 and 260 nM (Fig 2.27),
respectively. Efficacies of free drugs were also measured in CEM-SS CD4+ T cells
where EC50 of DRV and MDRV values were 1.5 and 2.6 nM, respectively. Similarly EC50
of the nanoformulations were assessed; NDRV (1.48 nM) and NM1DRV (0.97 nM)
exhibited comparable activity in CEM-SS CD4+ T cells, while NM2DRV (18.7 nM)
showed decreased activity compared to native DRV formulation (Fig 2.28). The
observed antiviral activities for NM1DRV and NM2DRV are likely linked to improved
cellular drug uptake and variable prodrug activation rates in HIV target cells. However,
unlike M1DRV that hydrolyzes back to DRV inside cells, M2DRV was found to be
hydrolytically stable, suggesting a probability that the prodrug could be intrinsically
active. Overall, these data suggest that both prodrug formulations could facilitate longlasting antiretroviral efficacy.
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Uptake of NM1DRV and NM2DRV in MDM and CD4+ T cells
Long acting stable DRV prodrug nanoformulations could affect drug cell penetrance and
tissue biodistribution. We therefore evaluated DRV nanoparticle interactions using both
MDM and CEM-SS CD4+ T cells. These were measured in parallel studies after a single
exposure to equivalent concentrations of drug formulations followed by quantitation of
cellular concentrations of native drug and prodrugs. Both NM1DRV and NM2DRV were
readily taken up in MDM, with concentrations increasing to peak levels at 24 hours
(Fig 2.29). At 24 hours, intracellular drug concentrations were 126 nmol/106 cells and
74 nmol/106 cells for NM1DRV and NM2DRV, respectively, more than 500-fold higher
than NDRV uptake. Intracellular drug levels remained less than 0.4 nmol/106 cells
over 24 hours after NDRV treatment. The amount of DRV formed from M1DRV was 2.8
nmol/106 cells at 24h, a >8-fold significant enhancement compared to peak drug levels
after NDRV treatment (0.31 nmol/106 cells). Levels of DRV cleaving from M1DRV
intracellularly were significantly more than levels of DRV from NDRV at all time points
(^^^^P < 0.0001) (Fig 2.29). Similarly, levels of M1DRV were higher than M2DRV levels
at all time points (****P < 0.0001). Moreover, DRV formation from M2DRV was
consistently at the limit of detection, suggesting that the prodrug was protected against
intracellular hydrolysis. Similarly, drug uptake performed in CEM-SS CD4+ T cells was
rapid for NM1DRV and NM2DRV. Intracellular peak drug levels for NM1DRV and
NM2DRV treatments were 71 and 49 nmol/106 cells, respectively (Figure 2.30). Levels of
M1DRV were higher than M2DRV intracellularly at 8 hours (***P = 0.0007) and 24 hours
(****P < 0.0001). In contrast, NDRV treatment did not produce detectable cell drug
concentrations at any time point. Taken together, these findings demonstrate formulation
stability and rapid prodrug uptake in HIV-1 target cells. Intracellular nanoparticle uptake
was further confirmed by TEM (Fig 2.31). After 4-hours of treatment, both NM1DRV and
NM2DRV

demonstrated

significant

nanoparticle

accumulation

in

macrophages
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compared to NDRV. The electron micrograph images corroborate our prior findings on
nanoformulated antiretroviral drug trafficking and storage in endosomal compartments79,
155

.

Retention and antiretroviral activities of NM1DRV and NM2DRV
M1DRV and M2DRV prodrugs were retained within macrophages for 14 and 31 days,
respectively, further suggesting their extended release potential (Fig 2.32). Prodrug
levels retained by MDM fell to 0.10 nmol/106 cells at two weeks for NM1DRV, while
NM2DRV treatment exhibited prodrug concentrations of 25.5 nmol/06 cells at day 31 (Fig
2.32). Levels of M2DRV retained were significantly higher than M1DRV levels from 1- to
4- weeks of the retention study (P < 0.0001). However, drug from NDRV was not
detected in MDM within hours of treatment. Drug released from MDM into culture media
showed a burst release followed by rapid decline of M1DRV compared to low but steady
concentrations of M2DRV during the 31-day observation period (Fig 2.33), presumably
due to slow intracellular dissolution of NM2DRV nanoparticles. Overall, these data sets
suggest that transformation of DRV into lipophilic prodrugs could facilitate creation of
long-acting and slow-release formulations for efficient intracellular drug delivery. To
assess long term intracellular antiretroviral responses, MDM were treated with NDRV,
NM1DRV or NM2DRV at equimolar concentrations for 8 h, followed by drug washout
and HIV-1ADA challenge at five-day intervals for a period of 1 to 30 days. In cells treated
with NM2DRV no HIV reverse transcriptase (RT) activity was detected during the 30-day
observation period (Fig 2.34). In contrast, viral breakthrough, as determined by RT
activity, was observed at days 5 and 20 after treatment with NDRV and NM1DRV,
respectively. Cross validation with HIV-1p24 antigen staining paralleled RT results,
demonstrating complete viral inhibition for up to 30 days after a single exposure of MDM
to NM2DRV and up to 15 days after a single dose of NM1DRV (Fig 2.35). These findings
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demonstrate that NM1DRV and NM2DRV nanoparticles could potentially sustain
therapeutic drug concentrations at cellular sites of infection.

Pharmacokinetics of NM1DRV and NM2DRV over a month
To affirm the idea that MDM and CD4+ T cell targeted lipophilic prodrug
nanoformulations would achieve sustained drug levels in plasma and tissues, a
preliminary pharmacokinetic study was performed in BALB/cJ male mice using 50 mg/kg
DRV equivalents for all treatments. In the pilot study, plasma drug bioavailability and
tissue distribution was assessed over 1 month. Plasma DRV levels from NDRV
treatment group fell below the EC50 levels of the drug (55 ng/mL) after day 1 post
injection where concentration fell rapidly from 77.2 ng/mL at day 1 to 8.7 ng/mL at day 3
and undetected at the end of the study (Fig 2.36). Similarly, plasma DRV levels cleaving
from NM2DRV treatment fell below EC50 of the drug after 3 days post injection. DRV
levels from NM2DRV treatment fell below 10 ng/mL after day 3, however DRV
concentrations remained detectable at the end of the study at concentrations of 5.4
ng/mL. However, plasma DRV levels were highest from NM1DRV treatment group
showing DRV levels above the EC50 for one-week post injection (Fig 2.36). DRV levels
from NM1DRV were significantly higher than DRV levels from NM2DRV (P < 0.0001).
DRV plasma levels from NM1DRV showed gradual decrease until day 29; 308.5, 107.7,
62.6, 20.4, 11.1, and 5.1 ng/mL. Moreover, blood DRV levels were assessed to
determine drug depots in circulation where drug levels from NDRV fell from 116.9 ng/mL
at day 1 to zero at the remaining time points. Notably, high prodrug levels were detected
in the blood of these animals for NM1DRV and NM2DRV, reflecting high drug depot in
circulation (Fig 2.36). NM2DRV showed highest prodrug levels in blood sustained until
the end of the study at 67.7 ng/mL whereas for NM1DRV 2.1 ng/mL of prodrug was
detected at day 28. DRV cleaving from NM2DRV in blood was not detected beyond day
1 (13.2 ng/mL) whereas higher DRV levels were detected from NM1DRV (Fig 2.36).

59
Similarly, high prodrug levels were detected in tissues; liver, spleen, and lymph nodes
for both drug nanoformulation treatments (Fig 2.37 and 2.38). NM2DRV reflected higher
prodrug concentrations in all three tissues especially in lymph nodes. DRV cleaving from
the prodrug nanformulations was not detected in spleen or lymph nodes (Fig 2.38). In
livers, DRV levels cleaving from NM1DRV were 23.7, 6.5 and 5.1 ng/g for animals
sacrificed at 1, 2, and 4 weeks whereas DRV cleaving from NM2DRV was below 4 ng/g
for all time points (Fig 2.37). DRV levels cleaving from NM1DRV in the liver tissues were
significantly higher than those measured from NDRV and NM2DRV at the different time
points (****P < 0.0001, ***P = 0.0004 and *P = 0.0104). More specifically, DRV from
NM1DRV was highest in livers at one week indicating that the drug is cleaving faster by
the esterase function than in the case of NM2DRV. Detection of high prodrugs in the
case of both NM1DRV and NM2DRV confirms that the prodrugs distribute efficiently in
the different tissues however they are not hydrolyzed at the same speed as concluded
from the liver-DRV data (Figure 2.37).

Pharmacokinetics of NM1DRV and NM2DRV in CYP3A humanized mice
To slow down metabolism of DRV, the drug is normally administered with a CYP3A4
inhibitor, ritonavir or cobicistat. Therefore, to assess the modification effect on the drug’s
metabolism and need for a CYP3A4 inhibitor, appropriate humanized mice were used.
This experiment was also done to enhance and boost DRV levels since in previous
BALB PK, DRV levels in tissues were not detected except in the liver. The models used
to test the significant of a booster carry the CYP3A4 human gene and the human
transcription factors responsible for its expression; primarily pregnane X receptor (PXR)
and the constitutive androstane receptor (CAR)153, 156, 157. Specifically, the mice models
used

are

the

PXR/CAR/CYP3A4/7

tADMET

(Taconic

Biosciences,

Inc)

and

PXR/CAR/CYP3A/NOG (hCYP3A-NOG developed and characterized in 153). The models
are of different backgrounds, C57BL/6 and NOG mice, respectively, however both mice

60
models carry the human CYP3A4 gene. The mice were administered a single 50 mg/kg
DRV equivalents doses for NM1DRV and NM2DRV, with or without repeated NRTV
doses (50 mg RTV/kg). PK in the tADMET model comparing the RTV-boosted NM1DRV
with the unboosted NM1DRV in humanized and control mice showed similar PK profiles
to the previously mentioned BALB/cJ study. Significance of RTV boost was seen in DRV
plasma levels cleaving from NM1DRV treatment at the first time point, one day post
injection, in both humanized and control mice when compared to unboosted NM1DRV
(^^^P = 0.0009 and **P = 0.0016) (Fig 2.39). High levels of M1DRV were detected in
blood in both boosted and unboosted groups confirming a high drug depot in circulation
(Fig 2.39). Interestingly, tissue M1DRV levels were significantly higher than levels in
BALB/cJ mice. In BALB/cJ mice, M1DRV levels in liver start at 226.9, 63.9, and 14.8
ng/g for 1, 2, and 4 weeks, respectively (Fig 2.37). On the other hand, in humanized and
B6 control mice, M1DRV levels in liver at 3 weeks ranged between 78.6 to 142.9 ng/g
reflecting the significance of different mice models (Fig 2.40). The remaining tissues,
spleen and lymph nodes, showed significantly higher M1DRV levels in all groups without
a significant RTV effect (Fig 2.40). In hCYP3A-NOG mouse model, RTV-boosted
NM1DRV and NM2DRV are tested similarly to the experimental design for the tADMET.
The mice showed RTV-enhanced plasma DRV levels cleaving from both groups,
NM1DRV and NM2DRV, only at day 1 post injection (Fig. 2.41) (^^^^P < 0.0001 and **P
= 0.0028) however the raw numbers of DRV cleaving from the boosted prodrugs were
higher than the unboosted ones. In this mouse model also, blood prodrug levels were
dramatically high in all groups, boosted and unboosted (Fig 2.41). Similarly, high prodrug
levels were detected in the livers, spleens, and lymph nodes of these mice (Fig 2.42) for
both with higher prodrug levels from NM2DRV as seen in BALB/cJ PK. Notably, in
animal models, tADMET and hCYP3A-NOG, DRV levels were detected for the first time
in the spleens of the mice (Fig 2.40 and 2.42). This is significant because in normal

61
BALB/cJ, DRV was only detected in the livers. From this study we can conclude that
boosting by RTV may have an effect with these modified DRV drugs however, further
studies are necessary to confirm such an observation.

Pharmacodynamics of NM1DRV and NM2DRV
Initial screening to assess prevention and efficacy of the prodrug nanoformulations in a
PrEP study using CD34+ HSC humanized mice failed to show protection against the
virus. Plasma viral loads (Fig 2.43) showed viral breakthrough in all treatment groups a
week after infection/two weeks after treatment. In addition, HIV-1 gag RNA and DNA
levels in the collected spleens measured by RT-PCR further confirming infection in all
groups (Fig 2.43).

Pharmacokinetics of NM1DRV and NM2DRV
Since the daily dose of DRV for humans is 600 mg twice or 800 mg once boosted with a
pharmacokinetic enhancer, PK was repeated in BALB/cJ mice using a higher dose 100
mg/kg DRV equivalents which corresponds to 488 mg in human dose to assess if higher
DRV cleaving from prodrugs could be detected in tissues88, 89. Specifically, mice were
administered a single intramuscular injection of NDRV, NM1DRV, or NM2DRV at 100
mg/kg DRV equivalents. M1DRV and M2DRV nanoformulations provided high and
sustained prodrug concentrations in plasma. M1DRV concentrations in plasma were
1297.7 ng/mL at day 1 and declined to 5.6 ng/mL at day 14. Plasma DRV levels cleaving
from NM1DRV treatment was significantly higher than that of NM2DRV and NDRV (****P
< 0.0001 and *P = 0.0438) at 1 and 2 weeks post injections (Fig 2.44). Plasma M2DRV
concentrations at day 28 were 252.4 ng/mL (Fig 2.44). Similarly, M1DRV concentrations
in blood were 826 ng/mL at day 1 and declined to 5.3 ng/mL at day 28. M2DRV blood
concentrations were 2890.2 ng/mL at day 1 and declined to 120.1 ng/mL by day 28 (Fig
2.44). Prodrug levels from NM2DRV were significantly higher than those from NM1DRV
in the blood of these mice one-day as well as one-week post injection (<<<<P < 0.0001
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and <<P = 0.0085). At day 28, levels of DRV generated from hydrolysis of M1DRV and
M2DRV in plasma were 2.2 and 8.4 ng/mL, respectively. In contrast, DRV levels after
NDRV treatment fell below the limit of quantitation within a day (Fig 2.44). Notably,
spleen (8216.5 ng/g ± 1745.2), liver (1516.8 ng/g ± 217.2), lymph nodes (26848.7 ng/g ±
15689.5) (^^P = 0.0074 higher levels of prodrugs from NM2DRV compared to NM1DRV
in lymph nodes), and brain (12.2 ng/g ± 3.5) exhibited high prodrug concentrations at
day 28 (Fig 2.46) after NM2DRV treatment while NM1DRV displayed prodrug
concentrations of 55.9 ng/g ± 11.7, 11.1 ng/g ± 2.3 and 42.7 ng/g ± 6.7 in the spleen,
liver and lymph nodes, respectively, with detectable DRV levels at day 28. At the end of
four weeks post injections, DRV levels cleaving from NM2DRV in lymph nodes and
spleens were significantly higher than those detected from NM1DRV and NDRV
treatments (****P < .0001 and *P = 0.0237). In contrast, NDRV treatment displayed low
drug levels in tissues at early and late time points whether with the low (50 mg/kg) or
high (100 mg/kg) doses (Fig 2.37 and 2.45). High prodrug levels in tissues compared to
plasma are suggestive of tissue drug depots for controlled and sustained release into
blood and other restricted sites of infection.

Discussion
Antiretroviral therapy has revolutionized HIV-1 treatment and enabled millions of patients
to lead a normal life. These regimens however require strict adherence in order to
remain effective and adequately suppress viral loads. Daily dosages of ART cause
adverse drug reactions that may yield poor outcomes such as associated anemia,
lipodystrophy, skin rashes, bone homeostasis impairment and reduction of bone mineral
density, toxicities to liver, heart, and skeletal muscle among others128-130. In addition, a
plethora of other factors like stigma, depression, bipolar spectrum disorder,
posttraumatic stress disorder and substance abuse, common between HIV-1 patients,
can negatively and significantly affect adherence131, 132. These may lead to avoidance of
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the prescribed daily regimens giving rise to emergence of drug resistance mutations133.
Moreover, many HIV-1 patients suffer co-infections of associated opportunistic infections
like herpes zoster, herpes simplex, hepatitis B/C viruses, tuberculosis and toxoplasma
further increasing the risk of drug-drug interactions and their associated side effects
135

134,

. All these factors ultimately lead to patterns of non-adherence to the oral regimens as

evident in the frequency of missed doses

136

. Therefore a paradigm shift towards long-

acting injectable ART formulations and delivery devices are being explored to lower
organ-specific and systemic toxicities and potentially improve the lifestyle of patients by
lessening the burden of pill fatigue. Hence improving on the current ART therapy
available for HIV-1 patients becomes a critical matter to study 158.
LA formulations could potentially have a significant impact on HIV treatment and
prevention strategies

84, 140, 142

. In a survey of 400 HIV-1 individuals, 73% expressed their

interest in long-acting injectable therapy

141

. Despite ongoing efforts and documented

benefits from long-acting agents in other chronic disease conditions, only two long-acting
ARV nanosuspensions containing water insoluble rilpivirine (RPV LA) and cabotegravir
(CAB LA) have successfully progressed into clinical trials76, 159-162. It is worth noting that
the design and selection of an agent for a LA injectable formulation requires compounds
with high potency and appropriate physicochemical features since there are limitations
for the volume that can be administered in a single injection

163

. Both CAB and RPV are

hydrophobic and potent compounds that require doses of less than 100 mg/day, making
them suitable candidates for extended release aqueous nanosuspensions. However,
these injectables are confounded by high injection volumes, injection site reactions and
limited access of native drugs to cellular and tissue reservoirs of infection74,

75, 164

.

Protease inhibitors are infamous for their short half-life, low plasma levels, poor cell
penetration, and low oral bioavailability120, 121. Chronic administration of PIs may lead to
complications such as hyperlipidemia, insulin resistance, and bone density loss121. Since
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darunavir and most protease inhibitors are hydrophobic, attempts have been made to
enhance drug targeting and metabolic stability through nanoformulation of parent
compounds106, 165. However, native drug formulations exhibited limited improvement in
drug biodistribution and PK parameters. Darunavir was also found to be incompatible
lipid-based nanoparticles due to poor formulation stability 166.
Others have explored prodrug strategies to improve ADME properties of PIs

121-124

. Such

attempts have either resulted in a marked loss of antiviral activity or exhibited
comparable half-lives to that of parent drugs

120, 126, 127

. Thus, the realization of long-

acting delivery systems for PI has remained elusive for decades. Our laboratory has
previously demonstrated extension of apparent half-lives of hydrophilic and hydrophobic
ARVs through synthesis and creation of lipophilic antiretroviral prodrug nanocrystals
coined as LASER ART77, 79, 80, 86. LASER ART enabled slow release and activation of
prodrugs within cellular and tissue reservoirs of infection after parenteral administration
75, 78

. We therefore sought to transform DRV into LASER ART nanocrystals. We

reasoned that conversion of DRV into prodrugs was not only feasible and economical
but also a much faster strategy for overcoming ADME and formulation challenges
associated with the parent drug. We herein describe the development of two long-acting
DRV prodrug formulations with extended in vitro antiretroviral activities and improved
drug half-lives.
To transform DRV into a LASER DRV, we successfully synthesized two hydrophobic
and lipophilic prodrugs M1DRV and M2DRV. M1DRV was synthesized through
conjugation of DRV with a tetradecanoade iodomethyl linker through a hemiaminal bond
on the amine of the aniline ring. To our knowledge, this modification has not been
explored for protease inhibitors. The second prodrug, M2DRV followed an ester
modification to the internal hydroxyl group of the drug by the conjugation of a stearoyl
chloride after the protection of the amine to avoid side product. Both of the resulting
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modifications increased the hydrophobicity of the drug by approximately 700-fold as
evident by the decreased aqueous solubility of the prodrugs compared to the parent
drug. In mice plasma, hydrolysis half-life for both drugs were < 20 hours. After
characterization, the prodrugs were developed into stable poloxamer stabilized
nanosuspensions of the prodrugs using high pressure homogenization, top down
technologies used in all of our LASER ART nanocrystal preparations as well as in other
pharmaceutical LA injectable products

75, 160, 162, 167

. Nanoformulating the prodrugs with

amphiphilic P407 stabilized and prevented particles’ aggregation

77

. Nanofromulations

offer a suitable vehicle for poorly water-soluble drugs and making them accessible to
their targets. The hydrophobic prodrugs interact with the hydrophobic polymer core
yielding a homogenous stable polymer coated nanocrystals; NM1DRV and NM2DRV.
Treatment with prodrugs’ nanofromulations yielded lower EC50 values when compared to
free drugs highlighting the importance of nanoformulations in case of highly hydrophobic
drugs. These efficacy studies confirmed the prodrugs maintained an inhibitory effect
against the virus. The amine modified ester prodrug formulation of DRV (NM1DRV)
demonstrated comparable EC50 to native DRV in human MDM and CEM-SS CD4+ T
cells. This is notable since previous studies with ester prodrugs of PIs in similar cell lines
demonstrated diminished potency when compared to native drugs. However,
modification of the hydroxyl functional group in DRV to form NM2DRV nanocrystals
resulted in a 10-fold loss in potency. Nevertheless, EC50 of NM2DRV against HIV-1 in
MDM and CEM-SS CD4+ T cells was in the nanomolar range and exhibited long-term
efficacy when compared to native drug or M1DRV nanoformulations. The observed
antiviral activity for NM1DRV and NM2DRV formulations is likely linked to improved
cellular drug uptake. However, unlike M1DRV that hydrolyses back to DRV, M2DRV was
found to be hydrolytically stable, suggesting that the prodrug is predominantly
responsible for efficacy. Prodrugs are generally pharmacologically inactive compounds
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that require enzymatic or chemical hydrolysis to produce the corresponding active parent
drugs

83, 168, 169

. The observed efficacy data sets for NM2DRV were surprising in the

context of previous studies that demonstrated an almost complete loss in antiviral
activity when the secondary hydroxyl group in PIs was irreversibly blocked from
interacting with the catalytic site of HIV protease

127

. Therefore, future studies will be

required to elucidate association of M2DRV with the viral enzyme. Development of longacting stable DRV prodrug nanoformulations could potentially lead to infrequent drug
administration and improve drug cell penetrance and tissue biodistribution.
Ideal LA ARV formulations should be potent, safe, scalable, and stable to deliver
therapeutic concentrations of active agents at infection sites. Given HIV-1 has been
shown to infect and replicate in macrophages and CD4+ T cells

170-172

, optimal drug

delivery strategies should target ART to these cell subsets and other tissue reservoirs of
infection where conventional therapies and parent drug formulations have limited access
172

. We have previously shown that macrophages can serve as drug depots

173, 174

and

play a pivotal role in nanoparticle trafficking and dissemination to CD4+ T cells and
tissues

78, 154, 175, 176

. We have also shown that macrophage targeting prolongs drug half-

life to improve efficacy and pharmacokinetic profiles

75, 78

. NM1DRV and NM2DRV were

rapidly taken up by MDM and CD4+ T cells compared to NDRV. Of significance, the
presence of high intracellular prodrug concentrations had no negative effect on cell
viability. It has previously been demonstrated that the presence of therapeutic drug
concentrations in plasma after administration of native ART formulations does not reflect
cellular and tissue levels presumably due to limited drug access to restricted sites of viral
growth

75, 78

. The previous data sets suggest that transformation of DRV into lipophilic

prodrugs could enable creation of long-acting and slow-release formulation with
improved cell-permeation profiles. Consequently, these prodrug nanoformulations were
retained in macrophages for 2 weeks and a month for NM1DRV and NM2DRV,
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respectively. The prodrug formulations exhibited superior antiretroviral activity compared
to native drug formulation. Notably, viral inhibition paralleled cell retention studies. Viral
inhibition was maintained for up to 15 and 30 days after treatment with NM1DRV and
NM2DRV, respectively, compared to only 5 days with NDRV. The antiviral activity
exerted by NM1DRV and NM2DRV is likely linked to improved cellular drug uptake as
evident from the uptake, retention and release studies. The ability of NM2DRV to protect
MDM from HIV-1 infection for extended periods of time is a significant step towards
transforming DRV into long-acting cell targeted formulations that could be used in
combination with other long-acting ART for HIV-1 treatment.
Previous attempts to further improve on the first DRV prodrugs yielded into M3DRV and
M4DRV. M3DRV was modified on the internal hydroxyl group through an ester bond
similar to M2DRV however the main difference was a succinic linker between the drug
and a 14-carbon fatty acid chain (Figure 2.47). The purpose of this was to tackle the
problem faced with M2DRV slow hydrolysis inside cells and its low potency compared to
DRV. The linker connects to the drug through an ester bond and itself contain another
ester bond to the fatty acid, which we posited would speed the hydrolysis back to the
parent drug. As expected, Ec50 values of the new prodrug in MDM showed
enhancements over NM2DRV values; 172.4 nM for M3DRV compared to 260 nM for
NM2DRV (Fig 2.48). In CEM CD4+ T cells, NM3DRV (14.4 nM) showed better yet
comparable EC50 values to NM2DRV (18.7 nM) (Fig 2.49). EC50 studies for both M2DRV
and M3DRV confirmed the importance of nanoformulating highly hydrophobic prodrugs
to make them more soluble accessible to the cells. Uptake and retention studies of
NM3DRV in MDM showed comparable uptake and retention levels to NM1DRV and
NM2DRV with retention closely resembling NM2DRV until day 30 after one-time
treatment (100 µM) on day 0 (Fig 2.50 and 2.51). However, similar to M2DRV, M3DRV
nanoformulation treatment in cells showed minimal to no hydrolysis; DRV was not being
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cleaved from the prodrug (Fig 2.50 and 2.51). In retention studies, DRV cleaving from
NM3DRV remained below 0.2 ug/million cells until day 15 and remained undetectable
until the end of the study at day 30 (2.46) (Fig 2.51). Uptake in CEM CD4+ T cells
showed lower uptake for M3DRV from NM3DRV treatment when compared to prodrugs’
concentrations detected from NM1DRV and NM2DRV over a 24hr uptake (Fig 2.52).
Antiretroviral activities of NM3DRV in infected MDMs failed to show a long sustained
protection up to 30 days as in the case of NM2DRV. Viral breakthrough could be seen at
day 20 (Fig 2.53). However the study will be confirmed in another study where NM1DRV
and NM2DRV will be included to further confirm the results and to rule out contamination
since the control group seemed to show viral breakthrough by day 30. Even though,
NM3DRV showed promising results in in vitro characterization, it performed poorly in PK
studies in BALB/cJ mice where DRV cleaving from the prodrug was lower than 14 ng/mL
at all time points in plasma (Fig 2.54). Plasma drug levels were gradually decreased
starting from 13.8 ng/mL at the first time point where we usually see a burst release of
DRV cleaving from the previous prodrugs; NM1DRV and NM2DRV. In tissues, DRV
cleaving from NM3DRV resembled NDRV treatments and was only detected in lymph
nodes with concentrations of 3.5 ng/g (data not shown). Therefore NM3DRV was not
used in further studies. M4DRV resembled a similar modification as M1DRV where the
aniline’s amine was derivatized (Fig 2.55). The amine was modified through a carbamate
bond with a 14-carbon fatty acid chain with a phenyl linker in attempts to make the drug
stay longer in circulation and cleave in higher concentrations however because of the
stability of the carbamate modifications, PK results were poor and showed significant low
plasma DRV concentrations for all time points; 7.4, 2.2, 1.4 and 0 for 1, 3, 7 and 14 days
(Fig 2.56). Therefore in vitro and in vivo characterization of NM1DRV and NM2DRV
shows more promising grounds for these drugs to be moved into future studies and used
as controls for future DRV prodrugs.
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Finally, NM1DRV and NM2DRV exhibited superior PK profiles in BALB/c mice over
NDRV, which was reflected in higher DRV and prodrug levels in plasma and blood of
treated mice as well as significantly high drug biodistribution in tissues. NDRV treated
mice showed no detectable DRV levels in plasma or blood beyond a day. Plasma DRV
levels cleaving from both NM1DRV and NM2DRV were detected until day 28 of the PK
after intramuscular injection on day 0. Moreover, M2DRV was detected in the brain
tissues at day 28 which is significant because protease inhibitors have limited to no
access through the blood brain barrier and show poor brain penetration preventing
protease inhibitors from accessing major viral sanctuary sites

121, 127

. High prodrug levels

in blood and tissue reflect the formation of drug depots in these mice achieving a longacting DRV. Moreover PK studies using the CYP3A humanized mice to assess the effect
of RTV boost revealed there is no major effect on plasma DRV levels except in the first
time point. Moreover, RTV boosting effect was not seen in DRV concentrations in
tissues however M2DRV levels in liver and spleens showed significant increases when
boosted. Previous study in our laboratory utilized the hCYP3A-NOG mouse model to
look at the RTV boosting effect with NDRV (50 mg/kg DRV-equivalents) (data
unpublished). Similarly, the study revealed that RTV showed improvement only on day 1
after injection, however DRV drug levels were entirely undetectable by day 3 for all
groups; for male and female mice (data not shown). DRV levels from NDRV followed
similar patterns seeing in the mentioned BALB/cJ PK studies where highest
concentrations are found in day 1 and rapidly drop to undetectable limits by the first
week. In a different study using the same hCYP3A-NOG model to study the CYP3Amediated ATV metabolism, RTV was found to enhance plasma and tissue ATV
concentrations by 2.7-fold in the humanized CYP3A model as compared to only a 1.9fold increase in the control background mouse model highlighting the importance of
using the right mouse model to study protease inhibitors as well as the effect of a boost

70
153

. Collectively these studies failed to see RTV boost with either parent drug

nanoformulation or prodrug nanoformulation. This could point to the use of unsuitable
mouse model for these studies. On the other hand, these studies could also be
confirmatory of the significance of the different modifications to DRV, which could
eventually reverse the need for a pharmacokinetic enhancer lessening the pill burden on
HIV-1 patients.
NM1DRV and NM2DRV failed to inhibit viral infection in infected mice in the PrEP study.
This could be explained in terms of the low dose (50 mg/kg) where 160 mg/kg would
more closely resemble the human dose for DRV in mice. Moreover, protease inhibitors
are not favorable in pre-exposure prophylaxis regimens due to the nature of the drug
where it is critical job lies in inhibiting chronic infection post virus integration177. Drugs
used in PrEP are usually NRTIs (such as TDF, 3TC, or FTC) as well as integrase
inhibitors because of their ability to prevent viral integration into host genome177,

178

.

Future studies will investigate the antiretroviral efficacy of these prodrugs in infected
animals in post exposure studies in combination with other integrase inhibitors and/or
nucleoside reverse transcriptase inhibitors. Overall, M1DRV and M2DRV show great
potential for long-acting protease inhibitors. Further modifications utilizing different fatty
acid chains and spacers might yield a prodrug with further superior PK profiles to
ultimately achieve a monthly or bimonthly long-acting DRV for treatment-experienced
patient.

Conclusions and future directions
In summary, hydrophobic DRV prodrugs, M1DRV and M2DRV were synthesized by
modification of the aniline’s amine and the hydroxyl group, respectively. The prodrugs
were successfully characterized. NM2DRV (130 ng/mL) was found to be significantly
more hydrophobic than NM1DRV (212 ng/mL). The drugs were nanoformulated and
characterized in vitro. EC50 studies confirmed that both drugs maintained antiretroviral
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activities against the virus, however only M1DRV showed comparable potency to DRV
whereas M2DRV showed a decrease in potency by more than 10-fold. Viability studies
confirmed that drug concentrations ranging from 50-400 µM were not toxic and did not
reflect a decrease in cells’ viability (macrophages and T cells). Uptake studies in both
macrophages and T cells showed a high uptake of prodrugs over 24 hours uptake with
DRV detected from NM1DRV treatment. Moreover, retention studies in macrophages
showed that M1DRV is retained for 15 days whereas M2DRV is retained for 30 days
after a one-time loading treatment of 100 µM for both prodrug nanoformulations. Longterm antiretroviral activities mirrored the retention studies where viral inhibition was
maintained for days 15 and 30 for NM1DRV and NM2DRV, respectively, as confirmed
by RT assay and P24 staining. NDRV (nanoformulated DRV) showed complete viral
inhibition protection on day 1, however viral breakthrough was detected by day 5. Even
though NM2DRV showed a decrease in potency, it reflected the longest protection
against the virus and this is because of the higher retention of the M2DRV inside the
macrophages compared to M1DRV.
Based on the current pharmacokinetics (PK) of NM1DRV and NM2DRV, it’s concluded
that both prodrugs cleave in plasma and distribute highly in blood and tissues. From the
studies, it is clear that NM1DRV cleaves faster as seen at earlier time points in plasma
DRV concentrations as well as the DRV levels in livers at day 7 which were highest
compared to all other time points and the different treatments injected. Once
intramuscular dose of NM1DRV (50 mg/kg DRV equivalents) is equivalent to around 244
mg DRV/day for a human dose. DRV plasma levels cleaving from NM1DRV seems to
remain above the EC50 (55 ng/mL) of the drug for a week. This is paralleled with the
highest DRV concentrations found in livers from the NM1DRV treatment compared to
consistently low DRV cleaving from NM2DRV at all time points in tissues. It is therefore
concluded that NM2DRV cleaves at a slower rate than NM1DRV based on the low
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plasma DRV levels detected over 28 days as well as low DRV levels cleaving from
NM2DRV in the different tissues; liver, spleen, and lymph nodes. However, a much
bigger prodrug depot is found in the plasma, blood, and tissues of mice treated with
NM2DRV compared to mice treated with NM1DRV on day 28 which further confirms the
faster hydrolysis rate of NM1DRV in plasma and tissues. Notably, M2DRV was detected
in the brains of the mice in the higher dose PK (once IM dose of 100 mg/kg DRV
equivalents). This could be due to the higher lipophilicity of M2DRV leading to increased
permeability through the blood brain barrier and distribution in the brains.
Futures studies on NM1DRV include a dose-finding PK in mice or rats to find the
appropriate dose for a long-acting effect. Because of the high dosing of DRV (twice a
day 600 mg or once 800 mg) PK is needed to determine the right dose to explore the
long-acting aspects of the drug as well as its antiviral efficacy in vivo. A human dose 800
mg/day is converted to 160 mg/kg DRV equivalents mouse dose, based on allometric
scaling that depends on the body surface area. However, a dose of 160 mg/kg is
considered small because it only counts for once-daily dose hence to convert to an initial
long-acting dose it may be multiplied by a factor of 5 yielding into 800 mg/kg, based on
previous studies in our laboratory on long acting DTG, CAB or RPV75, 78. We will perform
dose-finding PK study in rats since they have a bigger muscle mass, which may allow for
a slow dissolution of the drug from the injection site leading to a long-acting effect for
NM1DRV. Ultimately our goal is to find the right dose and appropriate animal model to
achieve DRV plasma IC90 levels (200 ng/mL). When the correct dose is determined and
the PK profile is determined, a post-exposure prophylaxis (PEP) pharmacodynamics
(PD) will be conducted to determine the in vivo antiviral efficacy of NM1DRV in infected
animals. NM1DRV will be injected soon after infection is confirmed in NSG (NOD/scidIL-2Rγcnull) mice-reconstituted with CD34+ human hematopoietic stem cells. Viral loads
will be determined based on the PK profile timing where DRV levels cleaving from
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NM1DRV are above IC90 of the drug. For NM2DRV, PK design may be different to
accommodate the slow hydrolysis of the drug as well as the high biodistribution in the
different tissues as well as plasma and blood. We may also switch to rats as a rodent
model because of their bigger muscle mass for injections. Initially, we will perform a long
term PK (2-3 months long) to determine the hydrolysis rate of NM2DRV at different time
points for plasma as well as in the different tissues. Finding out when the drug depots
start cleaving back into DRV will be essential for future PEP PD studies. Once the long
term PK profile for NM2DRV is determined we may perform a different PK administering
multiple/repeating doses of NM2DRV to determine how many doses of NM2DRV are
needed to build up and achieve the IC90 and IC50 of DRV. We may also include
NM1DRV as a control in the repeating-doses PK to highlight the importance of the
experimental design with the different prodrugs. When the right PK design is figured out
for both DRV prodrug nanoformulations, parallel PK studies in hCYP3A/NOG mice and
control NOGs will be performed to test the significance of a pharmacokinetic booster
(ritonavir) when administered with NM1DRV and NM2DRV. This experiment will also
highlight the difference, if any, in DRV metabolism rate in the case of mouse CYP3A or
human CYP3A.
To further explore and develop LA DRVs, future prodrug strategies will include the
synthesis of less stable drugs that can be cleaved faster by esterases in vivo. Future
DRV prodrugs syntheses will include different linkers between the fatty acid and DRV to
aid in propelling the fatty acid away. In the case of M2DRV, the long fatty acid chain was
conjugated to the internal hydroxyl group, which may have caused folding of the drug in
a way where the ester bond is concealed avoiding activation by esterases. To overcome
this in future studies, bulky groups containing phenyl linkers between the fatty acid chain
and the drug such as aminoacyl phosphorocholoridates linkers may be utilized. When
using aminoacyl phosphorocholoridates linkers we can avoid the solubility increase for
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future DRV prodrugs by the conjugation of long-chain fatty acids and shielding the polar
groups on the phosphates like in the case of NRTI ProTides86 from our laboratory.
Moreover, since M2DRV does not cleave fast enough, we can attempt the conjugation of
considerably short linkers/fatty acid chains on the hydroxyl functional group in hopes of
speeding up activation by esterases since with the long fatty acid chain, the molecule
was most likely too hindered and inaccessible for activation. Additionally, future
modifications would target the aniline’s amine since previous modification, M1DRV,
showed comparable EC50 values to DRV. Therefore further modifications to the same
group may guarantee the maintenance of potency. Since M1DRV seems to be cleaving
faster than M2DRV we will attempt the conjugation of longer fatty acid chains (C18 or
C22) to slow the prodrug hydrolysis while guaranteeing that the bond is accessible by
esterases. Furthermore, future perspectives will include the implementation of the
GO/NO GO guidelines from our laboratory. These entail that based on prodrug
characterizations and their corresponding in vitro characterization; we can determine
whether more time and efforts should be invested into the newly synthesized prodrug.
These guidelines will be based on significant values and cutoff values from the different
studies’ results. These studies include but are not limited to prodrug’s solubility, LogP,
stability in different pH, hydrolysis in plasma, potency, cytotoxicity, and uptake.
In summary, amine and alcohol ester lipophilic prodrugs of darunavir were successfully
synthesized

and

stabilized

into

long-acting

slow

effective

release

aqueous

nanosuspensions. NM2DRV was found to exhibit enhanced intracellular prodrug levels
with sustained retention and efficacy. Pharmacokinetics tests of NM1DRV and NM2DRV
administered in mice demonstrated sustained drug levels in blood and tissues with
higher concentrations of the prodrugs observed over 28 days. These data, taken
together, support the idea that tissue and cell targeted lipophilic prodrugs could facilitate
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transformation of DRV into long-acting sustained release formulations with improved
antiretroviral activities.

Figures

Figure 2. 1 Modification of DRV advantage
Modification of DRV into hydrophobic lipophilic prodrugs MDRV enhances the uptake of
the modified drugs and their retention profiles. The modification’s effect is seen in the
antiretroviral efficacy of the prodrugs. The prodrugs nanoformulation is capable of viral
inhibition up to 30 days post treatment. Nanoformulated DRV (NDRV) passes through the
cells’ membrane however it seems to be soon effluxed based on the very low uptake
concentrations after treatment with equivalent concentrations. Modified DRV drugs can
lead to the creation of long-acting darunavir nanoformulation for clinical settings.
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Figure 2. 2 M1DRV synthesis scheme
Myristoyl chloride is first used to synthesize iodomethyl tetradecanoate linker used for direct
conjugation on DRV in the presence of sodium hydride and THF to yield M1DRV, an amine
modified DRV through a hemiaminal bond.
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Figure 2. 3 M2DRV synthesis scheme
DRV (1) is first reacting with benzyl chloroformate in a Cbz protection to shield the amine group,
Cbz-DRV (2) and prevent side products while modifying the hydroxyl group of DRV. (2) is
conjugated to 18-carbon fatty acid (stearoyl chloride) to yield Cbz-M2DRV (3). Cbz-M2DRV is
subjected to catalytic hydrogenolysis using palladium on activated carbon and Et3SiH to deprotect
the amine of the aniline yielding the final product; M2DRV.
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1

Figure 2. 4 H NMR Characterization of M1DRV
1

H NMR spectrum reflects the additional terminal methyl (0.9 ppm) and methylene (1.26 ppm)
protons of the fatty esters.
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Figure 2. 5
13

13

C NMR Characterization of M2DRV

C NMR spectrum shows the addition of carbon peaks corresponding to the carbonyl groups at
173 ppm and aliphatic carbon atoms from the fatty acids where the methyl carbon is at 14.1 ppm
and the methylene carbons at 29.3 ppm.
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1

Figure 2. 6 H NMR Characterization of M2DRV
1

H NMR spectrum reflects the additional terminal methyl (0.9 ppm) and methylene (1.26 ppm)
protons of the fatty esters.
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Figure 2. 7
13

13

C NMR Characterization of M2DRV

C NMR spectrum shows the addition of carbon peaks corresponding to the carbonyl groups at
173 ppm and aliphatic carbon atoms from the fatty acids where the methyl carbon is at 14.1 ppm
and the methylene carbons at 29.3 ppm.
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Figure 2. 8 FTIR characterization of M1DRV
-1

Absorption bands at 2917, 2915 and 2848 cm represent asymmetric and symmetric C-H
stretches in the long chain fatty acids.

Transmittance (%T)

120

M2DRV

80

40

4000

DRV
M2DRV
Stearoyl chloride

3500

3000

2500

2000

1500

Wavenumber (cm-1)

Figure 2. 9 FTIR characterization of M2DRV
-1

Absorption bands at 2917, 2915 and 2848 cm represent asymmetric and symmetric C-H
stretches in the long chain fatty acids.
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Figure 2. 10 Characterization of M1DRV
Infusion into a Waters Xevo TQ-S micro mass spectrometer confirmed the desired molecular ion
peaks at 811.05 [M+Na+].
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Figure 2. 11 Characterization of M2DRV
Infusion into a Waters Xevo TQ-S micro mass spectrometer confirmed the desired molecular ion
peaks at 837.14 [M+Na+].
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Figure 2. 12 DRV modifications
DRV was modified on the aniline amine group to yield M1DRV – a modification that was rarely
explored for PIs. In addition, DRV was modified using the internal hydroxyl group – that has
previously been modified in other protease inhibitors to improve ADME profiles.

Figure 2. 13 Prodrugs’ aqueous hydrophobicity
Aqueous solubility demonstrated enhancement in prodrug hydrophobicity (****P<0.0001 for DRV
compared to M1DRV or M2DRV, *P=0.0258 for M1DRV vs. M2DRV.
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Figure 2. 14 M1DRV stability in different pH
The drug was chemically stable at pH 7 at different temperatures. Prodrugs’ stability was
evaluated in different pH; 1, 7 and 11. Stocks of M1DRV with concentrations of 1-2 mg/mL were
prepared in MeOH. For stability in acidic pH (pH 1) the drugs were incubated separately in a
solution of pH adjusted .1 M HCl. Similarly, drugs were incubated in pH adjusted .1 NaOH (pH
11) to test stability in basic environments. Finally, incubation in water (pH 7) determined stability
in neutral pH. Triplicate samples of both prodrugs were kept on a shaker either at room
temperature (25°C) or incubated at 37°C. Aliquots were collected from the samples at different
time points; 8, 24, 72, 120, 168, and 336 hours. Samples were dried under vacuum and
quantified by HPLC. The prodrugs were formulated using PBS.
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Figure 2. 15 M2DRV stability in different pH
The drug was mostly chemically stable at pH 7 as well as pH 1 at the different temperatures.
Prodrugs’ stability was evaluated in different pH; 1, 7 and 11. Stocks of M2DRV with
concentrations of 1-2 mg/mL were prepared in MeOH. For stability in acidic pH (pH 1) the drugs
were incubated separately in a solution of pH adjusted .1 M HCl. Similarly, drugs were incubated
in pH adjusted .1 NaOH (pH 11) to test stability in basic environments. Finally, incubation in water
(pH 7) determined stability in neutral pH. Triplicate samples of both prodrugs were kept on a
shaker either at room temperature (25°C) or incubated at 37°C. Aliquots were collected from the
samples at different time points; 8, 24, 72, 120, 168, and 336 hours. Samples were dried under
vacuum and quantified by HPLC. The prodrugs were formulated using PBS.
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Figure 2. 16 M1DRV and M2DRV hydrolysis in mice plasma
Hydrolysis of M1DRV and M2DRV in plasma over 48 hours at 37°C demonstrating enzymatic
degradation of the prodrugs over time. To evaluate plasma stability of M1DRV and M2DRV, 100
µL plasma samples from mouse were spiked with 1 µM M1DRV or M2DRV. Triplicate samples
were kept on a shaker at 37°C. At various time points (0, 2, 6, 24, and 48), 1 mL of MeOH was
added to each tube and vortexed for 3 minutes to stop enzymatic cleavage, then stored at -80°C
until drug quantitation. Negative controls were used to normalize for non-specific binding. 100 µL
ice cold plasma was added to 1mL MeOH followed by addition of the prodrugs. At various time
points, 1mL MeOH was added to the samples and drug was quantified by HPLC. Incubation of
the prodrugs in plasma resulted in a decline in prodrug concentrations by more than 45 % over 24
h. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 17 M1DRV and M2DRV hydrolysis in rat plasma
Hydrolysis of M1DRV and M2DRV in plasma over 48 hours at 37°C demonstrating enzymatic
degradation of the prodrugs over time. To evaluate plasma stability of M1DRV and M2DRV, 100
µL plasma samples from rat were spiked with 1 µM M1DRV or M2DRV. Triplicate samples were
kept on a shaker at 37°C. At various time points (0, 2, 6, 24, and 48), 1 mL of MeOH was added
to each tube and vortexed for 3 minutes to stop enzymatic cleavage, then stored at -80°C until
drug quantitation. Negative controls were used to normalize for non-specific binding. 100 µL ice
cold plasma was added to 1mL MeOH followed by addition of the prodrugs. At various time
points, 1mL MeOH was added to the samples and drug was quantified by HPLC. Incubation of
the prodrugs in plasma resulted in a decline in prodrug concentrations by more than 45 % over 24
h. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 18 M1DRV and M2DRV hydrolysis in heat inactivated rat plasma
The prodrugs are fairly stable in heat-inactivated plasma confirming their hydrolysis through
enzymatic activity. Negative controls were prepared using heat-inactivated plasma to determine
whether drug hydrolysis was due to enzymatic activity or non-enzymatic hydrolysis. 100 µL
plasma samples from rat were spiked with 1 µM M1DRV or M2DRV. Triplicate samples were kept
on a shaker at 37°C. At various time points (0, 2, 6, 24, and 48), 1 mL of MeOH was added to
each tube and vortexed for 3 minutes, then stored at -80°C until drug quantitation. Negative
controls were used to normalize for non-specific binding. 100 µL ice cold plasma was added to
1mL MeOH followed by addition of the prodrugs. At various time points, 1mL MeOH was added to
the samples and drug was quantified by HPLC.
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Figure 2. 19 NDRV stability
DRV nanoformulation (NDRV) stability measurements were observed over 13 weeks at
different temperatures. Stability with monitored using dynamic light scattering (DLS).
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Figure 2. 20 NM1DRV stability
M1DRV nanoformulation (NM1DRV) stability measurements were observed over 13 weeks
at different temperatures. Stability with monitored using dynamic light scattering (DLS).
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Figure 2. 21 NM2DRV stability
M2DRV nanoformulation (NM2DRV) stability measurements were observed over 13 weeks
at different temperatures. Stability with monitored using dynamic light scattering (DLS).
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Figure 2. 22 NM1DRV stability (PK formulation)
NM1DRV stability measurements over 18 weeks from concentrated formulations used for
PK dosing. Diluted NM1DRV were concentrated using differential centrifugation. First the
nanoformulation was pelleted at 5,000 x g for 5 minutes. Then supernatant was transferred to a
new centrifuge tube and centrifuged at 20,000 x g for 20 minutes. Supernatant was discarded and
both pellets were suspended in a total of approximately 500 µL of PBS.
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Figure 2. 23 NM2DRV stability (PK formulation)
NM2DRV stability measurements over 18 weeks from concentrated formulations used for
PK dosing. Diluted NM2DRV were concentrated using differential centrifugation. First the
nanoformulation was pelleted at 5,000 x g for 5 minutes. Then supernatant was transferred to a
new centrifuge tube and centrifuged at 20,000 x g for 20 minutes. Supernatant was discarded and
both pellets were suspended in a total of approximately 500 µL of PBS.
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Figure 2. 24 Transmission electron microscopy of the formulations
NDRV and NM2DRV were rod-shaped, while NM1DRV exhibited globular morphologies. The
three formulations have diameters in the nanometer range. Nanoparticle morphologies were
analyzed by TEM using negative staining. Small volume (10 µL) of diluted nanoformulation (1
mg/mL) was applied on a formavar/silicone monoxide coated 200 mesh copper grid. Grid was left
2-5 minutes to absorb the nanoparticles. Excess sample was dried carefully using a clean filter
paper and allowed to dry for 2 minutes. Pipet a drop of Nanovan negative stain on the grid and
allow to stain for no longer than a minute while shielding the sample using a filter paper tent to
minimize any air contaminants. Blot excess stain and allow grid to dry before viewing under TEM.
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Figure 2. 25 Cytotoxicity of NDRV, NM1DRV and NM2DRV in MDM
Cytotoxicity of NDRV, NM1DRV and NM2DRV in MDM assayed by MTT. A stock solution of each
drug nanoformulation was serially diluted in DMEM to produce drug concentrations ranging from
50-400 µM. Cells were treated for 24 hours, washed and incubated with 200 µL/well 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL) for 45 minutes.
Upon MTT removal, 200 µL/well of DMSO was added and absorbance measured at 490 nm on a
SpectraMax M3 plate reader. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 26 Cytotoxicity of NDRV, NM1DRV and NM2DRV in CEM-SS CD+ T cells
Cytotoxicity of NDRV, NM1DRV and NM2DRV in CEM CD4+ T cells assayed by Live/Dead
Fixable Dead Cell Stain Kits. A stock solution of each drug nanoformulation was serially diluted in
RPMI media to produce drug concentrations ranging from 50-400 µM. After 24 hours, cells were
centrifuged at 650 x g, dispersed in PBS, centrifuged again at 650 x g, and resuspended in PBS.
Excitation dye (0.1 µL) (Molecular Probes, Live/Dead Fixable Green Dead Cell Stain Kits) was
added to each well. Cells were excited at 488nm and the percent dead cells determined by flow
cytometery. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 27 Antiviral activities against HIV-1 were determined in MDM
Antiviral activities against HIV-1 were determined in MDM. EC50 determination was performed
using non-nanoformulated (DRV, M1DRV, and M2DRV) and formulated (NDRV, NM1DRV,
NM2DRV) compounds. Drugs were diluted in media at concentrations ranging from 0.005 nM-50
µM in tenfold dilution increments and cells were treated with the different concentrations for 60
min and replaced with drug-containing HIV-1ADA media at a multiplicity of infection (MOI) of 0.1.
After 4 hours, infection medium was removed, and the cells were incubated an additional 10 days
in the presence of the same concentration of drug prior to infection. Half media changes were
done every other day. After 10 days of infection, culture media was collected for measures of
HIV-1 reverse transcriptase (RT) activity. Data are expressed as mean ± SEM for n=3 samples
per group.
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Figure 2. 28 Antiviral activities against HIV-1 were determined in CEM-SS CD4+ T cells
Antiviral activities against HIV-1 were determined in CEM CD4+ T cells. EC50 tests were
performed using non-nanoformulated (DRV, M1DRV, and M2DRV) and formulated (NDRV,
NM1DRV, NM2DRV) compounds. Drugs were diluted in media at concentrations ranging from
0.0005 nM-5 µM in tenfold dilution increments and cells were treated with the different
concentrations for 60 min and replaced with drug-containing HIV-1NL4-3-eGFP media at a multiplicity
of infection (MOI) of 0.1 by spin-inoculation followed by incubation for 2 hours. Cells were kept at
37°C in a 5% CO2 incubator for 12 hours, after which media containing drug and FBS was added.
Twenty-four hours post infection, all cells were washed twice with PBS to remove extracellular
virus and drug-containing media was replaced with medium containing the same drug
concentration prior to infection. Every other day, cells were centrifuged at 650 x g and
resuspended in fresh drug-containing medium. After 10 days of infection, culture media was
collected for measures of HIV-1 reverse transcriptase (RT) activity. Ten days post HIV-1
challenge; supernatants were collected for RT activity measurements. Antiretorviral activities
were further confirmed using flow. Data are expressed as mean ± SEM for n=3 samples per
group.
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Figure 2. 29 Uptake of NDRV, NM1DRV and NM2DRV in MDM
Uptake of NDRV, NM1DRV and NM2DRV. Drug uptake studies in MDM demonstrated high
intracellular drug levels for NM1DRV and NM2DRV treatments compared to undetectable levels
for NDRV. MDM were cultured on 12-well culture plates and treated with media containing 100µM
of NDRV, NM1DRV or NM2DRV. At 2, 4 and 8 hours post treatment, media was removed and
adherent cells were washed twice with PBS then scraped into 1mL PBS. Cells were counted and
pelleted by centrifugation at 956 x g for 8 minutes. The cell pellets were reconstituted and
sonicated in 100 µL methanol for 5 minutes followed by centrifugation at 20,817 x g for 5 min and
quantified using HPLC. Data are expressed as mean ± SEM for n=3 samples per group.
^^^^P<0.0001 for NDRV vs. NM1DRV, parent drug quantitation and ****P<0.0001 for NM1DRV
vs. NM2DRV, quantitation of prodrugs

nmol/million cells

98
100
80
60
40
20

ns ns

****

***

NDRV
NM1DRV [DRV]
NM2DRV [DRV]
NM1DRV [M1DRV]
NM2DRV [M2DRV]

0.5
0.0

^^^^
^^^^
0

^^^^

^^^^
6

12
hours

18

24

Figure 2. 30 Uptake of NDRV, NM1DRV and NM2DRV in CEM-SS CD4 T cells
Uptake of NDRV, NM1DRV and NM2DRV. Drug uptake studies in CEM-SS CD4+ T cells
demonstrated high intracellular drug levels for NM1DRV and NM2DRV treatments compared to
undetectable levels for NDRV. The cells were plated on to poly-L-lysine pre-coated cell culture
plates that make it possible for these cells to adhere. At 2, 4 and 8 hours post treatment, media
was removed and adherent cells were washed twice with PBS then scraped into 1mL PBS. Cells
were counted and pelleted by centrifugation at 956 x g for 8 minutes. The cell pellets were
reconstituted and sonicated in 100 µL methanol for 5 minutes followed by centrifugation at 20,817
x g for 5 min and quantified using HPLC. Data are expressed as mean ± SEM for n=3 samples
per group. ^^^^P<0.0001 for NDRV vs. NM1DRV, parent drug quantitation and ****P<0.0001,
***P=0.0007 for NM1DRV vs. NM2DRV, quantitation of prodrugs.
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Figure 2. 31 TEM image of MDM loaded with NDRV, NM1DRV, and NM2DRV.
Transmission electron microscopy (TEM) was used to image the morphology of MDM-loaded with
the different drug nanoparticles. Cells were loaded with the different nanoparticles for 4 hours
then washed twice with PBS. Cells were collected in PBS, centrifuged, fixed in 2%
paraformaldehyde (PFA) and kept at 4°C until TEM processing.

100

nmol/million cells

120

80

****

NM1DRV
****

40

0

****

0

5

10

NM2DRV

****

15 20
days

****

25

30

35

Figure 2. 32 Drug retention in MDM
NM1DRV and NM2DRV were retained in MDM for 14 and 31 days, respectively, while NDRV was
washed out within hours. For drug retention studies, MDM were treated for 8 hours then washed
with PBS and maintained with half-media changes every other day until collection days.
Intracellular and supernatant drug content were analyzed using HPLC. Data are expressed as
mean ± SEM for n=3 samples per group. ****P<0.0001 for NM1DRV vs. NM2DRV.
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Figure 2. 33 Drug release from MDM
Drug release from MDM after a single treatment with 100 µM of drug. NM1DRV and NM2DRV
exhibited sustained release of drug into culture media. Data are expressed as mean ± SEM for
n=3 samples per group.
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Figure 2. 34 Antiretroviral activity in MDM
Antiretroviral activities in MDM after a single treatment with 100 µM of drug determined by RT
assay. To assess long-term antiretroviral efficacy, MDM were treated for 8 hours with 100 µM
NDRV, NM1DRV or NM2DRV as previously described for uptake studies. After treatment, cells
were washed twice with PBS and cultured in fresh media without drug followed by half-media
changes every other day. At 5-day intervals from days 1 to 30 after treatment, cells were
challenged with HIV-1ADA at a MOI of 0.1 for 16 hours. HIV-1ADA media was then replaced with
fresh media without drug. Ten days after viral challenge culture media were analyzed for RT
activity. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 35 Antiretroviral activity studies in MDM
Antiretroviral activity studies in MDM after a single treatment with 100 µM of drug assayed by
HIV-1p24 antigen staining. Adherent MDM were fixed with 2% PFA and assessed for HIV-1p24.
NM2DRV formulation demonstrated long-term viral suppression for a period of 30 days compared
to viral breakthrough within 15 days and one day for NM1DRV and NDRV, respectively.
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Figure 2. 36 Pharmacokinetics in mice
1-month pharmacokinetics in BALB/cJ mice - 50 mg/kg DRV equivalents. Plasma and blood
DRV, M1DRV and M2DRV levels. Mice were injected intramuscularly with 40 uL of 50 mg/lg DRV
equivalents for all three different nanoformulations. Blood and plasma samples were collected at
different time points. DRV plasma levels remains over EC50 for a week after once treatment
NM1DRV. Data are expressed as mean ± SEM for n=5 samples per group. ****P < 0.0001 for
NM1DRV vs. NM2DRV and ^P = 0.0165 for NM2DRV vs. NDRV.
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Figure 2. 37 Liver drug levels
1-month biodistribution in BALB/cJ mice - 50 mg/kg DRV equivalents. DRV and prodrugs levels in
livers on days 7, 14, and 28 post NDRV, NM1DRV or NM2DRV treatments. DRV cleaving from
NM1DRV is highest at day 7 compared to all other treatments and the different time points. High
prodrug levels are detected at the different time points for both prodrug nanoformulations. Data
are expressed as mean ± SEM for n=5 samples per group. ****P < 0.0001, ***P = 0.0004, and *P
= 0.0104 for DRV levels in liver. ^^P = 0.0055 and ^P = 0.0347 for liver prodrug levels in
NM1DRV vs. NM2DRV.

105

2000

Spleen

1500
1000

ng/g

500
60

NM1DRV [M1DRV]

40

NM2DRV [M2DRV]

20

28

14

7

0

ng/g

Days

*

200000 Lymph nodes
150000
100000
50000
50000
40000
30000
20000
10000

NM1DRV [M1DRV]

80
60
40
20
0

28

14

7

NM2DRV [M2DRV]

Days

Figure 2. 38 Spleen and lymph nodes prodrug levels
1-month biodistribution in BALB/cJ mice - 50 mg/kg DRV equivalents. High prodrug levels are
detected at the different time points for both prodrug nanoformulations in spleens and lymph
nodes. No DRV cleaved from the prodrugs is detected in these tissues over the different time
points. Data are expressed as mean ± SEM for n=5 samples per group. *P = 0.0100 for NM2DRV
vs. NM1DRV.
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Figure 2. 39 RTV-boost Pharmacokinetics in PXR/CAR/CYP3A4/7 tADMET
RTV-boost pharmacokinetics in PXR/CAR/CYP3A4/7 tADMET. DRV and M1DRV levels in
plasma and blood, respectively. Mice were administered 50 mg/kg DRV-equivalent dose of
NM1DRV intramuscularly. RTV-boosted groups were given an RTV nanoformulation (NRTV) IM
boost injections on days 0, 7 and 14 of the study. Plasma and blood samples were collected in
heparinized tubes on days 1, 7, 14 and 21. Plasma and blood samples were analyzed by LCMS/MS to determine parent and prodrug levels as well as the effect of the boost on drugs’
bioavailability. RTV boosting effect was only significant one day post injections. Data are
expressed as mean ± SEM for n=5 samples per group. **P = 0.0016 for DRV levels from
NM1DRV/r vs. NM1DRV in control mice and ^^^P = 0.0009 for DRV levels from NM1DRV/r vs.
NM1DRV in tADMETs.
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Figure 2. 40 Tissue drug levels in PXR/CAR/CYP3A4/7 tADMET
RTV-boost biodistribution in PXR/CAR/CYP3A4/7 tADMET. DRV and M1DRV drug levels the
different tissues. In the humanized mice model, DRV is finally detected in the spleens of the mice,
not only the livers. Data are expressed as mean ± SEM for n=5 samples per group
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Figure 2. 41 RTV-boost Pharmacokinetics in PXR/CAR/CYP3A/NOG
RTV-boost pharmacokinetics in PXR/CAR/CYP3A/NOG. DRV levels in plasma. M1DRV and
M2DRV levels in blood. Mice were administered 50 mg/kg DRV-equivalent dose of NM1DRV or
NM2DRV intramuscularly. RTV-boosted groups were given an RTV nanoformulation (NRTV) IM
boost injections on days 0, 7 and 14 of the study. Similar to the BALB/cJ PK studies, plasma and
blood samples were collected in heparinized tubes on days 1, 7, 14 and 21. Plasma and blood
samples were analyzed by LC-MS/MS to determine parent and prodrug levels as well as the
effect of the boost on drugs’ bioavailability. RTV boosting effect was only significant one day post
injections. Data are expressed as mean ± SEM for n=5 samples per group. ^^^^P < 0.0001 for
NM2DRV/r vs. NM2DRV and **P = 0.0028 for NM1DRV/r vs. NM1DRV.

109

Figure 2. 42 Tissue drug levels in PXR/CAR/CYP3A/NOG
RTV-boost biodistribution in PXR/CAR/CYP3A/NOG. DRV, M1DRV and M2DRV levels in
liver, spleen, and lymph nodes. In the humanized mice model, DRV is finally detected in the
spleens of the mice, not only the livers especially in the case of NM2DRV. Data are expressed as
mean ± SEM for n=5 samples per group.
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Figure 2. 43 Plasma viral loads
PrEP Pharmacodynamics in CD34+ NSG mice – 50 mg/kg DRV equivalents. Viral breakthrough
was measured in all treatments as confirmed by plasma viral load as well as HIV-1 gag RNA and
DNA copies in spleen.
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Figure 2. 44 DRV plasma levels (100 mg/kg eq.)
Pharmacokinetics in BALB/cJ mice after once IM 100 mg/kg DRV equivalents. Plasma DRV
levels demonstrating sustained drug release for NM1DRV and NM2DRV formulations. High
prodrug levels are detected in plasma and blood of these mice on day 28 especially for NM2DRV.
Data are expressed as mean ± SEM for n=5 mice per group. ****P < 0.0001 and *P = 0.0438 for
DRV levels from NM1DRV vs. NM2DRV, ^^^^P < 0.0001 for DRV levels from NM1DRV vs.
NDRV, and <<<<P < 0.0001 and <<P = 0.0085 for prodrug levels from NM2DRV vs. NM1DRV.
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Figure 2. 45 Tissue DRV concentrations at day 28.
Pharmacokinetics in BALB/cJ mice -100 mg/kg DRV equivalents. DRV levels are detected in
lymph nodes, spleen, and liver with the higher dose. Higher DRV is detected from NM2DRV on
day 28 based only on the raw numbers. Data are expressed as mean ± SEM for n=5 mice per
group. ****P < 0.0001 and *P = 0.0237 for DRV in tissues.
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Figure 2. 46 Tissue M1DRV and M2DRV concentrations at day 28.
Pharmacokinetics in BALB/cJ mice -100 mg/kg DRV equivalents. Prodrug levels in the lymph
nodes, spleen, liver, and brain demonstrating high prodrug concentrations for NM2DRV
compared to NM1DRV treatment. Data are expressed as mean ± SEM for n=5 mice per group.
^^P = .0074 for prodrug levels in NM2DRV vs. NM1DRV.

113

H

O

O

O

O
H

N

N
H
O

O O

S

O

O
NH2
6

O

Figure 2. 47 Structure of M3DRV
M3DRV was synthesized by the modification of the hydroxyl group of DRV to a 14-carbon fatty
acid chain attached to a succinate linker.
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Figure 2. 48 M3DRV Antiviral activities against HIV-1 in MDM
EC50 was determined in macrophages for free drugs and their nanoformulations; DRV, M3DRV,
NDRV and NM3DRV. Drugs were diluted in media at concentrations ranging from 0.005 nM-50
µM in tenfold dilution increments and cells were treated with the different concentrations for 60
min and replaced with drug-containing HIV-1ADA media at a multiplicity of infection (MOI) of 0.1.
After 4 hours, infection medium was removed, and the cells were incubated an additional 10 days
in the presence of the same concentration of drug prior to infection. Half media changes were
done every other day. After 10 days of infection, culture media was collected for measures of
HIV-1 reverse transcriptase (RT) activity. Data are expressed as mean ± SEM for n=3 samples
per group.
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Figure 2. 49 M3DRV Antiviral activities against HIV-1 in CEM-SS CD4 T cells
EC50 was determined in CEM-SS CD4 T cells for free drugs and their nanoformulations; DRV,
M3DRV, NDRV and NM3DRV. Drugs were diluted in media at concentrations ranging from
0.0005 nM-5 µM in tenfold dilution increments and cells were treated with the different
concentrations for 60 min and replaced with drug-containing HIV-1NL4-3-eGFP media at a multiplicity
of infection (MOI) of 0.1 by spin-inoculation followed by incubation for 2 hours. Cells were kept at
37°C in a 5% CO2 incubator for 12 hours, after which media containing drug and FBS was added.
Twenty-four hours post infection, all cells were washed twice with PBS to remove extracellular
virus and drug-containing media was replaced with medium containing the same drug
concentration prior to infection. Every other day, cells were centrifuged at 650 x g and
resuspended in fresh drug-containing medium. After 10 days of infection, culture media was
collected for measures of HIV-1 reverse transcriptase (RT) activity. Ten days post HIV-1
challenge; supernatants were collected for RT activity measurements. Data are expressed as
mean ± SEM for n=3 samples per group.
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Figure 2. 50 NM3DRV uptake in MDM

ug/million cells

High uptake of M3DRV was detected in macrophages treated with NM3DRV (100 uM). MDM
were cultured on 12-well culture plates and treated with media containing 100µM of NDRV or
NM3DRV. At 2, 4 and 8 hours post treatment, media was removed and adherent cells were
washed twice with PBS then scraped into 1mL PBS. Cells were counted and pelleted by
centrifugation at 956 x g for 8 minutes. The cell pellets were reconstituted and sonicated in 100
µL methanol for 5 minutes followed by centrifugation at 20,817 x g for 5 min and quantified using
HPLC. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 51 NM3DRV retention in MDM for a month
M3DRV was retained in cells for 30 days compared to no detectable levels of DRV from NDRV
treatment.For drug retention studies, MDM were treated for 8 hours then washed with PBS and
maintained with half-media changes every other day until collection days. Intracellular and
supernatant drug content were analyzed using HPLC. Data are expressed as mean ± SEM for
n=3 samples per group.
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Figure 2. 52 NM3DRV uptake in CEM-SS CD4 T cells
Uptake of M3DRV in T cells was lower than uptake of M1DRV or M2DRV. The cells were plated
on to poly-L-lysine pre-coated cell culture plates that make it possible for these cells to adhere. At
2, 4 and 8 hours post treatment, media was removed and adherent cells were washed twice with
PBS then scraped into 1mL PBS. Cells were counted and pelleted by centrifugation at 956 x g for
8 minutes. The cell pellets were reconstituted and sonicated in 100 µL methanol for 5 minutes
followed by centrifugation at 20,817 x g for 5 min and quantified using HPLC. Data are expressed
as mean ± SEM for n=3 samples per group.
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Figure 2. 53 NM3DRV antiretroviral activity in MDM
Antiretroviral activities in MDM after a single treatment with 100 µM of drug determined by RT
assay. To assess long-term antiretroviral efficacy, MDM were treated for 8 hours with 100 µM
NDRV, NM1DRV or NM2DRV as previously described for uptake studies. After treatment, cells
were washed twice with PBS and cultured in fresh media without drug followed by half-media
changes every other day. At 5-day intervals from days 1 to 30 after treatment, cells were
challenged with HIV-1ADA at a MOI of 0.1 for 16 hours. HIV-1ADA media was then replaced with
fresh media without drug. Ten days after viral challenge culture media were analyzed for RT
activity. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 2. 54 NM3DRV Pharmacokinetics in BALB/cJ mice
PK of NM3DRV in BALB/cJ mice - 100 mg/kg DRV equivalents. Plasma DRV levels from
NM3DRV were consistently low (below 15 ng/mL) until day 28. Mice were injected intramuscularly
with 40 uL of 50 mg/lg DRV equivalents for both drug nanoformulations. Blood and plasma
samples were collected at different time points. Data are expressed as mean ± SEM for n=5
samples per group.
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Figure 2. 55 NM4DRV structure
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M4DRV was synthesized using a 14-carbon fatty acid chain with a phenyl linker through a
carbamate bond.
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Figure 2. 56 NM4DRV Pharmacokinetics in BALB/cJ mice
PK of NM3DRV in BALB/cJ mice - 100 mg/kg DRV equivalents. Plasma DRV levels from
NM3DRV were consistently low (below 15 ng/mL) until day 28. Mice were injected intramuscularly
with 40 uL of 50 mg/lg DRV equivalents for both drug nanoformulations. Blood and plasma
samples were collected at different time points. Data are expressed as mean ± SEM for n=5
samples per group.
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Chapter 3: Development of Long-Acting Lamivudine
Abstract
Combination antiretroviral therapy (cART) has improved the quality and longevity of life
for those living with HIV/AIDS. Despite the measured advances in clinical care,
limitations in drug pharmacokinetics, bioavailability and inherent toxicities have often
paralleled patient regimen adherence. The emergence of antiretroviral resistant viral
strains has further limited long-term therapeutic success. We posit that the
pharmacological limitations are superseded by LASER ART to improve cell and tissues
drug delivery. To this end, we synthesized hydrophobic prodrug of lamivudine (S3TC).
This was prepared by covalent linkage of an 18-carbon chain hydrophobic fatty acid to
the parent compound by hydrolyzable ester bonds. Stable poloxamer 407 coated
prodrug

nanoformulations

were

produced

by

high

pressure

homogenization.

Myristoylated lamivudine control prodrug formulation (NM3TC) uptake was 0.48
ug/million cells and undetected after 8 hours while prodrug formulation (NS3TC) was
19.17 ug/million cells at 8 hour time point and detected after 24 hours at concentrations
of 27.09 ug/million cells. Of significance, nanoformulated S3TC exhibited improved
pharmacokinetics of the native drug following a single intramuscular administration into
mice. Specifically, plasma lamivudine concentration was detected in the prodrug
treatment arm through day 14 following a single dose of 45 mg/kg. In contrast, native
3TC was below the limit of detection at day one post dosing. This project aims to
improve the chemical and polymer chemistry for producing modified 3TC (S3TC), which
is used to manufacture drug formulations with optimal properties of cell entry, stability,
slow release and pharmacokinetic profiles by a spectrum of pharmaceutical approaches.
Ultimately, we seek a modified antiretroviral 3TC to combine with other long lasting
effective ARTs to achieve improved distribution and slow drug dissolution with limited to
no toxicity for long-term treatment of HIV/AIDS patients.
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Introduction
Human immunodeficiency virus infects its host integrating its DNA to the host and
establishes cellular and tissue reservoirs allowing for it to persist and chronically inhabit
its host. Therefore, HIV patients are burdened by strict drug adherence on daily basis to
control and suppress viral replication in addition to other anti-inflammatory drugs needed
to suppress inflammation associated with over activated macrophages releasing
proinflammatory cytokines to combat viral replication. Therefore, development of longacting antiretroviral (ART) drugs is essential to improve patient adherence and lifestyle.
Nanoformulating ARTs into long-acting therapies have great potentials to improve
patients’ health due to their capability of lowering drug toxicities that often accompany
daily dosage of ART combinations while sustaining viral suppression159, 179. Lamivudine
(3TC), a pyrimidine analog/nucleotide reverse transcriptase inhibitor (NRTI), is used in
treatment against HIV-1, HIV2 and Hepatitis B virus180. 3TC along with other NRTIs
enters the cells by binding at high affinity to the organic cation transporters OCT1,
OCT2, and OCT3 that are expressed on CD4+ T cells which are the main targets for
HIV-1181. Inside cells, 3TC is first phosphorylated to its active metabolites, 3TC
triphosphate, before it is capable of competing with deoxycytidine triphosphate (dCTP).
Triphosphorylated 3TC incorporates itself in the viral DNA inhibiting the viral reverse
transcriptase by chain termination182,

183

and prevents the virus from replicating and

proliferating. Studies are conflicted on whether triphosphorylated 3TC causes toxicities
to the host DNA180, 182. The half-life of the 3TC triphosphate in HIV-1-infected peripheral
blood lymphocytes ranges from 10.5 to 15.5 hours184. Prodrug strategies are currently
used in many contraceptives as well as antipsychotics where limitations such as short
half-lives and solubility can be avoided and whereby the modification can improve the
performance of the drug83. The prodrug, an inactive bioreversible derivative of the parent
drug, evades the disadvantages that accompany many native drugs such as short half-
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life, hydrophilicity, and high toxicity77, 83. Our laboratory has been working extensively on
nanoformulations for various ARTs to achieve long-acting effective ART formulations150,
154

. In addition to nanoformulations, various prodrugs of many antiretroviral therapies

were developed to achieve LASER ARTs such as prodrugs of abacavir (ABC) and
3TC79,

80

. Modifications of ABC and 3TC to MABC and M3TC, respectively, yielded

improvements in their half-lives, cell permeability, lower toxicities and antiretroviral
activity. Initial modification to 3TC was achieved by conjugating a 14 carbon fatty acid
chain through an ester bond yielding the myristoylated-3TC (M3TC)79. The modification
improved the hydrophilic nature of the drug, increasing its half-life from hours for the
parent 3TC to days for M3TC. Once inside the macrophages, M3TC is released from the
encapsulating polymer and is cleaved by esterases reverting back to 3TC whereby the
pharmacological effect of the drug takes place upon its phosphorylation. The
modification is suggested to have improved protein binding to the prodrug which leads to
sustained drug levels compared to the parent drug which is thought to be cleared out of
the system at a faster rate based on pharmacokinetic studies79. Building on this
successful modification, further improvements can be achieved by the conjugation of a
longer fatty acid chain to 3TC, which further increased the drug’s half-life enabling higher
uptake in cells and sustained antiretroviral activities. Herein, we describe the synthesis,
in vitro, and pilot PK study of the newly synthesized S3TC, stearolyated-3TC (S3TC).

Experimental Section
Reagents
Lamivudine was purchased from Boc Sciences (Shirley, NY). Anhydrous pyridine,
dichloromethane (CH2Cl2), dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF),
deuterated chloroform

(CDCl3), diethyl ether, tetrahydrofuran (THF), fmoc N-

hydroxysuccinimide ester, fmoc chloride, chlorotrimethylsilane (TMSCl), diethylamine
(DEA), pluronic F127 (P407), 4-dimethylaminopyridine (DMAP), stearoyl chloride,
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myristoyl chloride, paraformaldehyde (PFA), dichloromethane, methanol, ciprofloxacin
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased
from Sigma-Aldrich (St. Louis, MO). LC-MS grade methanol, acetonitrile, cell culture
grade water (endotoxin-free), gentamicin and bovine serum albumin (BSA) were
purchased from Fisher Scientific (Hampton, NH). CCK-8 was purchased from Dojindo
Molecular Technologies, Inc, Rockville, MD, USA. Palladium, 10% on activated carbon,
was purchased from STREM Inc. (Newburyport, MA). All chemical synthesis reactions
were performed under a dry argon atmosphere. Flash column chromatography was
performed on 32-63 µm flash silica gels from SiliCycle Inc. (Quebec, Canada). Reactions
were monitored by thin-layered chromatography on precoated silica plates (250 µm, F254 from SiliCycle Inc.). The compounds were visualized by UV fluorescence or stained
with potassium permanganate. Heat-inactivated pooled human serum was purchased
from Innovative Biologics (Herndon, VA). Dulbecco’s Modification of Eagle’s Medium
(DMEM) was purchased from Corning Life Sciences (Tewksbury, MA).

Methods
Synthesis and characterization of hydrophobic 3TC prodrug (S3TC)
S3TC was synthesized in three steps. 3TC (2 g, 8.724 mmol, 1 equivalent) was first
dried from pyridine prior to amine-protection reaction. 3TC was then suspended in
anhydrous pyridine and cooled to 0°C. To the suspension, TMSCl (2.77 mL, 21.81
mmol, 2.5 equivalents) was added drop-wise and left to react for 30 minutes to protect
the hydroxyl group followed by slow addition of Fmoc N-hydroxysuccinimide ester (3.53
g, 10.47 mmol, 1.2 equivalents) under cooling conditions to protect the amine group on
3TC. For the Fmoc-protection reaction, Fmoc-chloride and Fmoc N-hydroxysuccinimide
ester was used interchangeably. The reaction was stirred for 48hrs under an argon
atmosphere. . After completion, the reaction was quenched with water and ammonium
hydroxide (NH4OH) to hydrolyze the TMS group. The resulting product, Fmoc-3TC, was
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purified using silica column chromatography eluting with 95%DCM:05%MeOH. The
purified product was then concentrated and lyophilized before proceeding to the fatty
acid conjugation step. To derivatize the hydroxyl group, Fmoc-3TC was dissolved in
benzene and cooled to 0°C followed by addition of 1.3 equivalents of 4dimethylaminopyridine (DMAP). Two equivalents of stearoyl chloride were then added
and to the mixture and the reaction vessel was gradually warmed to 45°C for 24hr under
argon. Upon reaction completion, the mixture was concentrated and subjected to column
chromatography purification eluting with 95%DCM:05%MeOH to yield Fmoc-S3TC. The
Fmoc group was then cleaved using DEA in DCM to yield the final compound, S3TC that
was then purified using 98%DCM:02%MeOH and 95%DCM:05%MeOH. The fractions
containing the desired product were combined, concentrated and precipitated from ether
to give S3TC as a colorless powder. The final product and intermediates were
characterized by NMR spectroscopy. M3TC79 was also synthesized using the same
protocol for S3TC synthesis substituting stearoyl chloride with myristoyl chloride. S3TC
and M3TC successful syntheses were confirmed by NMR, FTIR, and MS. 1H NMR
where the different characterizations confirmed conjugation of the fatty acid by reflecting
the linker’s hydrogen peaks as well as the missing alcohol peak due to the ester bond
formation. FTIR showed additional vibrational bands reflecting the symmetrical and
asymmetrical C-H chemical stretches resulting from the conjugation of the fatty acid
chain. Additionally mass spectrometry infusions reflected the expected molecular.
Development and Characterization of NS3TC
S3TC is formulated following established protocols from our laboratory154. Briefly, S3TC
(1% w/v) was premixed in a 0.5% w/v P407 solution dispersed in 10 mM Hepes buffer
for 16h at room temperature. The premix suspension is homogenized using a highpressure homogenizer (Avestin EmulsiFlex-C3; Avestin Inc, Ottawa, ON, Canada) at a
pressure range 15,000 – 20,000 psi at 0°C until desired size is achieved. Particles will
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be characterized using dynamic light scattering (DLS) on a Malvern Nano-ZS
(Worcestershire, UK) to determine size, PDI, and zeta potential. Drug loading in the
nanoformulation was measured using Waters Alliance e2695 HPLC Separations
Module. For pharmacokinetic study, NS3TC was subjected to centrifugal concentration
to remove excess polymer and buffer and achieve low injection volumes. NS3TC was
first centrifuged for 5 min at 5000 x g, the supernatant was transferred to a new
centrifuge tube and the pellet is saved. The supernatant was centrifuged for 20 min at
20,000 x g. The supernatant was discarded and the pellet saved. Both pellets were
resuspended in 500 µL of PBS and the sample quantified for drug content using HPLC.
Cytotoxicity and cell viability
Monocytes-derived macrophages assays were used to evaluate the NS3TC compared
to NM3TC. Cytotoxicity of each formulation was evaluated using the cell counting kit-8
(CCK-8) (Dojindo Molecular Technologies, Inc, Rockville, MD, USA). Human monocytes
were isolated and cultured for 7-10 days in 96-well culture plates (80,000 cells/well) with
Dulbecco’s Modified Eagles Media (DMEM) supplemented with 10% heat-inactivated
pooled human serum, 1,000 U/ml of macrophage colony stimulating factor, 1%
glutamine, 10 µg/mL ciprofloxacin, and 50 µg/mL gentamicin in a 37°C in a 5% CO2
incubator148-150. A stock solution of each drug nanoformulation was serially diluted in
DMEM to produce drug concentrations ranging from 100-400 µM and the cells were
incubated 24 hours. After incubation in 37°C for 24 hours, 10 µL of the kit was added to
each well; drug treated and untreated cells as well as drugs in media were included.
Incubate plates at 37°C in a 5% CO2 for 1-4 hours. Finally, absorbance measured at 450
nm on a SpectraMax M3 plate reader with SoftMax Pro 6.2 software (San Jose, CA).
Percent of survival rate was calculated by this equation ((Asample-Ablank media)/(Acontrol cellsAblank media)) X 100.
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MDM drug uptake and retention
MDM were cultured on 12-well culture plates and treated with media containing 100µM
of NS3TC or NM3TC148-150. At different time points; 2, 4, 8 and 24 hours post treatment,
media was removed and adherent cells were washed twice with PBS then scraped into
1mL PBS. Cells were counted on an Invitrogen Countess Automated Cell Counter
(Carlsbad, CA), pelleted by centrifugation at 3000 x rpm for 8 minutes. The cell pellets
were reconstituted and sonicated in 100 µL methanol for 5 minutes followed by
centrifugation at 14,000 x rpm for 5 min. Drug levels in each time point for each
treatment will be assayed using Waters Alliance e2695 HPLC Separations Module.
Antiretroviral effects of the different treatments were evaluated following well-established
protocols in our laboratory. Briefly, cells were first loaded with each drug formulation for
8hr. At different days post drug loading, cells were infected with HIV-1ADA for 16 hours.
After infection, virus media is removed and cells are washed twice with PBS and
incubated in media to maintain survival of cells. 10 days post infection, cell media were
collected at different time points to evaluate antiretroviral activity using reverse
transcriptase assay (RT assay) of the different treatments. Cells were fixed in 2% PFA
for p24 staining for further confirmation of RT results.
PK analysis of NS3TC
Mice were administered intramuscular injections (50 mg/kg) of NS3TC and NM3TC. The
two groups NS3TC and NM3TC were compared to each other to evaluate the effect of
drugs’ increasing hydrophobicity. Each treatment was compared to show the effect of
nanoformulation on the control release of the drug and therefore its half-life. Plasma was
be collected from the mice at days 1, 3, 7, 10, 14, 21, and 28. Tissues (lung, liver,
spleen, gut, brain, lymph nodes and muscle injection sites) were collected to quantify
drug content and detect the drug peak of each treatment.
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Results
Synthesis and characterization of prodrug, S3TC
S3TC was successfully synthesized by the conjugation of stearoyl chloride to Fmocprotected 3TC followed by the deprotection reaction to cleave the protecting group
(Figure 3.1). S3TC is an ester prodrug of 3TC that will be hydrolyzed once inside the cell
back to 3TC through the action of esterases. The drug is then further phosphorylated
into the active moiety (Figure 3.2). The final compound S3TC structure was verified
using 1H NMR, FTIR, and MS. Broad peaks at 0.9 and 1.26 ppm correspond to the
terminal methyl and methylene protons of the fatty esters in the 1H NMR spectra for
S3TC (Figure 3.3). Characterization of S3TC by Fourier transform infrared (FTIR)
spectroscopy showed absorption bands at 2917, 2915 and 2848 cm-1 representing
asymmetric and symmetric C-H stretches in the long chain fatty acids as well as 1760
cm-1 corresponding for the carbonyl stretches chemical stretch (Figure 3.4). Infusion of
the S3TC into a Waters Xevo TQ-S micro mass spectrometer showed the desired
molecular ion peaks at 496.72 [M+H] (Fig 3.5). As a control M3TC79 was also
successfully synthesized and thoroughly characterized to be used as a control in
subsequent studies.

Nanoformulation of S3TC
S3TC was successfully nanoformulated (NS3TC) with P407 through top-down methods;
high pressure homogenization with a drug:polymer ration of 2:1 in 10 mM HEPES buffer.
As a control M3TC was also nanoformulated (NM3TC) following the same protocol79.
Both drug nanoformulations had drug encapsulation efficiencies of 80% for NS3TC and
55% for NM3TC. NS3TC and NM3TC exhibited uniform particles sizes of 300.27 and
521.83 nm, PDI of 0.25 and 0.35, and charges of -6.48 and -17.97 mV, respectively.
Stability measurements of NS3TC showed the particles to be stable at room temperature
for the recorded observation period (Figure 3.6).
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Cytotoxicity of NS3TC
Cytotoxicity of NS3TC in MDM was evaluated using cell counting kit-8 (CCK-8) and 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Parallel cytotoxicity
studies with NM3TC were used as a control. Treating with concentrations ranging from
50 to 400 uM showed no toxicity (Figure 3.7). Based on the viability studies, subsequent
in vitro studies were done using 100 µM of both NS3TC and NM3TC.

Uptake of NS3TC
NS3TC showed improved and sustained uptake in MDM over NM3TC. At 2hr post
treatments, concentration of M3TC peaked at 14.79 µg per million cells. However, by 4
and 8hr time points M3TC levels drop to 9.02 and 0.36 ug/million cells, respectively.
M3TC concentrations were not detectable at 24hr time point. On the other hand, NS3TC
treatment showed gradual increase in uptake over 24 hours period. S3TC concentration
was 27.84 µg/million cells and increased gradually to 70.10 µg/million cells by 24 hours
of uptake (Figure 3.8).

Retention of NS3TC
Loading MDMs with NS3TC or NM3TC (100 µM drug) for 8 hours revealed S3TC is
retained longer inside cells and detected until day 11 at concentrations of 0.27 µg/million
cells (Fig 3.9) compared to little or no retention of NM3TC as also suggested from
previous uptake studies in MDM.

Antiretroviral effects of NS3TC
MDM loaded with NS3TC showed protection from HIV-1ADA for 15 days whereas NM3TC
showed viral breakthrough by day 5 of the study as evident from the RT assay (Fig
3.10). This confirms that NS3TC showed better retention profiles inside MDM that
paralleled by the antiretroviral efficacies against HIV-1.
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Pilot pharmacokinetic study evaluation of NS3TC
To affirm that the modification improved bioavailability of the drug and its biodistribution
in tissues, BALB/cJ mice were administered a single intramuscular injection of 50 mg/kg
3TC equivalents of NM3TC or NS3TC. NS3TC showed superior PK profile compared to
NM3TC in terms of 3TC plasma levels (Fig 3.11). 3TC levels peaked for the NM3TC on
the first day with concentration of 245.87 ng/mL however, rapid decrease in 3TC
concentration was detected by day 4 where the 3TC concentration was only 24.20
ng/mL and continued to decrease to 1.23 ng/mL by 1 week. 3TC from NM3TC treatment
was undetectable for the rest of the study. On the other hand, NS3TC showed sustained
a gradual release of 3TC reflected in the concentrations detected at different time points;
116.86, 112.21, 33.81, 20.30, and 4.84 ng/mL on days 1, 4, 7, 10, and 14, respectively.

Discussion
NRTIs are considered a cornerstone in the treatment of HIV and hence are found in
most first line HIV regimens for adults and adolescents97. Optimal effective initial
regimens for majority of HIV-1 patients consist of triple ART therapy of two NRTIs and
an integrase inhibitor, NNRTI, or protease inhibitor185. Moreover, NRTIs are essential in
PrEP regimens because of their ability to inhibit viral reverse transcription into the DNA
hence eventually stopping the virus pre integration into the host DNA and therefore
these offer more protection than other ART drug classes such as protease inhibitors that
work post integration. Prevention of integration into host genome is generally the
preferred mode of action for PrEP regimens177. Based on the criteria for choosing PrEP
drugs, 3TC shows promising grounds. The NRTI drug is already being used in
developing countries and is cost effective. A study conducted in Rwanda and Uganda,
SIMBA, looking at the prophylaxis effects of 3TC in HIV-negative infants breast-feeding
from HIV-positive mothers showed protection effects with no infant infections177. Hence,
developing a long-acting 3TC represents a great advantage in the HIV current
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treatments and future PrEP regimens. Daily dosage of ARTs frequently cause many side
effects, thus long-acting injectables would greatly lower such toxicities and dramatically
improve the lifestyle of patients by lessening the burden of daily pills and thus
maintaining patient’s privacy77. Recently, ViiV healthcare submitted an application to the
FDA for monthly injectable of long-acting CAB and RPV. This would be the first long
acting antiretroviral to be available for clinical use. CAB and RPV are characterized by
certain physiochemical characteristics that make it possible for their use and
development

into

long-acting

therapeutics

by

nanoformulations161,

162

.

These

characteristics include low aqueous solubility, high potency and long half-life due to their
slow clearance. These characteristics enable formulation of these drugs as aqueous
nanosuspensions. However, many of ART therapies do not conform to these criteria
specifically NRTIs. Being an essential ART class for PrEP and HIV treatment, research
on long-acting NRTIs is essential and would greatly benefit the HIV community and
those at risk of infection. Therefore, in efforts to transform 3TC into a long-acting drug,
we sought to transform it first into a water insoluble compound. Hence to nanoformulate
3TC, overcoming the hydrophilic nature of the drug becomes essential. We successfully
synthesized a prodrug (S3TC) of 3TC increasing the hydrophobicity of the drug by the
conjugation of an 18-carbon fatty acid chain on the hydroxyl end of the drug. The
hydrophobic lipids are known to increase compound hydrophobicity, cell penetration and
slow down drug clearance142,

79

. We used NM3TC as a control. M3TC is an ester

derivative of 3TC modified with a 14-carbon chain on the terminal alcohol and had
previously shown superior in in vitro and in vivo characterization compared to free 3TC79,
186

. Agarwal et al. previously synthesized a library of 3TC prodrugs where 3TC was

modified with long-chain fatty acids on either the amine or hydroxyl group while
protecting the other group not being modified186. Myristolyation of 3TC by modification of
the alcohol (5’-O-derivative) showed dramatic increase in Log P of the drug from 0.06 to
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5.79 for 3TC and myristolyated-3TC, respectively186. Effect of modification was drastic in
efficacy studies against X4- and R5-tropic viruses. Myristolyated-3TC showed increase
in potency, decrease in EC50 values from 32.7 and 11.4 uM for 3TC to 0.5 and 0.2 uM
for myristolyated-3TC (M3TC) in X4- and R5-tropic viruses, respectively. Moreover,
M3TC was shown to have lower IC50 and IC90 values than 3TC when tested against
various resistant viruses. To this end, we sought to make further improvements on
M3TC by making a more hydrophobic 3TC prodrug (S3TC) with longer half-life to
eventually achieve more effective drug levels. The hydrophobic moiety modification
increases the hydrophobicity of the parent drug leading to higher protein binding which in
turn extends the drugs circulation time in blood thereby facilitating intracellular and tissue
redistribution79. Moreover, to our knowledge, an aqueous nanosuspension of
stearoylated 3TC prodrug (a stearoyl modification to 5’ hydroxyl of 3TC) has not been
previously explored. Theoretically, the hydrophobic modification is reversibly hydrolyzed
by esterases present in plasma, cells and tissues yielding the parent drug that
undergoes intracellular triphosphorylation by kinases to exert antiretroviral effects79, 186
(Fig 3.2). Based on previous studies, we posit that the log P and intracellular uptake of
S3TC would be greater than that of the parent drug. Consequently, enhancements in
intracellular delivery and activation of the prodrug would lead to improved efficacy
compared to 3TC.
Nanoformulating ARTs showed promising advantages in many studies done in our lab77,
79, 80, 149, 150, 154

as well as pharmaceutical companies such as GSK and Janssen as

discussed previously with their CAB LA and RPV LA74. Nanoformulations slows down
the release of the drugs leading to lowering frequent dosing. Ideally, using different
polymers to coat the drugs also lowers the possible drug toxicities and allows a more
efficient drug penetration into cells when compared to free drugs77, 150, 154. Building on
this and previous work in our laboratory, nanoformulation of S3TC (NS3TC) improved
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the long-acting effect of the drug by controlled release from the polymer encapsulating it
as well as lowering drug toxicities. Characterization of the nanoparticles confirmed
stability and uniformity of the particles. From bench to patient’s bedside, nanoformulation
stability is a critical factor for future use of these nanoformulation in clinical settings.
Since HIV-1 infects and replicate in T cells as well as macrophages hence representing
major viral cellular reservoirs172, 187 it is essential for NS3TC to be able to be taken up,
retained, and effective inside these cells. For proof-of-concept we tested NS3TC in
MDMs. Uptake of NM3TC peaked at 2hr post treatment and rapidly decreased until it
reached undetectable levels. On the other hand, uptake of NS3TC showed sustained
and gradual increase inside MDMs. This was also paralleled by high retention compared
to M3TC. The superior uptake and retention profiles of NS3TC were reflected in the
antiretroviral assay where protection against virus onset was extended 10 days beyond
NM3TC. NM3TC showed viral breakthrough by day 5, which reflects the long-acting
activity of NS3TC. The advantage of using macrophages lies in more than them being
viral reservoirs. Our laboratory has previously shown that drug depots form at the
injection

sites

in

mice

treated

with

prodrug

nanoformulations75

and

notably

macrophages, as major phagocytic cells, infiltrate in the injection site and phagocytose
these formulations188 followed by their migration to local lymph nodes. Additionally, since
HIV is characterized by chronic inflammation and immune system activation, we posit
that these macrophages would travel where the chemokine gradient attractants and
ongoing viral replication are. Therefore it is significant that NS3TC is taken up and
retained in macrophages at higher concentrations than NM3TC.
Moreover to test if the improved in vitro characterization is also reflected in vivo, NS3TC
was tested in BALB/cJ mice in a pilot pharmacokinetic study to test bioavailability of the
drug in plasma as well as its tissue distribution. Compared to NM3TC, 3TC levels from
NS3TC were detectable up until 14 days post injection whereas 3TC from NM3TC was

133
not detected beyond 1 week after the intramuscular injection. This confirms the longacting advantage of NS3TC over NM3TC. Further analysis will look into tissue-drug
biodistribution. Guo et al. showed that targeting of NM3TC using folic acid (FA) targeted
polymer to nanoformulate M3TC improved its pharmacokinetics profiles79. FA-targeted
NM3TC provided better 3TC plasma drug levels by more than 2-fold compared to 3TC
levels from NM3TC. Moreover, 3TC levels in liver, spleen, and lymph nodes showed 2fold increases in the FA-NM3TC treatment arm over NM3TC79. Folic acid receptor on
macrophages are able to internalize FA-tagged molecules and drugs as it was shown in
FA-drugs targeted to folate receptor expressing cancerous cells189. Moreover, ongoing
human clinical trials to investigate the advantage of folate-conjugated drugs confirm the
significance of targeted therapies. FA targeting on the macrophage has been exploited
for treatment of rheumatoid arthritis, an autoimmune disease, where activated
macrophages contribute to disease pathogenesis hence targeting therapeutics to these
macrophages in the arthritic joints would be most effective while avoiding toxicity in
normal tissues190.

Therefore, future studies will explore FA-targeting of NS3TC to

improve the in vitro and in vivo profiles while lowering toxicities to other cells and tissues.
Future studies on 3TC will include the development of a di-3TC prodrug formulation that
is essentially consisting of two 3TC molecules conjugated by a linker through ester
bonds (Fig 3.11). Different length linkers may be explored to achieve the optimum yet
slow release of the drug in vivo.
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Figure 3. 1 Synthesis scheme of S3TC
3TC is first protected with an Fmoc group to shield the amine group prior fatty acid conjugation
yielding into Fmoc-3TC. Fmoc-3TC is then reacted with stearoyl chloride (18 carbon fatty acid
chain) to produce Fmoc-S3TC. The protecting group is eventually cleaved in a deprotection
reaction to yield the final product, S3TC.
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Figure 3. 2 Proposed mechanism of S3TC hydrolysis and activation
Once inside cells, various esterases can hydrolyze the ester bond on S3TC reverting it back to
3TC. Different kinases then can activate the parent drug into its active moiety – a triphosphate
3TC, this can induce antiretroviral activities in the form of chain elongation termination halting the
viral cycle.
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Figure 3. 3 H NMR characterization of S3TC
NMR spectrum of S3TC reflecting the additional terminal methyl (0.9 ppm) and methylene
1
protons (1.26 ppm) of the fatty esters. Lower panel reflects H NMR of 3TC.
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Figure 3. 4 FTIR characterization of S3TC
-1

Spectrum for S3TC reflects absorption bands at 2917 and 2848 cm representing asymmetric
and symmetric C-H stretches in the long chain fatty acid. Additionally, absorption band at 1690
-1
cm represents the carbonyl chemical stretch resulting from the conjugation and addition of the
carbonyl group from the fatty acid.
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Figure 3. 5 Characterization of S3TC
Infusion into a Waters Xevo TQ-S micro mass spectrometer confirmed the desired molecular ion
peaks at 496.72 [M+H] as well as smaller peaks resulting from the addition of other hydrogen
isotopes.
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Figure 3. 6 Nanoformulating S3TC and stability measurements
S3TC is encapsulated in P407 through high pressure homogenization to yield NS3TC. NS3TC
was prepared in HEPES buffer (10 mM) using 2:1 drug to polymer ratio. The formulation was
premixed overnight and subjected to high pressure homogenization (C3 Avestin) applying 15,000
– 20,000 psi. Size of particles was monitored using dynamic light scattering (DLS).
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Figure 3. 7 Cytotoxicity assay of NS3TC and NM3TC in MDM
Cytotoxicity of NM3TC and NS3TC was assayed by MTT in MDM. A stock solution of each drug
nanoformulation was serially diluted in DMEM to produce drug concentrations ranging from 100400 µM. Cells were treated for 24 hours, washed and incubated with 200 µL/well 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL) for 45 minutes.
Upon MTT removal, 200 µL/well of DMSO was added and absorbance measured at 490 nm on a
SpectraMax M3 plate reader. Data are expressed as mean ± SEM for n=3 samples per group.
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Figure 3. 8 Uptake of NS3TC in MDM
S3TC uptake levels are dramatically higher than M3TC drug levels inside MDM after one
treatment of 100 µM drug. MDM were cultured on 12-well culture plates and treated with media
containing 100µM of NDRV, NM1DRV or NM2DRV. At 2, 4 and 8 hours post treatment, media
was removed and adherent cells were washed twice with PBS then scraped into 1mL PBS. Cells
were counted and pelleted by centrifugation at 956 x g for 8 minutes. The cell pellets were
reconstituted and sonicated in 100 µL methanol for 5 minutes followed by centrifugation at 20,817
x g for 5 min and quantified using HPLC. Data are expressed as mean ± SEM for n=3 samples
per group. ****P < 0.0001 for NS3TC vs. NM3TC.
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Figure 3. 9 Retention of S3TC in MDM
For S3TC retention studies, MDM were treated for 8 hours with 100 uM of NS3TC then washed
with PBS and maintained with half-media changes every other day until collection days.
Intracellular and supernatant drug content were analyzed using HPLC. Data are expressed as
mean ± SEM for n=3 samples per group.
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Figure 3. 10 Antiretroviral activity of NS3TC
Antiretroviral activities in MDM after a single treatment with 100 µM of drug determined by RT
assay. To assess long-term antiretroviral efficacy, MDM were treated for 8 hours with 100 µM of
NM3TC or NS3TC. After treatment, cells were washed twice with PBS and cultured in fresh
media without drug followed by half-media changes every other day. At 5-day intervals from days
1 to 30 after treatment, cells were challenged with HIV-1ADA at a MOI of 0.1 for 16 hours. HIV-1ADA
media was then replaced with fresh media without drug. Ten days after viral challenge culture
media were analyzed for RT activity. Data are expressed as mean ± SEM for n=3 samples per
group.

ng/ml of 3TC
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Figure 3. 11 Pharmacokinetics of NS3TC
Pharmacokinetics in BALB/cJ mice using 50 mg/kg 3TC equivalents. Mice were injected
intramuscularly with 40 uL of 50 mg/lg 3TC equivalents for both NM3TC and NS3TC. Plasma
samples were collected at different time points. Data are expressed as mean ± SEM for n=5
samples per group.

H 2N
N
O
N
O

O
S

O

S

O
O

n

O
N
O
N
NH 2

Figure 3. 12 Di-3TC molecule
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Chapter 4: Conclusions and Future Studies
Prodrug strategies proved to be essential for antipsychotic and contraceptive84, 191 drug
regimens and are soon going to play critical roles in HIV-1 therapeutics to transform the
daily regimens into long-acting drugs. Prodrugs are capable of altering drug tissue
distribution, efficacy and improve toxicity profiles83. Currently, CAB LA and RPV LA of
GSK and Janssen are taking the lead when it comes to long-acting HIV-1 treatments76,
159

. These drugs, however, possess unique innate characteristics like poor water

solubility and high potency that allow them to be nanoformulated and used as longacting regimens. In order to apply the same characteristics with many other HIV drugs,
poor physiochemical characteristics of the drugs need to be overcome to efficiently
nanoformulate the drugs. This is where prodrug strategies play a major role in the
transformation of most HIV-1 drugs into long-acting slow effective release drugs77.
Prodrugs of DRV, M1DRV and M2DRV, showed superior uptake and retention in
macrophages and T cells, known cellular reservoirs of HIV-1. In addition, antiretroviral
efficacies of these drugs were comparable to the parent drug or maintained in the
nanomolar range for M1DRV and M2DRV, respectively. In vivo studies in mice revealed
DRV

prodrug

nanoformulations,

NM1DRV

and

NM2DRV,

showed

better

pharmacokinetics than the nanoformulated native drug. Limitation of the DRV prodrug,
however, lies in the levels of DRV cleaving from the prodrugs in vitro and in vivo.
Although, DRV cleaving from both prodrugs in vitro is not detected except for NM1DRV,
this could be a limitation in the HPLC detection method hence there is a need for more
sensitive HPLC methods to ensure whether the problem lies in detection limitation or
hydrolytic stability of the drugs. Long-term efficacy studies in cells showed that the
prodrugs’ nanoformulation were able to protect the cells for up to 15 and 30 days for
NM1DRV and NM2DRV, respectively. These studies paralleled the retention studies that
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showed prodrugs within cells for 15 and 30 days for NM1DRV and NM2DRV,
respectively. The long-term antiretroviral efficacy studies can be explained by the in vitro
antiviral activity of DRV where the EC50 ranges between 1-5 nmol/L and EC90 from 2.712 nmol/L in HIV-1/2 infected cells such as MT-4, PBMCs, and macrophages

89

. Hence

this protection could mean cleavage of the prodrugs are taking place but in very small
concentrations that are not detected by the current HPLC methods. An additional
limitation along the same lines is the low therapeutic DRV levels detected in mice
plasma after once intramuscular injection of 100 mg/kg DRV equivalents for the
prodrugs. NM1DRV treatment outperformed NM2DRV in terms of plasma DRV levels
above the EC50 of the drug (55 ng/mL). DRV cleaving from NM1DRV remained above
the EC50 of DRV for 1-week post-injection and dropped below 10 ng/mL by 28 days postinjections. DRV cleaving from NM2DRV remained above EC50 only at days 1 and 3 and
rapidly decreased below 55 ng/mL reaching similar DRV levels as NM1DRV by day 28
days. However it is important to note that the mice were not dosed with an equivalent
dose to the human dose. DRV is dosed in humans either 600 mg twice a day or 800 mg
once daily. Using the once/daily dose of 800 mg to calculate a mouse dose would yield a
dose around 164 mg/kg based on allometric scaling considering the body surface
area192. The highest dose we used for our PK studies was 100 mg/kg to avoid possible
toxicities in mice. Therefore, to further confirm our results, repeating PK studies in rats or
mice at an equivalent dose to humans becomes essential to better understand the
pharmacokinetics of the DRV prodrugs and to rule out possible dosing discrepancies.
Pharmacodynamics (PD) will be explored to assess the antiretroviral efficacy of
NM1DRV and NM2DRV in post infection studies in humanized mice. Previous
pharmacodynamics study did not show a protective effect from NM1DRV or NM2DRV
compared to control infected and uninfected treatments. This observation could be due
to the dose used (50 mg/kg), which is not high enough of a dose compared to the human
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dose equivalence. Additionally, the PrEP PD study design is not ideal for protease
inhibitors. Protease inhibitors are least preferred when considering PrEP regimens as
their mode of function is post-integration of HIV into host genome. PrEP studies depends
more on the prevention of integration of the proviral DNA into host genome177.
Additionally, future PD studies will include combinational LA therapy that might include
dual therapy along with long-acting NRTI or integrase inhibitors such as M3TC or
MDTG78,

79

. Moreover, toxicity studies in animals will be performed to ensure the

prodrugs safety profiles. Liver enzymes such as alanine aminotransferase, alkaline
phosphatase, and aspartate aminotransferase will be measured to ensure the health of
the animals. Moreover, studies will be performed to measure the different lipids levels
and their precursors since changes in lipids are common with the administration of many
protease inhibitors121.
Future studies involving DRV may include the synthesis of less stable drugs that can be
cleaved easily by esterases in vivo. In our in vivo studies, we were able to detect
dramatically high concentrations of prodrugs in plasma, blood and tissues for both
prodrugs and specifically for M2DRV. The accumulation of the prodrugs may indicate
that the prodrugs are not easily accessed by the esterases hence failing to be activated
and released as the active molecule, DRV. Therefore future DRV prodrugs syntheses
may include different linkers between the fatty acid and DRV to aid in propelling the fatty
acid away. Previously, we synthesized M3DRV prodrug. The prodrug consisted of a
hydroxy modification that consisted of a linker between a 14-carbon fatty acid chain and
the DRV. The linker was conjugated to the fatty acid and the drug through ester bonds.
However in vitro and in vivo cleavage of the drug was not improved over that of previous
drugs formulations especially in vivo, where cleavage profiles were far less superior than
with M2DRV, a hydroxyl-modified-DRV. This could have resulted from two different
aspects. Modification to the internal hydroxyl of protease inhibitors had previously shown
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the prodrugs to be more stable and have a longer hydrolysis half time126, 127. Additionally,
the linker used in M3DRV was a short alkyl succinic linker that may have failed to propyl
the fatty acid out of the drug. This modification may have caused folding of the drug
concealing the ester group and avoiding activation by esterases. To overcome this in
future studies we can try using bulky groups containing phenyl linkers between the fatty
acid chain and the drug such as animoacyl phosphorocholoridates linkers shown to yield
effective results in NRTI ProTides86. Previous attempts to improve protease inhibitors
through modifications yielded fosamprenavir, a phosphate ester prodrug of amprenavir,
structurally similar to darunavir125. The phosphate modification increased solubility of
amprenavir and rendered it impermeable through cells. Fosamprenavir maintained
elevated plasma amprenavir levels where the modification was readily reversible by the
action of alkaline phosphatases125. The prodrug offered an advantage in oral
administration regardless of food intake, which did not affect the absorption of
amprenavir when administered as fosamprenavir tablets (regular oral amprenavir
regimens are taken with food). Hence using aminoacyl phosphorocholoridates linkers
would avoid the solubility increase for future DRV prodrugs by the conjugation of longchain fatty acids and shielding the polar groups on the phosphates. Additionally future
modifications would target the amine of the aniline to ensure the synthesis of a prodrug
with comparable or better EC50 values than DRV as seen with M1DRV. M2DRV and
M3DRV showed decrease in potency as reflected in their increased EC50 values
(Chapter 2).
In vivo studies in mice using 100 mg/kg DRV equivalents of M2DRV showed prodrug
detected in the brain of NM2DRV treated mice. This is significant because previously no
drug was detected in these tissues. This could be due to the increased lipophilicity of
M2DRV as compared to M1DRV and DRV. Further studies on protease inhibitors had
shown that the difluorid-nation of the bis-THF moiety on DRV and its analogues can
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increase drug permeability through the blood brain barrier

193, 194

. Ghosh et al showed

that difluorination modification of the bis-THF moiety on DRV and its analogue (TMC126) lead to increaseed drug lipophilicity and improved concentrations permeable in an
in vitro model of the blood brain barrier. The modified drugs were more lipophilic and
showed comparable or superior EC50 than DRV193. The modifications led to strong
interactions between the fluorides with the carbonyl oxygen of Gly48 on the protease
flap which further increased binding affinity to the substrate193. Hence for future
directions, fluoridation of the DRV prodrugs may be explored to improve targeting and
permeating into the brain for treatment of HIV-1-associated neurocognitive disorders
(HAND). This would require the initial synthesis and fluoridination of DRV to incorporate
these modifications193. Additionally, similar in vitro assays to determine blood brain
barrier permeability of these drugs will be explored as well as binding assay and X-ray
structures to determine their inherent binding to the proteases. In addition future
optimization of drug nanoformulations is needed to ensure the hydrophobic drugs are
efficiently encapsulated in stable formulations that are capable of slow release of the
drugs.
3TC modification into S3TC yielded more promising data than the previously published
M3TC79, however further studies are needed to fully confirm S3TC efficacy and
superiority to M3TC. These studies include formulation optimization as well as longer
stability assays to ensure the best formulation for the drug. Efficacy studies will also be
performed comparing S3TC to the efficacy of M3TC and 3TC. Moreover, uptake and
retention studies will be repeated in macrophages and T cells to evaluate the
intracellular levels of triphosphorylated levels of 3TC hydrolyzed from S3TC using SepPak QMA cartridges and published processing methods86. Prodrug cleavage and
hydrolysis will be evaluated in different plasmas where prodrug levels will be measured
and monitored over 24 hours. Additional PK studies will be also performed to further
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determine S3TC biodistribution in tissues as well as the triphosphorylated-3TC levels in
plasma, blood and tissues. Finally PrEP PD study will be performed to determine the
antiretroviral efficacy in vivo. Moreover, a PD study that includes NM1DRV or NM2DRV
administered with NS3TC will be explored to evaluate the antiretroviral efficacies of
combinational long-acting therapy. Current studies confirmed the non inferiority of a dual
therapy that includes lamivudine and boosted DRV compared to triple therapy that
includes RTV-boosted darunavir and 2 nucleotides; tenofovir disoproxil fumarate and
emtricitabine or abacavir and lamivudine102. Additionally, exploring the different animal
models to select the most suitable model for testing of ester prodrugs is essential to rule
out discrepancies resulting from species differences in esterase actions/expressions as
well as P450 drug metabolism195, 196.
To better target these long-acting nanoformulations, future studies will explore targeting
schemes to specifically target these drugs to macrophages, the cells that come in
contact with the injectable drug nanoformulations first to ensure the drug formulations
are not cleared out of the system quickly leading to a prolonged slow sustained release
in circulation and tissues. This would better harness the macrophage carriage system as
a depot and disseminator of antiretroviral therapy (ART). Targeting could be done by
exploiting the C-type lectin receptor (CTLR)197 to permit nanoformulated antiretroviral
drug particle recognition and uptake into monocyte-macrophages. CTLR signaling is
coordinated with other innate receptors to facilitate immunity to infection. Thus, the
advantage of targeting schemes rests in its utility to combat a spectrum of microbial
infections

by

facilitating

intracellular

immunization

where

the

pathogen

can

replicate/reside198. Use of pathogen-associated molecular patterns (PAMP) for drug
carriage can accelerate phagocytosis. CD206 is a type I transmembrane c-type lectin
receptor that recognizes D-mannose, N-acetyl-D-glucosamine, and L-fucose199 hence by
modifying different poloxamers with these ligands we theoretically can increase drug
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nanoformulation binding and uptake while enhancing innate immunity for microbial
clearance. Many studies showed increased selective targeting with mannose-decorated
drug carriers into CD206-expressing macrophages and dendritic cells; MR+ cells200-211.
Specifically, Stahl and his colleagues found that receptor mediated mannose
glycoconjugates were endocytosed by alveolar macrophages where uptake of mannose
ligands was time and concentration dependent202. Moreover, receptor blocking studies
on MDM using soluble mannan or mannose-BSA to block the mannose receptors
decreased phagocytosis of certain virulent Mycobacterium tuberculosis strains such as
Erdman M. tuberculosis and H37Rv212. Another study reported that mannosylation of
solid lipid nanoparticles (SLN) increased targeting of rifampicin (RIF) into alveolar
macrophages by 2-fold (80%) compared to free drug (20%) and non-mannosylated SLN
(40%)213. Different lengths of fatty acids conjugated to mannose ligands to achieve
optimized hydrophobic/lipophilic balance to stabilize the particles therefore the ligands
had bi-functional values in being a functionalizing agents and surfactants. MannoslyatedSLNs RIF improved retention of the drug inside the cells. Notably, the longer
hydrophobic chain used for functionalization showed slower release, in vitro, in
comparison to free RIF and the shorter hydrophobic functionalized ligands-SLN213. In a
different study, mannosylated lipid emulsions were more rapidly cleared and eliminated
from the blood circulation accumulating into the liver compared to lower-mannose
content

nonmannosylated

emulsions

showing

high

drug-tissue

distribution214.

Amphotericin B (AB) or paromomycin-loaded mannosylated chitosan nanoparticles
better targeted the drugs to the macrophages where Leshmania protozoans reside
(obligate intracellular parasites) and showed increases in drug delivery compared to untargeted particles215,

216

. Additionally, thioalkylated mannnose-decorated dendrimers

were found to be effective antigen-presenting cell-selective carriers; thus targeting the
siRNAs to RAW264.7 mouse macrophage cells203 and providing further proof that
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mannose-decorated particles have better selectivity to MR+ cells. Targeting the dendritic
cell receptor, DEC-205, a type I cell-surface protein C-type multilectin217, using targeted
nanoparticles encapsulating an antigenic peptide (melanoma associated) yielded both
increased internalization and higher cross-presentation efficacy of the antigen compared
to the untargeted nanoparticles218. In a similar experiment, treating dendritic cells with
mannosylated antigens resulted in a more selective targeting followed by a higher
presentation efficacy compared to the non-mannosylated antigens219. Our laboratory
previously demonstrated increased uptake of ART nanoparticles that are folic aciddecorated polymer via folic acid receptor-mediated endocytosis compared to the
unmodified polymer79,

150, 154

. Collectively, these discoveries pave highly promising

grounds for targeting schemes to specifically deliver ART nanoformulations to cells. In
addition to folic acid targeting, CD206 targeting will be explored by first synthesizing a
spectrum of mannose ligands. Successfully synthesized and characterized mannose
ligands will be moved forward in decoration of different polymers, specifically P407,
since many studies in our laboratory utilized this polymer for formulation of different ART
drug classes and proved to be compatible with the majority of drug formulations.
Mannose-decorated P407 will be used for ART nanoformulations to eventually target
nanoparticles to mannose receptors on the macrophages/CD206+ cells being treated
where they would be eventually internalized.
Prior studies to target mannose-decorated nanocarriers to macrophages had explored
variant mannose densities and linkers to achieve highest uptake and targeting200, 201. Dmannose along with different peptide spacers, carbon chains, phenyl, PEGs, or biphenyl
linkers are used to synthesize different spectrum of mannose ligands with different
conformations and mannose densities. In a series of organic chemistry reactions starting
with a D-mannose (mannospyranose) and reacting it to different linkers; biphenol linker,
phenyl linker, GABA/lysine-GABA spacers, yielded final protected ligands. The protected
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ligand can later be deprotected to react with the amine group of the amine-terminated
polymer. Refer to Figure 4.1 for a scheme of different mannose ligands (1,2,3 & 4).
Characterization of the ligand will be done through nuclear magnetic resonance (NMR)
along with Fourier transform infrared spectroscopy (FTIR). One limitation in the
characterization of these modified P407 structures is that 1H NMR characterization will
show chemical shifts around 3.1 – 4 ppm which masks and overlaps with the mannose
peaks representing a problem in quantification of the mannose densities on the modified
polymer. To overcome this, a fluorine tag [4-Azido-2,3,5,6-tetrafluorobenzoic acid]220
may be used to tag the structures of mannose to shift their signals downfield on the
NMR spectra around 237 ppm which would provide tremendous clarity in viewing the
mannose peaks as well as quantification of mannose ligand densities that are found on
each polymer sample.
The developed ligands will vary from the mannose densities on each ligand to the
spacer/linker length that will ensure the ligand is well positioned on the polymer and
propelled out to maximize ligand-receptor interaction. The ligand-modified polymers
generated will produce ART nanoparticles characterized by size, shape, polydispersity
index and charge. The developed particles will be screened in macrophages to targeting
advantage on uptake, retention, release, and eventually antiretroviral activities. It is
essential to ensure that the targeting schemes do not interfere with the long-term
antiretroviral activities of the drugs. Therefore targeted and untargeted drug
nanoformulations will be tested in parallel studies to ensure the targeted nanoparticles
retain their efficacy against the virus. Moreover, targeting and trafficking of these
mannose-modified systems to the cells can be tracked by antibodies to the different
markers of endosomal compartments79. In addition, tagging the finalized targeting
system with a dye would also facilitate tracking the systemic trafficking by fluorescence
microscopy in the absence and presence of fluorescent probes for specific endocytotic
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markers. The mannose-targeting schemes will be compared to the folic acid targeting
schemes for effect on targeting efficacy and exploring the possibility of combining
different targeting schemes. Folate and CD206 receptors will be assayed for by flow
cytometry in the cells/cell lines that will be used to test the targeting schemes.
Antiretroviral targeting using the mannosylation schemes has not been explored enough
however some studies reported promising results by targeting of lamivudine using
mannosylated-poly propyleneimine dendrimers to efficiently target MT2 cells where
uptake of these particles was improved as well as its anti-retroviral activities against HIV1 compared to untargeted dendrimers or free lamivudine221. Using these targeting
schemes to target our prodrug nanoformulations may lead to higher uptake inside the
cells leading to higher retention hence the targeting schemes were shown to lead to
slower release outside the cells. This may be reflected in pharmacokinetics studies
where the macrophages would uptake targeted prodrug nanoparticles more efficiently
from the injection site.
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Figure 4. 1 Mannosylated ligands for targeting schemes
Different mannose ligands synthesized/in progress starting from D-mannospyranose.
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